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epatocellular carcinoma (HCC) is the third leading cause of cancer death in the U.S. Notably, 
most HCCs display c-Myc hyperactivity but this transcription factor participates in the 
regulation of as many as 15-20% of genes of the entire human genome. To better 
understand its oncogenic activity, a mass spectrometry-based proteomic approach was employed to 
search for disease regulated proteins in HCC. 
Specifically, the first part of the thesis describes a simple and reliable protocol for serum proteome 
analysis that combines an optimized resolution of 2-D gels spots and improved sample-matrix 
preparations for MALDIMS analysis was developed. The protocol allowed automated data acquisition 
for both CHCA and DHB and simplified the MS data acquisition therefore avoiding time-consuming 
procedures. The simplicity and reliability of the developed protocol may be applied universally. 
Specifically, in the present work an integrated serum and tissue proteomic approach was applied to a 
c-Myc transgenic mouse model that specifically developed HCC. By use of the α-1 antitrypsin 
promoter, targeted overexpression of c-Myc to the liver was achieved as originally reported by 
Dalemans et al.  
In the second part of the thesis, a total of 90 differentially expressed proteins in HCC of c-Myc 
transgenic disease model were identified with retinol binding protein 4, transthyretin, major urinary 
protein family, apolipoprotein E and glutathione peroxidase being regulated in common in tissue and 
serum of HCC mice. 
Moreover, this study identified n=22 novel tumor regulated proteins that could be traced back to either 
cell cycle regulation and proliferation, nucleotide biosynthesis & DNA metabolism, as well as regulation 
of ribosomal proteins. In this regard, bioinformatics revealed the coding sequences of regulated 
proteins to be either direct or indirect targets of c-Myc. 
Translation of the findings to human disease was achieved by Western immunoblotting of serum 
proteins and by immunohistochemistry of human HCC.  
This study therefore helps to define a c-Myc proteome suitable for diagnostic and possible therapeutic 
intervention strategies. 
In the third part of the thesis, research focused on the glycosylphosphatidylinositol-specific 
phospholipase D (GPI-PLD) protein. Specifically, to better understand the role of c-Myc in the 
regulation of GPI-anchored proteins gene expression, Western blotting of regulated proteins as well as 
enzyme activity of GPI-PLD was investigated in sera of transgenic mice and human HCC. Since the 
expression and activity of GPI-PLD was also elevated in sera of patients diagnosed with HCC and 
non-alcoholic steatohepatitis, transcriptional regulation of GPI-anchored proteins in cultures of human 
hepatocytes under conditions of NASH was investigated as well. Here gene expression data 
evidenced down-regulation of 25 and 9 GPI-anchored coding genes in mouse HCC and human 
hepatocyte cultures, respectively, most of which presented E-box motifs in the promoter of regulated 
genes. Thus, a link between c-Myc activity and modulation of transcriptional response of targeted 
genes can be proposed. Furthermore, the findings of the present study are highly suggestive for the 
GPI-PLD to stabilize the c-Myc protein and that induction of the lipoprotein ApoE and PON1 facilitate 
sustained activity of GPI-PLD to foster survival signalling in malignancy. With human HCC induction 
and activity of GPI-PLD depended on the complexity of disease and was most pronounced in patients 
diagnosed with NASH and diabetes mellitus while activity was reduced in alcoholic steatohepatitis. 
Taken collectively, this study evidences a novel role of GPI-PLD in liver cancer and modulation of 
other GPI-anchored proteins by c-Myc.                               
 
 
 
 
 
 
 
 
 
 
Keywords: hepatocellular carcinoma, c-Myc, proteomics, biomarkers. 
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as hepatozelluläre Karzinom (HCC) ist die dritthäufigste Todesursache bei Krebspatienten in 
den USA. Häufig wird in HCCs eine c-Myc-Hyperaktivität beobachtet.  
Das Ziel der Doktorarbeit war deshalb spezifische Biomarker für die Diagnostik von HCC und 
deren Regulation in Tumorgewebe zu finden. Hierzu wurde ein c-Myc trangenes Maus Model 
untersucht.  
 
Im ersten Abschnitt der Doktorarbeit wurde zunächst ein einfaches und zuverlässiges Protokoll zur 
Serumproteomanalyse entwickelt, das zugleich eine optimierte Auflösung von 2-D-Gel-Spots und 
Verbesserungen bei der Aufbereitung der Probenmatrix für die MALDI MS-Analyse bietet. Durch 
Entwickeln einer automatisierten Datenerhebung sowohl für CHCA als auch DHB Matrix-Protein 
gemischen konnte die aufwendige massenspektrometrische Datenerhebung vereinfacht werden, so 
dass mit hoher Zuverlässig eine Identifizierung von Proteinen erfolgten konnte.  
 
Im zweiten Abschnitt der Doktorarbeit wurden nach differentiell exprimierte Proteinen des HCC 
gesucht. Insgesamt konnten 90 differentiell exprimierte Proteine identifiziert werden, wobei Retinol-
Binding-Protein 4, Transthyretin, die Major-Urinary-Protein-Familie, Apolipoprotein E und 
Glutathionperoxidase sowohl im Gewebe als auch im Serum von Tumormäusen gemeinsam reguliert 
waren. 
Es wurden 22 bisweilen unbekannte tumorregulierte Proteine identifiziert, die an der Regulation des 
Zellzyklus, in der Zellproliferation, der Biosynthese von Nukleotiden und dem DNA-Stoffwechsel bzw 
der Regulation ribosomaler Proteine beteiligt sind.  
Anhand Western-Immunblotting und durch immunhistochemische Färbungen konnte zahlreiche 
Ergebnisse für das menschliche HCC übertragen werden.  
 
Im dritten Abschnitt des Doktorarbeit wurde die Activität des Glykosylphosphatidylinositol-spezifischen 
Phospholipase D (GPI-PLD) untersucht. Mit Hilfe von Genexpression Analysen, Western-Blots sowie 
Bestimmung der Enzymaktivität konnte die Regulation insbesondere in Patienten mit HCC und nicht-
alkoholische Steatohepatitis (NASH) gezeigt werden. Darüber hinaus wurde die differenzielle 
Regulation weiterer GPI-verankerter Proteine in HCC und Kulturen menschlicher Leberzellen unter 
NASH-Bedingungen untersucht, so dass ein Zusammenhang zwischen c-Myc-Aktivität und den 
transkriptionellen Antwort der betroffenen Gene gezeigt werden konnte. Insgesamt liefert diese Studie 
Beweise für eine bislang unbekannte Rolle von GPI-PLD bei Leberkrebs und eine Modulierung 
anderer GPI-verankerter Proteine durch c-Myc. 
 
 
 
 
 
 
 
 
 
Schlagwörter: hepatozelluläre Karzinom, c-Myc, Proteomik, Biomarker 
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yperactivity of c-Myc is frequently observed in human cancers as has been 
evidenced for hepatocellular carcinoma (HCC).  
Indeed, HCC is on the rise and estimated to be the fifth most common cause of 
cancer and the third leading cause of cancer related deaths more in men than 
women [Jemal,A et.al., 2008].  
While early detection of hepatocellular carcinoma significantly improves survival and 
prognosis, it is a finding by chance as most patients are asymptomatic until the 
disease has progressed considerably. As of today only a few serum biomarkers are 
used for disease diagnosis and therapeutic-monitoring and primarily include alpha-
fetoprotein (AFP) [Durazo,FA et.al., 2008]. Unfortunately, serum AFP levels are 
within normal range in about 40 percent of patients with hepatocellular carcinoma of 
less than 2 cm in diameter while in patients with tumors of 2 to 5 cm in diameter 
nearly 30% have normal AFP serum levels [Giannelli,G et.al., 2006, Zinkin,NT et.al., 
2008]. Moreover, not all hepatocellular carcinomas secrete AFP. Finally, AFP was 
shown to be elevated in pregnancy, by other tumors of gonadal origin and in acute or 
chronic viral hepatitis without a tumor [Robinson,L et.al., 1989, Xuan,SY et.al., 2007]. 
 
The work described in this thesis aims to identify candidate biomarkers for HCC. For 
this purpose, a c-Myc mouse model, which specifically develops HCC, was 
investigated in detail using a modified method in proteome research. As shown in the 
first part of the Results and Discussion section, an improved method for the detection 
of serum proteins was used, while in the second part of this thesis, novel tissue and 
serum biomarkers of HCC could be identified. The work has been complemented by 
gene expression studies and further validation by Western immunoblotting and 
immunohistochemistry. Importantly, the relevance of the animal findings was 
assessed in human HCC to further validate the importance of the newly identified 
disease regulated proteins. In the third and final part of this thesis, regulation of GPI-
phospholipase D (GPI-PLD) activity was studied in detail and in relation to other GPI-
anchored proteins with the aim to link c-Myc hyperactivity with aberrant signalling 
activity by GPI-PLD. 
Overall, a total of 28 different proteins are novel and reported for the first time in 
HCC. Knowledge on the activity of these proteins will help to define new biomarkers 
of HCC and possible represent therapeutic targets in intervention strategies. 
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The role of Myc transcription factor in normal biology and cancer 
 
                        
Figure 1. The Statue of Janus (Janus - Roman God of Gates & Doors, Wilstar.com) 
 
A paradox for cancer biology is represented by the fact that some oncogenes, such 
as c-myc, provide an advantage to cancer cells by stimulating uncontrolled 
proliferation while, at the same time, they exert a pro-apoptotic activity. 
For that reason, c-myc has recently been portrayed as Janus, the old Roman deity 
with two faces who presides over everything, by regulating cell proliferation and cell 
death [Supino et al. 2004]. 
 
More than 20 years ago, Myc was originally defined as an oncogene (v-myc) 
transduced by a number of avian retroviruses capable of potently inducing neoplastic 
disease [Dellafavera,R et.al., 1982]. Subsequently c-myc, the cellular homolog of v-
myc, was identified and eventually shown to be a member of a family of proto-
oncogenes comprising c-myc, N-myc, and L-myc [Vennstrom,B et.al., 1982].  
The c-Myc protein may be O-linked glycosylated and phosphorylated, and those post-
translational modifications may alter its half-life. The c-Myc sequence contains 
several conserved N-terminal domains, termed Myc boxes, which are found to be in 
closely related Myc proteins, N-Myc and L-Myc (Figure 2). 
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NTS: Nuclear Targeting Signal 
bHLH LZ: basic region/helix-loop-helix/leucine zipper domain 
MBI/MBII: Myc boxes or conserved sequences among Myc protein family 
TRD: TransRegulatory Domain 
 
Figure 2: Scheme of specific N- and C-terminal sequences on Myc gene. The N-terminal presents Myc boxes 
domains (MBI and MBII), whilst C-terminal is characterized by the helix-loop-helix zipper domain, important for the 
heterodimerization Myc-Max. 
 
The Myc proteins encoded by myc family genes are predominantly localized in the 
cell nucleus and their expression generally correlates with cell proliferation.  
At the C-terminal region, c-Myc contains a dimerization motif, termed basic 
region/helix-loop-helix/leucine zipper domain (bHLHZip). The Myc dimerization 
provides its role as transcriptional activator. Specifically, Myc protein 
homodimerization (Myc-Myc) have been reported as unstable and to bind DNA in a 
non-efficient manner [Soucek,L et.al., 2002]. In 1991, the bHLHZip protein Max was 
identified as a c-Myc obligate partner (Myc-Max) allowed instead a stable DNA 
binding by its evolutionary conserved bHLHZip at the protein´s COOH terminus. Max 
was shown to interact specifically with all Myc family proteins, and the resulting 
heterocomplexes recognize the hexameric DNA sequence CACGTG (belonging to 
the larger class of sequences known as E-boxes, CANNTG) at concentrations at 
which binding by either partner alone is undetectable [Blackwood,EM et.al., 1991, 
Prendergast,GC et.al., 1991].  
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Importantly, Myc requires Max to act on genes containing canonical or non-canonical 
E-box binding sites [Amati,B et.al., 1992]. DNA-bound Myc-Max complexes activate 
transcription through the amino terminal 143 amino acids of c-Myc, termed the 
transcriptional activation domain (TAD).  
Transcriptional activation by c-Myc involves the recruitment of histone 
acetyltransferases and other coactivators [McMahon,SB et.al., 2000]. These 
enzymes modify the chromatin surrounding c-Myc target gene loci, thereby facilitating 
increased transcription.  
In contrast, transcriptional repression by c-Myc appears to involve multiple, distinct 
mechanisms [Gartel,AL et.al., 2003, Kleine-Kohlbrecher,D et.al., 2006]. At the 
biochemical level, the best characterized of these mechanisms depends on c-Myc 
binding and inhibiting the activity of the transcriptional activator Miz-1 (Myc-interacting 
zinc-finger protein-1) [Facchini,LM et.al., 1998, Patel,JH et.al., 2006]. In the absence 
of c-Myc, Miz-1 binds to specific genes and activates their transcription [Liu,Q et.al., 
2010]. When over-expressed, c-Myc binds directly to Miz-1 and blocks this 
transcription (Figure 3) [Li,LH et.al., 1994].  
Finally, the N-terminal transregulatory domain (TRD) of c-Myc is required for cell 
transformation and that likely both its activation and repression functions are required 
for neoplastic transformation.  
 
 
 
 
 
 
 
 
 
Figure 3: Scheme of gene target regulation by Max and Miz-1 heterodimers of c-Myc. 
Max Myc
E-box
Max Myc
Core promoter
Miz-1
Gene target activation
x
Gene target suppression
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Myc biological functions 
The continuous and intense scrutiny with which myc has been still studied after its 
discovery derives mainly from its involvement in a wide range of cellular proliferation, 
differentiation and tumorigenesis  [Larsson,LG et.al., 2010]. The initiation or 
stimulation of tumor formation is obviously not the normal function of Myc proteins but 
a reflection of its ability to stimulate cell cycle progression. Indeed, expression of c-
myc in normal cells is regulated by external (such as growth factors) and by internal 
signals (cell cycle) [Pelengaris,S et.al., 2003]. Cellular abnormal or ectopic over-
expression of c-myc activates protective pathways, such as p19/p14ARF and a p53-
depenent cell death, hence eliminating those cells [Felsher,DW et.al., 1999]. In 
contrast, ligands such as transforming factor beta and gamma interferon, can even 
cause rapid down-regulation of c-myc expression [Pietenpol,JA et.al., 1990, 
Ramana,CV et.al., 2000].  
The expression of Myc genes and proteins are strictly controlled at multiple levels. 
The c-myc gene is expressed during all stages of the cell cycle in dividing cells and is 
normally down-regulated during differentiation. Its expression is induced by various 
mitogenic signalling pathways, such as Wnt, Notch and STAT. Myc proteins, 
however, are turned over at a very high rate via ubiquitin/proteasome pathways, in a 
complex mechanism (Figure 4)  [Adhikary,S et.al., 2005, Schulein,C et.al., 2009]. 
                     
                       
 
 
 
 
 
 
 
Figure 4: Scheme of activation of c-myc gene by STAT, Notch and Wnt. In particular, the β-catenin acts in 
conjunction with the transcription factor TCF4 to activate the c-myc gene target. 
In red is highlighted the degradation of c-Myc protein through ubiquitin/proteasome pathway (MAPK: Mitogen-
Activated Protein Kinase; GSK3β: Glycogen Synthase Kinase 3β; PP2A: Protein Phosphatase 2A) 
Wnts
Frizzled receptors
β-catenin
c-myc p21 G1 to S progression
Cell cycle
c-myc
c-myc
c-myc
Ub
c-myc
Ub
Proteasome
PP2A
GSK3β
Ser62-P
Tyr58-P
MAPK
Ser62-P
Tyr58-P Tyr58-P
TCF4
stable
unstable
Notch
c-myc promoter
C promoter-
binding factor 1
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cdc25a
STAT3
STAT3
P
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Myc and cancer 
The findings that human cancers frequently display altered expression of human c-
myc underscore the importance of this gene in the cause of human cancers. 
Indeed, the ability of over-expressed c-Myc to facilitate proliferation and inhibit 
terminal differentiation fits well with the fact that tumors of diverse origins contain 
genetic rearrangements involving myc family genes. For instance, increased c-myc 
gene transcription may account for the observed elevation of Myc in human colon 
carcinoma [Arango,D et.al., 2003, Santi,V et.al., 2007]. Moreover, since the co-
activator beta-catenin might activate myc expression through TCF4 transcription 
factor, it is not surprising that activated beta-catenin proteins have been found in 
liver, colon and other cancers with concomitant Myc deregulation [van de Wetering,M 
et.al., 2002]. 
In addition, ras oncogene appears to stabilize the c-Myc protein through a putative 
post-translational mechanism [Kerkhoff,E et.al., 1998, Sears,R et.al., 1999]. 
In the 1980s Weinberg and co-workers demonstrated that rat embryo cells were 
transformed by c-myc/ras co-transfection [Land,H et.al., 1986]. Further studies on 
animal models showed that tissue-targeted expression of c-myc leads to tumor in 
those targeted tissues [Arvanitis,C et.al., 2005]. 
Although a link between c-myc and cancer is well established both in vivo and in 
vitro, the molecular mechanisms of c-myc-mediated transformation are not fully 
known. 
Recently, a role of c-Myc in cell cycle progression, metabolism, apoptosis and 
genomic instability has been reported.  
Most studies have focused on the effect of c-Myc on regulatory proteins of the G1-S 
phase transition of the cell cycle. c-Myc has been implicated in inducing cyclin D1 
and D2, cyclin E, CDK4 and cdc25A (Figure 5).  
 
   
 
 
 
Figure 5: The check-points of c-Myc in the cell cycle 
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Moreover, c-Myc may provoke genome instability through cell cycle proliferation 
[Anderson,GR, 2001]. The term genome instability refers to genetic changes (i.e. 
point mutations, deletions, duplications, amplifications, translocations, inversions and 
aneploidy) that affect the normal organization and function of genes and 
chromosomes.  
Finally, some studies suggested that c-Myc may induce reactive oxygene species 
(ROS) production by mitochondria and consequently, DNA damage and genomic 
instability [Vafa,O et.al., 2002].  
 
High capacity proliferation requires increased energy supply and availability of 
molecular substrates to meet the demand for increased cellular activity. 
According to the Warburg effect, malignant cell growth is caused by the strategy that 
tumor cells use to generate energy mainly by glycolysis [Warburg, 1956]. This is in 
contrast to "healthy" cells which mainly generate energy from oxidative breakdown of 
pyruvate (Krebs cycle). Then, following his hypothesis, cancer may be considered a 
mitochondrial dysfunction.  
After more than 50 years of the Warburg theory, in term of propensity of the cancer to 
take up glucose avidly and convert it in lactate (aerobic glycolysis), novel hypothesis 
have been suggested recently.  
Up to now, the high glucose uptake has been documented by positron emission 
topography (PET) scanning of human cancers with radiolabeled 2-deoxyglucose 
[Chen,X et.al., 2008, Larson,SM, 2004]. 
The doubts were fuelled by the evidence that not all cancers are PET-positives. To 
this end, a “rethinking” about the Warburg hypothesis has been suggested recently 
by Dang (Figure 6) [Dang,CV, 2010]. According to his review based on recently 
published evidences, an alternative energy and anabolic source of carbon and 
nitrogen for nucleotide biosynthesis is glutamine, an amino acid highly present in 
human blood. Additionally, previous studies were carried on mainly in vitro, condition 
with which is difficult to encompass the high capability of tumor cells to adapt and 
tolerate hypoxia. Indeed, tumor tissues are generally hypoxic with some sporadic 
oxygenated areas.  Commensally relations among cancer tissue areas and other 
evidences which have shown hypotoxic tumor cells producing lactate, let to think a 
symbiotic mechanism including mitochondrial biogenesis, oxygen consumption, and 
glycolysis; in that, Myc seems to drive both aerobic glycolysis and oxidative 
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phosphorylation [Dang,CV et.al., 1999b, Dang,CV et.al., 2008]. When the oxygen is 
limited in cancer tissue, deregulation of c-Myc plays an important role in collaboration 
with the hypoxia-inducible factor 1 (HIF-1) in decreasing mitochondrial respiration.  
However, it does not mean that other functions of mitochondria must be unpaired, 
such as their biosynthetic functions. An independent discovery by the Thompson 
laboratory that c-Myc stimulates glutamine metabolism, makes this hypothesis more 
concrete [Wise,DR et.al., 2008]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Rearranged scheme from Dang C.V, Cancer Research 2010. The boxes evidence the c-Myc targets 
 
In this regard, the “re-thinking” model may explain the role of Myc in increasing 
mitochondrial biogenesis and glutamine metabolism for ATP production, anabolic 
carbon and nitrogen sources, in oxygenated tissues, and, in increasing glucose flux, 
which provides anabolic carbons for ribose and fatty acid biosynthesis.  
 
Protein production is driven by protein translation and relies on ribosomal biogenesis, 
globally essential for cell growth and proliferation. Deregulation of these sophisticated 
cellular processes leads to abnormal homeostasis and carcinogenesis.                
MYC has also been shown to serve as a direct regulator of ribosome biogenesis 
[Oskarsson,T et.al., 2005, van Riggelen,J et.al., 2010]. It is a key function in 
stimulating transcription of a number of genes encoding proteins essential for 
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ribosomal biogenesis and protein translation, including ribosomal proteins. It is 
debating whether this increase in ribosomal biogenesis is merely the 
consequences/side effects of cancer transformation or whether an active role in cell 
transformation (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 7: MYC–MAX stimulates the transcription of protein components in an RNA pol II-dependent manner. This 
includes proteins of the small ribosomal subunit (RPS) and large ribosomal subunit (RPL), nucleolin (NCL) and 
nucleophosmin (NPM1), which are involved in rRNA processing and export, UBF that serves as a cofactor for 
RNA pol I-dependent transcription as well as eukaryotic initiation factors that control the initiation of translation. 
TFIIIB, transcription factor IIIB. Nature Reviews 2010 
 
The understanding of Myc´s role as an oncogenic switch has evolved through various 
paradigm shifts over the past two decades but still is not completely understood. 
However, deregulation of c-Myc is reported in various cancers, including 50% of 
human HCCs.  
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Hepatocellular carcinoma 
 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death in the U.S 
and 11.3% of cancer mortality worldwide (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Font “Liver Cancer Incidence and Mortality Worldwide in 2008, GLOBOCAN” 
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In most cases, the cause of liver cancer is usually scarring of the liver (cirrhosis). 
Cirrhosis may be caused by alcohol abuse (the most common cause in the United 
States), certain autoimmune diseases of the liver, diseases that cause long-term 
inflammation of the liver, aflatoxin B1 (mycotoxins found in stored food), chronic 
hepatitis B or C virus infection or  hemochromatosis (abnormal amount of iron in the 
body) (Figure 9).  
 
 
 
 
 
 
 
 
 
Figure 9: Early stages of liver cancer. Alcoholic and non-alcoholic steatohepatitis or chronic viral infection 
(HBV/HCV viruses) are the most common causes of cirrhotic liver, an irreversible stage of liver disease which 
leads to primary liver cancer. Other causes of liver malignancy are aflatoxins, haematochromatosis as well as 
diabetes. 
 
Diagnosis of HCC 
Unfortunately, diagnosis of the hepatocellular carcinoma occurs at the last stages of 
the malignancy, since symptoms at the early stages, whether any, are generally not 
specific and they do not conduct clearly to liver malignancy (fever, feeling of fullness, 
weight loss, easy bruising or bleeding, enlarged abdomen, yellow skin or eyes –
jaundice-).   
Clinically, invasive techniques (such as biopsy or liver scan) are used to monitor liver 
cancer but are of limitated value due to the heterogeneity of disease. 
Healthy liver Fatty liver
Liver cancer
Infected liver
Cirrhotic liver
early stages
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Treatment of HCC 
Cryotherapy, radiofrequency ablation and hepatic artery embolization all are 
techniques for debulking unresectable tumors (mainly liver metastasis) in order to 
decrease tumor burden and to treat the carcinoid syndrome. Effective debulking can 
improve the carcinoid syndrome and also prolong survival. Probes that freeze 
(cryotherapy) or deliver radiofrequency waves (RF ablation) can be inserted into the 
liver to debulk the liver of metastases from carcinoid tumors.  
Hepatic artery embolization involves blocking the arterial blood supply to carcinoid 
tumors (using oil-gelatin sponge particles) in the liver followed by chemotherapy to 
debulk the remaining the liver tumors. Alternatively, radioactive microspheres can be 
injected into hepatic arteries to kill the liver tumors.  
 
Even novel targeted medicines are monitored for non-invasive treatment of the 
hepatocellular carcinoma, such as sorafenib (Nexavar®, Bayer), the survival rate of 
patients after diagnosis does not overcome the 5% at 5 years (Figure 10).  
Sorafenib is a multi-tyrosine kinase inhibitor drug which has been approved for 
treatment of advanced primary liver cancer. 
 
 
               
 
 
Figure 10: Structure of sorafenib 
 
It has shown a 44% improvement in patients who received sorafenib compared to 
placebo (hazard ratio 0.69; 95% CI, 0.55 to 0.87; p=0.0001). However, it is not 
without side effects, such as skin rash, hand-foot skin reactions, diarrhea, 
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hypertension and development of reversible posterior leukoencephalopathy 
syndrome and reversible erythrocytosis [Alexandrescu,DT et.al., 2008] and some 
countries, such as U.K., have declined to approve the drug, since the effectiveness 
does not justify the high price -at up to 3600 Euro per patient per month!-   
The role of c-Myc in HCC 
Most HCCs over-express c-Myc transcription factor that may participate in the 
regulation of as many as 15% of genes of the human genome.  
At the molecular level, genetic analyses had revealed that c-Myc is frequently over-
expressed, i.e. in up to 70% of human viral and alcohol-related HCC [Schlaeger,C 
et.al., 2008] and high throughput tissue microarray analysis had clearly demonstrated 
c-Myc as an important driver in HCC and chronic liver diseases [Chan,KL et.al., 
2004]. Moreover, studies on hepatitis B virus infected HCC patients had revealed a 
strong activation of MYC gene by HBx while activation of c-Myc accelerates the HBx 
oncogenic potential, resulting in a central role of c-Myc in HCC promotion and 
progression.  
Given the importance of c-Myc in HCC carcinogenesis, it is not surprising that it is an 
attractive target for novel therapies, as recently reviewed [Larsson,LG et.al., 2010].  
Biomarkers for HCC 
Since the liver can not tolerate doses of radiation and the disease is not responsive 
to chemotherapy, immunotherapy, biological therapy, and gene therapy techniques 
are being tested, and the scientific community is working hardly to search for markers 
which can be easily detected and specifically recognised at early stages of HCC. 
According to the official NIH definition, a biomarker is "a characteristic that is 
objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention". 
Search for those “characteristics” are carried on generally in bio fluids, such as 
plasma, serum or urine. Indeed, general blood and urine analyses are not invasive 
and they are well-tolerated from patients. 
Up to now, few serum biomarkers are used in clinical trials for detecting HCC, such 
as alpha-fetoprotein (AFP) [Durazo,FA et.al., 2008]. 
AFP is a glycoprotein of 591 amino acids and a carbohydrate moiety. The human 
fetus has the highest amount of AFP levels found in humans. These AFP levels 
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gradually decrease after birth down to the low, but detectable levels found in adults 
by the time a newborn reaches 8 to 12 months. AFP has no known function in 
healthy adults. However, this protein has been reported as high concentrated in 
serum of HCC patients. At the clinical level, the protein is still analysed for HCC 
detection, but its low specificity and sensitivity has doubted its efficiency as HCC 
biomarker. Moreover, serum AFP levels are reported within normal range in about 40 
percent of patients with hepatocellular carcinoma of less than 2 cm in diameter while 
in patients with tumors of 2 to 5 cm in diameter nearly 30% have normal AFP serum 
levels. Thus, it is excluded for early detection of HCC. Finally, not all hepatocellular 
carcinomas secrete AFP. For instance the AFP was shown to be elevated in 
pregnancy, by other tumors of gonadal origin and in acute or chronic viral hepatitis 
without a tumor [Castelli,A, 2009, Sherman,M, 2001].   
Other serum candidate biomarkers for HCC are object of study and they were 
recently evaluated for their clinical utility that included a comparison of AFP-L3 and 
des-gamma- carboxy prothrombin (DCP) with DCP being a more robust and reliable 
marker as reported elsewhere [Durazo,FA et.al., 2008]. Other candidates were also 
suggested that function in metabolism, calcium homeostasis, cytoskeleton dynamics 
tumor suppression, and apoptosis. Owing to the complexity of the disease such 
candidate biomarkers need to be validated for specificity and usefulness in the 
diagnosis and the monitoring of disease progression. 
Animal models of HCC 
The drawback in searching for specific candidate biomarkers in human beings is 
mainly the high variability among different patients. To overcome this problem, 
biomedical researchers use animal models, such as mice or rats.  
The research involves a long-term objective, such as developing a new drug for 
diabetics, screening a particular compound for human toxicity, studying a gene or 
mutation found in both animals and humans or studying a fundamental process such 
as gene transcription. The short-term objective is to use the animal model in 
experiments to determine how it responds to the treatments. If it is a faithful model of 
humans, then humans should respond in the same way. Animal models are used 
because the research can not be done on humans for practical or ethical reasons. 
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Hepatocellular carcinoma is a complex malignancy and several transgenic mouse 
models have been employed to exploit molecular mechanisms behind the promotion 
and progression of this primary liver cancer (Table A). 
Among them, there are implantation models and engineered mouse models. 
The implantation models are among the most widely used models to accomplish 
HCC formation in mice, since they are suitable for studies in preclinical evaluation of 
anticancer agents. The earliest implantation model is the syngeneic transplantable 
tumor model, in which a HCC cell line or liver tissue fragment is implanted in mice. 
However, this method is less used now, since it has been overcame by the use of 
immunodeficient mice which can be implanted with human HCC cell lines, such as 
HepG2 or Hep3B (xenograft models). The implantation in both cases can be made in 
an ectoptic (subcutaneously) or orthotopic (either by subserosal injection of HCC 
cells or by surgical orthopical implantation of liver tumor fragments) manner. 
The xenografts of human HCCs are generally used in preclinical evaluation of 
anticancer agents. However, recent studies have shown that subcutaneous 
implantation do not always lead to spontaneous metastasis, but they do in 
orthotopical ones.  For that reason ectopic implantations are often validated by 
orthotopical ones. On the other hand, orthotopical implantations are more difficult and 
very expensive. Finally, it has been demonstrated that these models have a poor 
predictive value for the anti-tumor effects in patients, since the cultured cells are 
maintained for long period and not longer maintained in the original environments. 
The introduction of transgenic mouse models in the earlier 1980´s made it possible to 
study the molecular features of human malignancies in vivo [Palmiter,RD et.al., 1982, 
Shuldiner,AR, 1996].  
In particular, the use of genetically engineered mouse models (GEM) is of a great 
importance to understand the role of specific genes in combination with malignancy. 
In the development of HCC, different pathways are thought to be involved, even 
though no exact genetic events in hepatocarcinogenesis are fully clarified. 
However, it seems that alterations of p53, Rb and Wnt/β-catenin pathways are 
involved during HCC.  
Overexpression of c-myc and transforming growth factor-alpha (TGF-α) has been 
frequently observed in human hepatocellular carcinoma (HCC), suggesting a pivotal 
role played by these protooncogenes in liver oncogenesis [Calvisi,DF et.al., 2005b].  
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Often Myc activation has been associated with chronic viral HCC [Singh,M et.al., 
2003, Terradillos,O et.al., 1997]. These GEM have been useful in understanding 
genes role in hepatocarcinogenesis. 
A c-Myc transgenic mouse model of HCC 
The α-1-antitrypsin (AAT) transgenic mouse model was developed in 1990 by 
Dalemans and co-workers. This HCC mouse model employs the α-1 antitrypsin 
promoter, thereby targeting overexpression of c-Myc to the liver. [Dalemans, W et.al., 
1990]. 
 
transgene promoter mouse strain references 
TGF-α metallothionein-1 CD1 [Jhappan,C et.al., 1990, Lee,GH et.al., 1992] 
SV40 T-Ag antithrombin 3 C57BL/6 x DBA2 [Dubois,N et.al., 1991] 
E2F-1 albumin C57BL/6 x CBA/J [Conner,EA et.al., 2000]       
c-myc/TGF-α albumin,  metallothionein-1 C57BL/6 x CBA/J x CD1 [Thorgeirsson,SS et.al., 1996] 
c-myc/E2F-1 albumin C57BL/6 x CBA/J [Calvisi,DF et.al., 2005a] 
c-myc albumin C57BL/6 x CBA/J [Thorgeirsson,SS et.al., 1996] 
c-myc α1-antitrypsin C57BL/6 [Dalemans,W et.al., 1990] 
 
 
TGF-α: transforming growth factor alpha 
SV40 T-Ag: simian vacuolating virus 40 TAg 
E2F-1: transcription factor E2F1 
CD1: albino mice 
C57BL76: C57 black 6 mice 
CBA/J: CBA substrain, blind mice  
DBA2: Dilute Brown Non-Agouti mice 
 
 
Table A. Here are listed the major mouse models used for the study of hepatocellular carcinoma (HCC). 
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This transgenic mouse model develops HCC between 8-12 months of life, as 
confirmed by histopathology (Figure 11).  
  
 
 
 
    
 
 
 
Figure 11: Histology of mouse livers from healthy (C57BL/6) and HCC bearing mice (AAT-c-myc transgenic) at 
different ages. Macroscopically evidence of HCC was clear only in 12 months aged mice. 
 
 
Proteomics-based biomarker discovery 
 
The ability of protein biomarkers to provide indications of physiological states or 
change makes them an important diagnostic and predictive tool in many clinical 
settings. Since disease processes involve very complex interactions of large numbers 
of proteins, there is a considerable interest in the technologies and data analysis 
techniques specially designed to handle this level of complexity, making it possible to 
study the entire complement of proteins, the “proteome”, of a blood or tissue sample. 
The simultaneous analysis of many proteins in a single sample may reveal patterns in 
their presence, abundance and modifications that result in a “protein signature” 
associated with the presence or absence of disease at a stage when it is otherwise 
undetectable. The same techniques may also be used to analyse a complex disease 
process and identify key molecules that could be targets for drug development.  
Two main strategies are used for protein profiling studies, gel-based and gel-free 
proteomics, which differ on the use of mono- and two-dimensional gel electrophoresis 
as separation techniques. 
 
C57BL/6 mouse AAT-c-myc transgenic mice
Age: 6 months Age: 6 months Age: 12 months
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In the gel-based approach the proteins are separated by two dimensional gel 
electrophoresis (2DE), an established technique since the late 1970s [O’Farrell, 
1975], according to their isoelectric point (pH=pI) in the first dimension (1-2) 
   
                            pI = (pKa1 + pKa2) / 2                                           (1) 
                                                                (2) 
                                                  
 (1)  The isoelectric point (pI) is the pH at which a particular molecule or surface carries no net electrical charge. 
 (2)   Henderson-Hasselbach Equation  
 
 
and to the molecular mass weight (Mw) in the second dimension (Figure 12). 
 
 
 
 
 
     
      
 
 
Figure 12: The figure depicts ironically the run of proteins in the second dimension of SDS-PAGE. In particular, it 
is shown an acrylamide matrix in gradient gels (University of Bologna, Italy). 
 
After the separation, a constellation of protein spots obtained from the different 
samples can be visualized (Figure 13) and compared using appropriate 
bioinformatics tools, and the differently expressed proteins can be excised, in-gel 
digested and identified by mass spectrometry [Huang,HL et.al., 2006, Penque,D, 
2009, Wulfkuhle,JD et.al., 2003]. 
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Figure 13: Two-dimensional SDS-PAGE gels at pH 4-7 from mouse serum and tissue extracts. 
 
 
 
The gel-free protein profiling approaches are based on the study by mass 
spectrometry of the fingerprint (or protein pattern) of proteins characteristic of a 
specific sample or biological state [Rocchiccioli,S et.al., 2010]. A typical mass 
spectrometry protein profiling approach can be performed by enrichment of proteins 
according to their physical/chemical features followed by MALDI-TOF analysis. The 
comparison among spectra, one of the critical points of this approach, allows for the 
evaluation of the proteins differentially expressed which can be identified by MALDI-
TOF-TOF analysis or by isolation of the proteins of interest followed by tryptic 
digestion and MS analysis. The surface-enhanced lasers desorption/ionization 
(SELDI) TOF MS technology, an extension of MALDI MS, can be also used for these 
purposes. 
 
Mass spectrometry has been a key part of biomarker discovery for the sensitivity and 
selectivity in detection, multi-analyte analysis, and for the ability to provide structural 
information. Nearly 20 years after its introduction to biology research, MS has 
become a tremendous success [Cravatt,BF et.al., 2007]. It has revolutionized the way 
in which biological information, especially related to proteins, can be obtained. With 
time, MS will become a routine technique to tackle a wide variety of biological 
questions. Due to its ability to acquire high content of information, mass spectrometry 
has emerged among the proteomic techniques as the method of choice for analysing 
pH pH
Mw
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tiss
ue
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the study of the composition, regulation and function of protein complexes in 
biological systems [Aebersold,R et.al., 2003, Cravatt,BF et.al., 2007, Domon,B et.al., 
2006, Yates,JR, 2004]. Mass spectrometers are used either to measure simply the 
molecular mass of a polypeptide or to determine additional structural features 
including the amino acid sequence or the site of attachment and type of 
posttranslational modifications [Domon,B et.al., 2006]. 
A mass spectrometer can be split into three main parts: the ionization source where 
the gas phase ions are produced from sample molecules, the mass analyser where 
the ion separation occurs and the mass detector where the signal is recorded. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Structure of a mass spectrometer for protein analysis. 
 
 
Specifically, Matrix-Assisted Laser Desorption/Ionization-mass spectrometry (MALDI-
MS) consists in ion generation and desorption of analytes embedded in a solid matrix 
by using laser irradiation. In MS mode, the ions are all given the same kinetic energy, 
and the time of flight (TOF) depends on the mass of the analyte. Only fragments 
formed in source (in-source decay, or ISD) are detectable. In MS/MS mode (Figure 
15), a LIFT cell is inserted in the ion flight path, which selects a parent ion and its 
fragments formed after the source (post-source decay, or PSD) on the basis of their 
flight time in the first TOF region. The parent and fragment ions are then re-
accelerated, and therefore travel with different velocities according to their masses, 
and are focused on the detector after passing through the reflectron. 
SourceSource AnalyzerAnalyzer DetectorDetector
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Figure 15: The heart of the ultraflex TOF/TOF system is the LIFT module. This technology has been 
especially designed to utilize the metastable ions generated by LID (Laser-Induced Decomposition)(Font: Bruker 
Daltonics Website). 
    
 
The LIFT™ is a patented technology by Bruker Daltonics which is considered as an 
high sensitive method to acquire TOF/TOF spectra with high-energy detection of 
either LID or CID (high-energy Collision-Induced Decomposition). Basicallly, the 
fragmented ions are post-accelerated in the LIFT module and detected. 
Mass spectrometry (MS) provides a promising strategy for biomarker discovery of 
HCC and applications of MALDI-TOF MS as an effective technology to profile serum 
proteome have already been suggested [Beckhaus,T et.al., 2005, Pan,S et.al., 2009].  
As shown in Scheme 1, a general workflow of serum proteome study was developed, 
coupled with immune validation and translational research. 
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Scheme 1: Workflow of the work described in this thesis. 
a: extraction of proteins,  
b: gel electrophoresis (2-DE),  
c: Image analysis and MALDI-MS;  
d: immunovalidation  (d1:WB, d2: Immunohistochemistry 
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Aims of the Doctoral Thesis 
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The aims of the doctoral thesis project can be summarized as follow: 
  
 
PART 1 
• Development of an improved method for serum protein identification 
• Map the serum protein of healthy mouse sera 
 
PART 2 
• Search for novel serum biomarkers of HCC in the c-myc transgenic    
        mouse model of liver cancer 
• Confirm of disease-regulated proteins identified in the c-Myc  
           mouse model of HCC in human HCC by Western immunoblotting  
           of patient sera and immunohistochemistry of human HCC 
 
PART 3 
• Investigate the role of GPI-phospholipase D in liver cancer 
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  Applied methods                
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Mantainance of transgenic mice   
 
The c-Myc transgenic mice are a kind gift from Dr. Dalemans [Dalemans,W et.al., 
1990]. 
All animal work followed strictly the Public Health Service (PHS) Policy on Human 
Care and Use of Laboratory Animals. Formal approval to carry out animal studies 
was granted by the ethical review board of the city of Hanover (Germany). 
Transgenic mice were the kind gift of Dr. Dalemans. They were maintained as 
hemozygotes in the C57/Bl6 black round. The transgene was verified by PCR using 
the forward primer: 5´-CACTGCGAGGGGTTCTGGAGAGGC-3´and the reverse 
primer: 5´-ATCGTCGTGGCTGTCTGCTGG-3´ and the following assay conditions: 15 
min 95°C, 1min 60°C, 1min 70°C, 1min 95°C, 31 cycles.  
N=6 healthy non-transgenic (C57BL6), n=6 HCC bearing mice aged between 10-12 
months and n=3 transgenic mice without cancer aged between 5.5-6.5 months were 
kept individually with food and water given ab libitum. 
Patient characteristics 
 
The Ethical committee of the Medical School of Hanover had approved the use of 
human samples. 
Patient characteristics are given in Chart 1. Human tumor tissue blocks from patients 
group A (IHC analysis) were provided by Dr. Ferdinand Hofstädter, Institute of 
Pathology, University of Regensburg (Germany). Tissue blocks were sectioned and 
processed as described below. 
Characteristics of patient group B. Sera of HCC patients were obtained from Dr. 
Arndt Vogel, Hanover Medical School, and used for WBs analyses. Here individuals 
were chosen according to their tumor staging (i.e. T3/T4, no regional lymph node 
involvement –N0- and no distant metastasis –M0-). 
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Staging of 
HCC A) Sera from:  Patient ID 
T N M 
Sex Age AFP Therapy 
13 0 0 0 female 21 13  
25 0 0 0 male 18 25  
55 0 0 0 female 19 55  
70 0 0 0 male 36 70  
60 0 0 0 male 27 60  
18 0 0 0 male 19 18  
31 0 0 0 male 42 31  
35 0 0 0 male 23 35  
36 0 0 0 female 24 36  
52 0 0 0 female 19 52  
Healthy 
individuals 
59 0 0 0 male 24 59  
347 T3 0 0 male 73 60 Sorafenib 
352 T4 0 0 male 57 7 Sorafenib 
353 T3 0 0 male 78 5 Trans-arterial chemoembolization (TACE) 
364 T4 0 0 male 58 33405 Sorafenib 
373 T3 0 0 male 73 60 Sorafenib 
375 T4 0 0 male 59 174639 Sorafenib 
386 T4 0 0 male 81 24 Trans-arterial chemoembolization (TACE) 
393 T4 0 0 male 52 31 Trans-arterial chemoembolization (TACE) 
399 T4 0 0 male 73 66 Sorafenib / percutaneous ethanol injection (PEI) 
401 T4 0 0 male 60 - Sorafenib 
115 T4 0 0 female 45 18666 Sorafenib 
163 T4 0 0 female 51 33114 Sorafenib 
200 T3 0 0 female 65 10 Trans-arterial chemoembolization (TACE) 
265 T4 0 0 female 72 5 Sorafenib 
299 T4 0 0 female 84 540 Sorafenib 
359 T4 0 0 female 39 8298 Sorafenib 
366 T4 0 0 female 72 15917 Sorafenib 
HCC patients 
383 T4 0 0 female 53 10 Trans-arterial chemoembolization (TACE) 
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Chart 1: Here, characteristics of patients, whose sera (A) and liver (B) were used for WB and 
immunohistochemistry (IHC) analysis, are shown. The HCC patients were almost all T3 (T= extent of the tumor; 
N= cancer cells spread to nearby (regional) lymph nodes; M= metastasis).  
 
 
Tissue and serum proteome analysis 
 
Mouse serum and liver tissue protein extraction 
Blood serum was collected from the vena cava and allowed to clot for 2 hours at 
room temperature. The clotted material was removed by centrifugation at 3000 rpm 
for 15 min. The obtained sera were immediately frozen in liquid nitrogen and stored at 
-80˚C until further analysis.  
Approximately 0.1 g of each mouse liver from n=6 different wild-type and transgenic 
mice (10-14 months old) was ground in a mortar under liquid nitrogen flow. Then, the 
samples were processed with 0.5 mL of a buffer containing 40 mM tris base, 7 M 
 
Staging of HCC  
B) Liver tissues from: 
 
 
Patient ID 
 
T 
 
N 
 
M 
 
 
Sex 
 
 
Age 
24943/D10(08) 0 0 0 female 68 
14389/E7 (08) 0 0 0 male 54 
17874/B7 (08) 0 0 0 female 72 
22983/6 (08) 0 0 0 male 84 
15374/5 (08) 0 0 0 male 70 
Healthy individuals 
17152/7 (08) 0 0 0 female 61 
11899/3 (08) 3 0 0 male 44 
25178/2 (06) 3 0 0 male 80 
22204/ (05) 3 0 0 male 65 
04605/1 (07) 3 0 0 male 56 
22602/3 (06) 3 0 0 male 73 
24954/5 (05) 3 0 0 male 65 
08616/3 (06) 3 0 0 male 72 
12585/8 (08) 3 0 0 male 51 
17798/21 (05) 3 0 0 male 61 
10458/C6 (07) 3 0 0 male 28 
6564/B1 (09) 1 0 0 male 67 
HCC patients 
6564/B4 (09) 1 0 0 male 67 
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urea, 2 M thiourea, 4% CHAPS, 100 mM DTT and 0.5% (v/v) biolyte. The 
suspensions were homogenized by sonication (3 × 20 s) and after addition of 3 μL of 
benzonase for degradation of RNA/DNA they were incubated at room temperature for 
20 min. The samples were then centrifuged at 12,000 g for 20 min. The pellets were 
washed and sonicated for 5 min with further buffer (see above) and centrifuged at 
12,000 g for another 20 min. The supernatants were collected. 
 
Protein separation and quantitation by 2-DE  
 
Protein determination 
Serum protein concentration was determined by the Bradford assay (Protein Assay 
Dye Reagent Concentrate, BioRad), using bovine gamma globulin as the standard 
and ranged between 108 to 128µg/µl for non-transgenic, 128 to 145µg/µl for AAT- c-
Myc transgenic mice aged between 5.5-6.5 months and in the case of HCC bearing 
mice (aged between 10-12 months), the serum concentration ranged between 135 to 
160µg/µl; protein concentration for healthy individuals and HCC patients ranged 
between 90-185µg/µl and between 125-252µg/µl, respectively. 
 
 
 
                             
Figure 16: Structure of Coomassie blue G-250. The Bradford Test is based on colorimetric property that 
Coomassie blue G-250 has at different pHs (it is red at very acid pH-absorbance 470nm- green at “neutral pH- 
absorbance 670nm- blue when protein linked-absorbance 595nm-) 
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Two-dimensional electrophoresis 
For gel electrophoresis, 500 µg/gel of total proteins from either tissue or serum were 
loaded and subjected to two-dimensional electrophoresis (2-DE) as described 
previously. Specifically, proteins were focused by their isoelectric behaviour by use of 
IPG strips of the same lot/each experiment (12 gels). IPG strips (BioRad) 
consecutively numbered were used and each IEF experiment (12 gels) was started in 
the morning, after 12 hours of equilibration. IPG strips were run at pH ranges of 4-7, 
3-10 and, in case of liver extracts, of 5-8. Each IEF experiment (12 gels) was followed 
by 12% SDS-PAGE (DodecaCell, BioRad) after IPG treatment with DDT (2%, w/v) 
and iodoacetamide (4%, w/v). The second dimension was run to 20mA/gel for 2 
hours, followed by 120mA/gel overnight.  After washing and fixing steps, the gels 
were stained with G250 Coomassie Blue. The Coomassie-stained 2-D gels were re-
hydrated in ultra pure water for exactly 5 minutes and recorded as digitalized images 
using a high-resolution scanner (Expression 10000XL, Epson). For the biomarker 
discovery, the samples from n=6 mouse controls (10-15 months) and the n=6 HCC 
bearing AAT-c-myc transgenic mice (10-13 months) were run in duplicate in two 
experiments/each pH (120 gels, in total). 
The software analysis was performed using the PDQuest™ software (version 8.0.1, 
Bio-Rad) with the Spot Detection Wizard (Figure 17). 2-D spots were automatically 
matched to a master (=reference) gel, after images warping and manual adding of 
landmarks present in all gels. Image warping was used to transform gel images so 
that matched spots can be viewed as overlapping regardless of gel distortion.  
Gel images were further processed to remove background noise. Unmatched spots 
were manually revised and added to the master-gel only when they were present in 
both replicates and at least in 2 out of 3 biological samples/each group. Spots were 
considered regulated if quantified in at least 2 out of 3 biological samples/one groups. 
Specifically, as a group, biological samples from C57Bl6 (control group) and AAT-c-
Myc mice (tumor group) were considered. The spot intensity was calculated as 
normalized values with LOESS (Local Regression Model); data were expressed in 
ppm. Normalization was used to remove systematic gel intensity differences 
originating, for example, from variations in staining, scanning time and protein loading 
by mathematically minimizing the median expression difference between matched 
spots. This allows a satisfactory quantification and comparison of different gels.  
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Quantification of the 2-D spots was done by means of intensity (total intensity/pixel 
number) with the PDQuest™ quantity tool. Missing spots were estimated 
automatically, revised manually and added to the master-gel when present in about 
80% of individual animals studied. Technical missing values (within replicas) were 
discarded. A total of 40% and 20% of missing values remained in serum and tissue  
2-DE experiments, respectively. 
Spot variation between groups (control and tumour groups) was estimated by the 
univariate test, foldchange (FC) and coefficient of variation (CV). Differentially 
expressed proteins were determined with the Student t-test and Mann-Whitney test  
(p <0.05) of proteins with an FC ≥ 2 for at least one pH range. 
 
                       
 
Figure 17: Workflow for detection of 2-D spots and preparation for MALDI MS analysis; a: 2-DE analysis and 
PDQuest™ analysis; b: 2-D spot excision and (c) trypsin in-gel digestion; d: 2-D analysis set is exported to 
MALDI-MS and the tryptic peptides are analysed with either CHCA or DHB matrix. 
 
Statistical analysis of differential expressed 2D gel spots 
All statistical analyses of 2D spots were done by PDQuest™ software. To reach 
statistical power, the 2-D maps of replicate gels in order to verify the quality of the 
experiment were studied. After normalization and before quantitation (Analysis Set, 
PDQuest™), the scatter plot of 2-D spots from the same biological sample in the two 
different gels (replicates) were checked and in case needed also manually improved. 
Overall a linear correlation coefficient of 0.90 was reached. 
The Mann-Whitney Signed Rank test, which applies non-parametric statistics, 
converts all values to ranks, and operates on the ranks was used. This type of test 
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does not make assumptions about the underlying statistical distribution as opposed 
to the Student’s T-test, which does make certain statistical assumptions about the 
data. To take the information about reproducibility of the 2-D maps according to the 
single replicas into account, analysis of the spot volume datasets for the different 
experiments by the Partial Least Squares (PLS) as multivariate statistical 
discriminating analysis technique was performed (Eriksson et.al., Umetrix Academy, 
1999). The choice was set down by the fact that univariate statistical tools (such as 
Student´s T-test) treat each individual variable as being independent, and, thus, can 
not easily capture information about correlated trends. Finally, univariate tools may 
increase false-positive results after repeatedly applications. Since proteomic studies 
based on 2-DE generate large datasets, it is important to be able to achieve 
statistically reliable decision tools for distinguishing between groups. For that reason, 
the multivariate statistic tools available in PDQuest™ software (PLS) were used. Spot 
values were standardized (normalized) for each spot by taking mean and standard 
deviation of the values across all gels for a spot, and then subtracting the mean and 
dividing by the standard deviation (namely “Scale spots to ignore size difference”). 
Overall, for between group comparisons (control vs tumor) the Student’s t-test and 
the Mann-Whitney Signed-Rank test were used, the latter test being more robust 
against violations of normality. In case of 2-DE of serum proteins, PLS did not always 
reach significance. For that reason, serum regulated proteins where cross-validated 
with immunoassay. 
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MALDI-TOF/TOF mass spectrometry  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Scheme of the Matrix-Assisted Laser Desorption Ionization  
 
 
Tryptic digested peptides were spotted onto a 600 µm/384 well AnchorChip™ sample 
target  and PMF and tandem MS were done with an UltraFlex™ II MALDI-TOF/TOF 
equipped with a smartbeam™ laser (Bruker Daltonics, Bremen, Germany). 
Specifically, for sample/matrix preparations we used the α-cyano-4-hydroxycinnamic 
acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB) matrices; CHCA was saturated in 
97% Acetone/0.1% TFA solution; DHB was dissolved in 30% ACN/0.1% TFA at final 
concentration of 5mg/ml. The matrix-analyte preparations were loaded by the thin 
layer and the matrix layer (ML) method as described recently [Garaguso,I et.al., 
2008]. A mix of peptide standards was used to calibrate the instrument and as 
external calibration of spectra (Peptide Calibration Standard for Mass Spectrometry, 
covered mass range ~1000-4000Da, Bruker). Additionally, internal calibration was 
achieved using trypsin autolysis products (m/zs 1045.564, 2211.108 and 2225.119) 
resulting in a mass accuracy of ≤50ppm. Spectra were collected by FlexControl ™ 
(2.0, Bruker) without smoothing or baseline subtraction and when peak resolution 
was higher than 6000 or 7000a.u. in case of DHB and CHCA, respectively. Then, the 
spectra were sent to FlexAnalysis ™ (v.2.4, Bruker), which labelled the peaks for 
protein identification by ProteinScape ™ v.1.3 or BioTools ™ v.3.1 (Bruker). Trypsin 
autolysis products, tryptic peptides of human keratin and matrix ions were 
automatically discarded by ProteinScape™ (mass control list). ProteinScape™ Score 
Booster feature was used to improve database search results by automatic iterative 
recalibrations and background eliminations. Protein scores greater than 53 were 
laser
analyzer
MALDI target
[MH]+
detector
Desorption
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Separation
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considered significant (p < 0.05, Mascot) (Mus) [Ritorto,MS et.al., 2008]. In addition, 
mouse proteins were requested as the top candidates in the first pass search when 
no restriction was applied to the species of origin. Identified proteins were checked 
individually for further considerations. Peptide masses were searched against the 
Swiss-Prot database (download 2005 - 197228 sequences, 71501181 residues - ) 
employing MASCOT (in-house MASCOT-server, Matrix Sciences Ltd, 
http://www.matrixscience.com/, revision 2.0.0), taking into account carbamidomethyl 
of cysteines -Carbamidomethyl (C)- as fixed modification and possible oxidation of 
methionine –Oxidation (M)-  as a variable modification but allowing one missed 
cleavage. Based on initial data, ion precursors were selected by ProteinScape ™ for 
tandem MS data acquisition. In the MASCOT MS/MS ions search, restriction at 
Mammalia species was applied with peptide tolerance of ±70ppm and MS/MS 
tolerance of ±0.9 Da (fixed and variable modifications as PMF). A result was 
considered acceptable when the Individual ion scores was > 27, ndicating identity or 
extensive homology (p<0.05). A wide peptide tolerance was not chosen to avoid long 
searching time and, mostly, without significant effect on the score. This is because 
most of the discrimination comes from the MS/MS fragment ion matches. On the 
other hand, a tighter peptide tolerance, in an effort to improve discrimination, may 
result in lost peptide matches, which would dramatically reduce the overall score.  
 
 
                                                     
Figure 18: On the right, an example of peptide mass fingerprint (PMF) and peptide fragment fingerprint (PFF) 
which leads to the identification of serum retinol binding protein (RBP4). On the left, the MALDI TOF-TOF MS, 
Ultraflex II, Bruker. 
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Validation of protein regulations 
 Western immunoblotting  
 
Serum protein extracts were subjected to Western immunoblotting using polyclonal 
goat and/or rabbit antibodies against alpha-fetoprotein, apolipoprotein E, serum 
retinol binding protein 4, serum amyloid P in a 1:200 dilution and major urinary 
protein and transthyretin in a 1:100 dilution (Santa Cruz Biotechnology) and 
apolipoprotein M in a dilution of 1:10000 (BD Bioscience). Polyclonal monospecific 
antibodies against PIGR and PHLD were purchased by Atlas Antibodies (Sweden). 
Notably, total protein extracts from HepG2 human hepatoma cells and Hela total cell 
extracts served as positive control. Detection was based on the ECL (PerkinElmer) 
and WesternDot™ 625 (Invitrogen) systems according to the manufactory 
recommendations. Images were recorded on the Kodak ds (IS 440CF) or 
alternatively with the Pharos FX™ Plus Molecular Imager with External laser 
Molecular Imager FX (BioRad) in the case of the Qdot® 625 nanocrystals of 
streptavidin conjugates. Band semi-quantitation was achieved with the QuantityOne® 
1D Analisys software (version 4.6.1; BioRad) using local background subtraction, 
while data were expressed relative to alpha-tubulin (T/C 1.01±0.25) that served as a 
housekeeping protein. 
Immunohistochemistry 
 
Healthy livers of n=5 individuals aged between 53 and 83 and n=12 cases of HCC 
aged between 26 and 77 were analyzed. Each tumor section (2-4µm in thickness) 
was de-paraffinized with Roti-Histol and dehydrate in a descending alcoholic solution 
according to standard protocols. To unmask the antigens the sections were 
immersed in citrate buffer and placed in an autoclave for 15 minutes. Endogenous 
peroxidase activity was blocked with a 3% hydrogen peroxide/methanol peroxidase 
blocking solution for 30 minutes. Then, the sections were washed with water and 
incubated with a solution containing the primary polyclonal antibody either against 
apolipoprotein E or serum amyloid P (at dilution 1:200); staining for hemopexin, 
paroxonase 1 and major urinary protein was at 1:30. In the case of c-Myc, glutathione 
peroxidase 3, retinol binding protein and prealbumin a1:50 dilution of primary 
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antibody was used and incubated for 45 minutes. After a further washing step a 
streptavidin horseradish peroxidase detection kit (Envision DAKO) was employed to 
visualize the protein of interest as recommended by the manufacturer. Harris 
Hematoxylin (Roth) was used as a counter-stain. The specificity of the reaction was 
further validated by use of mouse immunoglobulin G instead of the primary antibody. 
 
Gene expression data of regulated proteins 
 
All genomic data from Arraytrack were filtered through the total bag flags (<40%), 
mean intensities (>200), p-value (<0.05) and fold change (>2).  
 
Extraction of total RNA 
RNA-extraction was performed on three control mice and three AAT-c-myc 
transgenic mice at 2, 6 and 12 months, respectively, with the RNeasy Mini Kit 
(RNeasy MidiKit Qiagen, Santa Clarita, CA, USA) according to the manufacturer’s 
instruction and measured by NanoDrop ND-1000 (NanoDrop software, version 3.0.0).  
 
Sample preparation for analysis with Affymetrix GeneChip® System 
Total RNA (5µg) was used to generate biotin-labeled cRNA (10 µg) by means of 
GeneChip® One-Cycle cDNA Synthesis Kit and GeneChip® IVT Labeling Kit 
(Affymetrix). Quality control of cRNA was performed using a Bioanalyzer (Agilent 
2001 Biosizing, Agilent Technologies) and labeled cRNA of each sample was 
hybridized to Affymetrix GeneChip® Mouse Genome - 430 2.0 arrays by 
Hybridization Oven 640. The arrays were scanned using the GeneChip® Scanner 
3000.  
 
GeneMANIA 
To predict the gene networking, the GeneMANIA algorithm was employed. It consists 
of two parts: an algorithm, based on linear regression, for calculating a single, 
composite functional association network from multiple networks derived from 
different genomic or proteomic data sources; and a label propagation algorithm for 
predicting gene function given this composite network [Mostafavi,S et.al., 2008].  
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Bioinformatics 
Search for c-Myc binding sites in promoters of regulated genes/proteins 
The Mus Musculus Promoter Database was used to extract the promoter regions of 
genes coding for the regulated proteins [Zhang,MQ, 2003]. For each promoter, the 
lengths of the 1000bp upstream region and 100bp downstream region of 
known/predicted transcript start was chosen [Haggerty,TJ et.al., 2003]. The 
promoters were then analysed with positional weight matrices (PWMs) by 
TRANSFAC® (professional rel 10.1, BIOBASE GmbH, Germany). Specifically, 
TRANSFAC®-integrated MATCH™ (Matrix Search for Transcription Factor Binding 
Sites, 2010.1) was exploited. The matrix profile was done by us (MATCH™ Profiler) 
including 6 different matrices (M00118, M00322, M00615, M01034, M01145, 
M01154) in high quality mode (Figure 20). Finally, the default cut-off values for matrix 
similarity was used, whereas the cut-off for the core similarity at 0.75 was set 
[Reymann,S et.al., 2008].  
 
 
 
 
 
 
 
 
 
 
       
 
Figure 20: Scheme of matrices used for E-box sequence search (BIOBASE). 
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GPI-anchored protein predictors 
The search for GPI-anchor protein genes was made using four predictors:  
BigPI-Metazoa-, PredGPI, GPI-SOM-no taxon-specific- and Franganchor. 
According to a study conducted in 2006 at the Swiss Institute of Bioinformatics on the 
prediction performance of three programs (BigPI, DGPI and GPI-SOM) the BigPI 
predictor has reported the minor amount of false positives and therefore, it was 
chosen for first identification of ω-sides. BigPI-algorithm is based on sequence 
properties extracted from a positive set; while GPI-SOM is supposed to predict GPI-
anchoring for unknown proteins, based on Kohonen´s SOM (Self Organising Map) 
approach.  The Kohonen neural networks are known to be powerful tools for 
classification of hidden information in large datasets. FragAnchor is based on the 
tandem use of a Neural Network predictor and a Hidden Markov Model predictor. The 
Neural Network is used to select the potential GPI-anchored sequences and the 
Hidden Markov Model classifies the selected sequences according to four different 
levels of precision (highly probable, probable, weakly probable, potential false 
positive). The Hidden Markov Model proposes also up to three possible locations for 
the anchor/cleavage site. PredGPI (2008) is a prediction method that, by coupling a 
Hidden Markov Model (HMM) and a Support Vector Machine (SVM), is able to predict 
efficiently both the presence of the GPI-anchor and the position of the ω-site. 
PredGPI is trained on a non-redundant dataset of experimentally characterized GPI-
anchored proteins whose annotation was carefully checked in the literature [Deeg,MA 
et.al., 2001a]. 
Gene Ontology  
PubGene beta and ProteinLounge beta were used for classification of the proteins, 
according their most reported GO association in literature and their pathways. 
PubGene beta has been designed to present information on genes, proteins and 
related keywords in an organized and intuitive form by graphic interfaces connecting 
to published data citations and co-cite gene identification records [Jenssen,TK et.al., 
2001]. All information that were considered significant were collected (p<0.05). 
ProteinLounge beta represents a comprehensive and free web-based database 
which allows for protein pathways, protein-protein interactions and transcription factor 
database, as the most. The detailed information obtained from the database was the 
basis of the system biology study in this work. 
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Part 1: 
 
 - Development of an improved method for serum protein identification 
 - Map the serum protein of healthy mouse sera 
 
 
 
This part of the doctoral work was published in 2008: 
 
 
 
 
 
 
 
 
Background 
 
Searching for potential candidate biomarkers in bio fluids, such as serum, is a 
challenging task, whether it is considered that they may be present in blood at low 
abundance and may be masked by several other proteins working as carriers and 
present abundantly.  
To overcome this drawback, a modified proteomic protocol based on conventional 
proteomic workflow has been developed. 
 
 
 
 
 
 
“A simple and reliable protocol for mouse serum proteome profiling 
studies by use of two-dimensional electrophoresis and MALDI TOF/TOF 
mass spectrometry “ 
 
Maria Stella Ritorto and Jürgen Borlak 
 
Proteome Science 2008, PMID: PMC2563006 
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Two-dimensional electrophoresis of serum proteins 
 
By this study, narrow 2-D gels improved detection of low abundant proteins in sera, 
thereby avoiding any pre-fractionation. The 2-DE proteomics carries the advantage of 
visualizing changes in Mw and pI of a protein, which is helpful in highlighting 
biologically significant processes. This electrophoresis technique has been applied 
successfully to identify oncoproteins in human serum and tissues [Chen,R et.al., 
2005, Cho,WCS, 2007, Gorg,A et.al., 2004, Juan,HF et.al., 2004] . Notably, mouse 
serum proteins were separated by 2-D electrophoresis (2-DE) and resolved in the 
first dimension in a broad pH range with IPGphor strips (pH 3 to 10 NL), and 
subsequently in a 12% gradient polyacrylamide SDS gel in the second dimension. On 
average, 350 spots could be detected and 77 unique mouse proteins were identified, 
of which more than 30% were in the basic region of the gel. 
The sample complexity was further reduced by the use of IPG strips in the pH range 
of 4 to 7. The number of spots was increased by 2-fold. Approximately 660 spots 
were detected and 59 proteins were identified in this pH range. When compared with 
gels of the 3 to 10 pH-range, multiple isoforms of proteins can now be visualised and 
may have arisen from a combination of post-translational modifications as well as 
chemical modifications that occur during sample preparation [Gorg,A et.al., 2004]. 
Apart from high abundant proteins, on average three spots for each protein at pH of 4 
to 7 could be detected, when compared to one spot for each entry or smears 
observed with gels at pH of 3 to 10 (Figure 21). 
 
 
 
 
 
 
 
 
 
Figure 21: Examples of resolution of the protein smears by the use of narrow ranges of pH (rearrangement of 
Figure 2 – Ritorto MS, Borlak J, Proteome science 2008) 
3-10 pH gel 4-7 pH gel
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Improved MALDI TOF-MS analysis of serum proteins 
 
To increase the number of ionized tryptic-digested peptides, the properties of two 
commonly used matrices, CHCA and DHB were exploited. These matrices differ 
considerably upon MALDI ionization. CHCA is perceived as more efficient in 
ionization, often resulting in higher signal intensity, and is preferred for low-
abundance peptides. DHB, on the other hand, produces less background signals 
from matrix clusters and thus better reveals signals in the lower m/z region and is 
preferred in protein posttranslational modification (PTM) studies since modifications 
are likely to remain intact during ionization. 
 
 
 
Matrix  structure Matrix full-name Suggested solvent 
  
α-cyano-4-hydroxycinnammic acid  
(CHCA) 
satured in (97% Acetone, 0.1% TFA) 
 
2,5-dihydroxybenzoic acid 
(DHB) 
5mg/mL in (30% AcN, 0.1% TFA) 
 
Scheme 6: Here the two matrices used in the work are shown, namely the CHCA and the DHB. The solutions in 
which either CHCA (Bruker´s instruction) or DHB (ML matrix, Garaguso et al, 2008) were prepared are also 
described. 
 
 
 
 
 
However, one the main challenge in using DHB is its low homogeneity onto the 
target. The AnchorChip® technology (Bruker), equipped with hydrophilic patches 
surrounding ("anchors") in hydrophobic surroundings which allows for concentration 
of material in the anchor was used; however, the commonly method for preparing 
sample-matrix, namely dried droplet deposition, has given difficulties when an 
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automated acquisition was applied. As shown below, the homogeneity of the sample-
DHB is compromised and mostly not reproducible, making difficult any automatic 
movement of the laser by the MS software. 
In the improved method described here, DHB was prepared in 0.1% TFA acidified 
solution containing 30% ACN. DHB concentration was set at 5 g/L, in order to 
achieve crystallization solely on the anchor surface but keeping an optimum of 
analyte-to-matrix ratio. Similar to the conventional CHCA TL preparation, for the DHB 
preparation method the matrix solution is deposited onto the MALDI target and 
allowed to dry. Subsequently, an acidified analyte solution is deposited onto the dried 
DHB matrix. Finally, the preparation is recrystallized “on-target” using a solution 
containing ethanol/0.1% TFA (80:20 v/v) (Figure 22).  
 
 
 
 
   
 
 
´  
 
 
Figure 22: Here is depicted the shape of sample: DHB mix on the AnchorChip. The distribution of the modified 
thin layer preparation described above resulted high homogeneous, in comparison with conventional dried droplet 
 
 
 
The re-crystallization of the sample-matrix mixtures loaded on the target increased 
considerably the number of identifiable peptide ions in an automated MS and MS/MS 
spectra acquisition mode. Striking differences in the MALDI MS spectra of peptides 
were observed when the two matrices were compared (Figure 23).  
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Figure 23: Spectra comparison between CHCA and DHB. Here the spectra of the mouse alpha-2-antiplasmin 
(A2AP_MOUSE) and glutathione peroxidase 3 (GPX3_MOUSE) are compared. Rearragment of Figure 3 in PMID: 
PMC2563006. In blue are the modified peptides or matrix clusters.  
DHB
m/z
CHCA
Mouse plasma glutathione peroxidase
m/z
DHB
CHCA
m/z
m/z
Mouse alpha-2-antiplasmin
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Better ionization of peptides from the tryptic-digested proteins was observed with 
DHB as compared with CHCA. Indeed with CHCA, frequently peaks at m/z 1044, 
1060, 1066, 1082, 1249 and 1271 were observed. Matrix ion suppression in 
deflection mode of m/z 800 was applied. These abundant matrix clusters display high 
s/n ratio and resulted in poor acquired PMF spectra [Smirnov,IP et.al., 2004]. 
Previous reports had already highlighted differences in PMF because of different 
behaviour of the two matrices [Laugesen,S et.al., 2003, Padliya,ND et.al., 2004]. In 
particular, Zhu and Papayannopoulos tested several matrices and reported that DHB 
gave the best results without interferences from matrix ion peaks [Zhu,X et.al., 2003]. 
Furthermore, common interferences from matrix-adducts of CHCA were observed, in 
particular in the range of m/z 800–1100 of the MALDI spectra. 
Nonetheless, there are obvious benefits in the use of the CHCA matrix in the MALDI 
MS analysis. This included a high uniform layer, which it forms, especially on the 
AnchorChip™ (data not shown). Its ability to induce desorption of ions at lower laser 
energies demonstrates transfer of sufficient energy for the pre-formation of ions. In 
some cases, metastable ions of matrix ion fragments were less formed when 
compared with DHB [Krutchinsky,AN et.al., 2002]. This enabled acquisition of less 
ambiguous spectra for the identification of proteins. The different behaviours of both 
matrices are the subject of several published studies. In particular, Luo et al. [Luo,GH 
et.al., 2002] reported loss of internal energy of ions generated by MALDI and the role 
of the two matrices in desorption and ionisation processes. 
Indeed, in a complex mixture such as serum, it is not really clear why in some cases 
diagnostic PMFs are obtained with DHB rather than CHCA and vice versa and it is 
difficult to predict which matrix would deliver best PMFs. For that reason, both 
matrices were exploited in order to redress any drawbacks of one matrix by the use 
of the other one especially in automatic data acquisition procedures. 
Application of the improved method: mapping of the mouse serum 
To establish the usefulness of this proteomic approach, mapping of the serum protein 
content of C57BL6 wild type mice was performed. A total of 90 unique proteins were 
identified, some of which were reported to be identifiable only after sample pre-
treatment or sophisticated and time consuming procedures. For instance, several 
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members of complement factor family [CFAB_MOUSE, CFAI_MOUSE, 
CO3_MOUSE, CO4_MOUSE, CO9_MOUSE and C1QB_MOUSE], properdin 
[PROP_MOUSE] and mannose binding protein A [MBL1_MOUSE] were identified at 
the basic pH region of the 2-D gels. None of them were reported in previous mouse 
serum proteome profiling studies using 2-DE and MS analysis [Duan,XB et.al., 2004, 
Duan,XB et.al., 2005, Wait,R et.al., 2005]. Indeed, when the serum was albumin-
depleted, other high abundance proteins were lost as well. Furthermore, complement 
factor 3 and transthyretin were found in both fractions, albumin-rich and depleted 
(Table 1) [Chen,YY et.al., 2005]. This necessitated repetitive analyses.  Indeed, 
complement factor 3 was shown to be up-regulated in human lung   
adenocarcinomas [Kuick,R et.al., 2007], as were increased serum levels of 
transthyretin and down-regulation of transferrin in human type-2 diabetes 
[Sundsten,T et.al., 2006]. 
This protocol enabled automated data acquisition and improved significantly the 
identification of proteins based on higher sequence coverage and the number of 
matched peptides. For instance, CFAH_MOUSE was identified with a Mascot score 
of 269, a 31% sequence coverage and 29 matched peptides, instead of 23% 
sequence coverage and 6 and 18 matched peptides as reported previously (Table 1). 
Similarly, the sequence coverage of apolipoprotein H (APOH_MOUSE) was 
increased by 17% with 5 additional peptides that could be mapped to this protein 
[Chen,YY et.al., 2005, Duan,XB et.al., 2005]. 
A total of 13 different serum proteins were identified as novel (see Table 2). 
For instance, members of complement cascade activation, a positive mediator for 
angiogenesis (ANGL6_MOUSE), proteins specifically regulated in several tumor cells 
such as KPYM_MOUSE and proteins playing an important role in protein degradation 
and protein ubiquitinylation, whose altered activity could allow for abnormal cell 
proliferation (CUL-1_MOUSE), were newly identified and, interestingly, some of them 
might serve as cancer biomarkers  [Lai,KKY et.al., 2008, Nalepa,G et.al., 2003, 
Oike,Y et.al., 2004, Roigas,J et.al., 2003].              
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Perspectives 
 
Proteomics experimental design should include decisions regarding how to reduce 
the complexity of the sample (depletion, fractionation, digestion, tagging, affinity 
capture, and optional clean-up) and how to analyze the sample (LC-MS, LC-MS/MS, 
MS/MS, MALDI/SELDI MS, 2-D gel electrophoresis, FTMS). In general, with each 
additional step, reproducibility will decrease and loss of proteins will increase. The 
combination of zoom in gels and the use of two different sample-matrix preparations 
in sequence improved protein identification of mouse serum proteins considerably 
and allowed for automated data acquisition as compared to previous methods using 
2-DE and MALDI-MS. 
The first part of this doctoral work describes a simple and reliable identification of 
mouse serum protein and as shown in Table 2, and evidences an improved 
identification when compared with previous studies based on pre-treatments of serum 
or other sophisticated methods. 
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Part 2: 
 
 - Search for novel serum biomarkers of HCC in the c-myc transgenic mouse model of liver  
    cancer 
 - Confirm disease regulated proteins identified in the c-Myc mouse model of     
    HCC in human HCC by Western immunoblotting of patient sera  
   and immunohistochemistry of human HCC 
 
 
This part of the doctoral work is included in a second article: 
 
 
 
 
 
 
Background 
 
There is strong evidence for c-Myc to be frequently over-expressed and to be 
hyperactive in liver cancer [Dang,CV et.al., 1997, Dang,CV et.al., 1999a, Hui,LJ 
et.al., 2008]. Notably, the c-myc proto-oncogene encodes a transcription factor 
known to influence expression of a large number of genes, including cell proliferation 
and differentiation [Chan,KL et.al., 2004, Guo,QM et.al., 2000] and there is strong 
evidence for c-myc to function as an oncogenic transcription factor in 
hepatocarcinogenesis. 
To better understand its role in carcinogenesis, a c-Myc transgenic mouse model of 
HCC was investigated by the improved proteomic approach described in Part 1. 
Based on a combined serum and tissue proteomic approach, novel c-Myc regulated 
proteins were identified and further validated by IHC and WB in tissue and serum of 
HCC patients to explore their usefulness as disease biomarkers and for their possible 
use in targeted therapeutic intervention strategies. 
 
 
“A combined serum and tissue proteomic study applied to a c-Myc 
transgenic mouse model of hepatocellular carcinoma identified novel 
disease regulated proteins suitable for diagnosis and therapeutic 
intervention strategies “ 
 
Maria Stella Ritorto and Jürgen Borlak 
 
Journal of Proteome Research 2010, under review 
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Proteomic approach 
 
Following the model described by Dalemans and co-workers, transgenic mice for c-
Myc which specifically developed HCC around at 8-12 months of life were produced. 
The transgenicity was verified by PCR, as described in Applied Method section and 
the serum and total liver protein extracts from wild type and AAT c-Myc transgenic 
mice were analysed with the protocol described above. 
In total, 49,430 MS spectra were obtained to give rise to more than 9,000 peptide 
mass fingerprints (PMF) and ~3000 peptide fragment fingerprints (PFF) which were 
selected automatically by the ProteinScape™ database according their goodness. 
The search was done against SwissProt database and was validated against NCBI 
non-redundant protein database. Overall, the amount of PMF identifications, which 
represented the differentially expressed and de novo regulated proteins, was 1968 
(PFF= 381) and 989 (PFF= 496) for sera and tissue, respectively. Proteins, 
commonly regulated in tissue and serum, were also searched.  
A total of n=17 serum proteins were regulated of which 4 are novel while a total of 73 
regulated proteins are tissue specific of which 22 are new. In total, the study results in 
n=28 newly regulated proteins in HCC and demonstrate 5 of them being commonly 
regulated in serum and tissue (see Figure 24).  
 
 
                
 
 
 
 
Figure 24. Diagram of regulated proteins in tissue and serum of AAT-c-myc transgenic mice. In white are 
highlighted the number of newly identified proteins in HCC. 
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The identification obtained by peptide mass fingerprints were further validated by 
tandem MS (MS/MS).  
 
Validation 
 
Once potential candidates are recognized, the key step becomes validation. Indeed, 
a combination of 2D–PAGE and MS/MS allows for identification of few abundance 
proteins that differed in abundance between the two sample types (e.g. tumor vs 
control).  
MS spectra obtained by the improved method described above, were easily validated 
by tandem MS (MS/MS), since it was demonstrated that this improved MALDI sample 
preparation enabled high quality MALDI-TOF MS and MS/MS automated spectra 
acquisition, due to an improved analyte/matrix distribution and high crystals surface 
homogeneity. 
As an example, the most MS identifications regarding the differentially expressed 
proteins in mouse sera were validated by MS/MS (Table 3) 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Here is depicted a MS spectrum which identified serum retinol binding protein and the MS/MS of the 
parental ion at m/z 1226, which confirmed the identification.  
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Immunological validation and translational research 
 
Traditionally, MS has been used for discovery in a handful of carefully selected 
samples, whereas antibody-based techniques have been used for larger scale 
validation. Moreover, to render the identified candidate biomarkers in animal models 
of interest for clinical trial, the results must be translated on human samples. 
In the light of that, regulation of some proteins was investigated by Western 
immunoblotting and immunohistochemistry of mouse and human HCC. Notably, 
alpha-fetoprotein was up-regulated in serum of HCC mice, while its expression varied 
considerably amongst patients. 
Based on WB of serum proteins, a clear pattern could be observed. With 5-6 months 
old mice expression of apoE, retinol binding protein 4, transthyretin, 
glycosylphosphatidyl-inositol specific phospholipase D (GPI-PLD) and the secretory 
component of polymeric immunoglobulin receptor (SC-PIGR) increased with disease 
progression being strongly up-regulated in 12 months HCC bearing mice (Figure 25). 
 
With mouse apoE an additional immunoreactive band was visible, probably 
corresponding to one of the two fragments, detected early in 2-D gels of serum 
proteins. In contrast, expression of MUP(s) declined with progressive disease and 
was below detection in 12 months old HCC mice. 
With human HCC and in the case of GPI-PLD, serum amyloid component P and SC-
PIGR a similar up-regulation was observed, while expression of afamin was 
completely abolished (Figure 26).  
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  Figure 25: Western blot band-quantitation by QuantityOne® software. The * indicate variations statistically 
significant (p<0.05). PLD1 and PLD2 are two isoforms of GPI-PLD. + indicates the positive control (HepG2) and 
LC stands for loading control (α-tubulin). 
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Figure 26: Western blot analysis of mouse (A) and human (B) sera from healthy and tumor samples, respectively. 
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Further serum proteins of considerable interest were retinol binding protein 4 and 
transthyretin. Regulation of these serum proteins was studied by Western 
immunoblotting of n=31 patients diagnosed with either non-alcoholic steatohepatitis 
(NASH), alcoholic cirrhosis, chronic viral infection (HBV and HCV) or diabetes 
(DDMII). Here it has been demonstrated that retinol binding protein 4 and 
transthyretin were strongly up-regulated in HCC cases with DDMII and alcoholic 
cirrhosis, but less so in NASH or DDMII with NASH (Figure 27).  
 
               
Figure 27. Western blot for the serum retinol binding protein (RET4) and transthyretin (TTHY) on sera from a 
cohort of HCC patients with different concomitant diseases is depicted. NASH cases without HCC were also 
analysed. The α-tubulin was used as loading control, whilst HepG2 extracts as positive control (+). 
 
 
 
 
Additionally, disease regulated proteins were studied at the gene expression level 
with 41% and 52% of regulated proteins in serum and liver tissue being unchanged at 
the mRNA-level (Figure 28). 
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     Figure 28.  Correlation between protein and gene expression in mouse HCC. 
 Figure 6: Comparison of gene and protein regulations in HCC transgenic mice 
 
A. Depicted is the comparison of significantly regulated proteins found in serum of HCC transgenic mice.  
Their regulation is also studied at the gene and protein level in liver cancer. 
B. Depicted is a comparison of significantly regulated genes and proteins found in liver tissue of HCC mice. 
The pie charts are coded as follow: 
blue = regulation only at the protein level 
purple = common regulation at the gene and protein level 
yellow = opposite regulation when gene and protein expression is compared. 
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Regulation of proteins was also investigated by IHC in mouse and human liver tissue. 
As depicted in Figure 29, a similar distribution of hemopexin (mostly cytoplasmatic) 
but opposite regulation of the major urinary protein family in human and mouse liver 
tissue was observed. Moreover, nuclear staining for Mup in human control tissue was 
high, while a predominant cytoplasmatic staining in liver tissue of control and AAT-c-
Myc transgenic mice was noted. 
                
Figure 29. Immunohistochemistry of hemopexin and major urinary protein in health and HCC bearing mouse 
andhuman liver tissue, respectively. Typical images of hemopexin (HEMO) and major urinary protein (MUP) are 
depicted.  Note HEMO is opposite regulated in tissue and serum and nuclear MUP staining of  
control tissues was evident only in human livers. 
 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            63
Bioinformatics 
 
The oncoprotein c-Myc plays an important role in cell proliferation, transformation, 
inhibition of differentiation and apoptosis. These functions most likely result from the 
transcription factor activity of c-Myc. As a heterodimer with Max, the c-Myc protein 
binds to the E-box sequence (CACGTG). 
The position weight matrices (PWM) to search for c-Myc recognition sites in genes 
coding for regulated proteins was applied. As been shown in Table 4, 71% of the 
newly identified proteins presented E-boxes (32% for E-box for Myc/Max and 39% for 
a generic E-box recognition motif) (Figure 20). 
Moreover, the gene expression study was suggestive for regulation of ribosomal 
proteins. As shown in Table 5, a total of 15 ribosomal protein Ls and 6 ribosomal 
protein Ss were regulated; 4 of them have been already reported as up-regulated in 
human HCC 17 while 9 of them correlated with c-Myc over-expression [Guo,QM 
et.al., 2000, Menssen,A et.al., 2002]. To the best of our knowledge, 10 of the 
ribosomal encoding genes had not been reported so far. Of particular interest is the 
protein  Rpl11 that was identified in 2-D gels (pH 3-10, data not shown); however, the 
quantitation was not possible due to the difficulty in resolving spots at that high pI 
(pH>8). For acidic ribosomal proteins regulation was not observed (data not shown). 
Overall, 73 regulated proteins in liver tissue (Figure 24) have been identified, of 
which 22 are novel and had not been reported in HCC tissue so far. Based on their 
biological ontologies, the majority of disease-regulated proteins influence cell cycle, 
cell growth, differentiation, survival and apoptosis, nucleosome stability, such as 
histone H2A and ribosomal protein assembly and transport, including nucleophosmin. 
Figure 30 depicts ontologies of the regulated mouse tissue proteins, according to 
Gene ontology. 
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Figure 30: Pie charts from Gene Ontology classification of regulated proteins in mouse liver tissue (tumor vs 
control) according to the PubGene beta database. 
 
Myc overexpression and hepatocellular carcinoma 
 
Identification of disease regulated proteins in liver tissue 
Activation of c-myc may be achieved by gene amplification, by chromosomal 
translocations, beta-catenin co-activation, removal of the 3’ UTR destabilizing 
sequences (elevation of myc-mRNA), or co-expression of ras which stabilizes the 
Myc protein by posttranslational modifications. This protein affects cell cycle 
progression from the G1 to S phase to foster proliferation; metabolism by increasing 
the cell mass required for the initiation of DNA synthesis (S-phase), and c-Myc 
redirects energy supply even in hypoxic state of rapid-proliferating cells. Likewise, c-
Myc activity may result in  genomic instability with high production of reactive oxygen 
species (ROS) but cells remain recalcitrant to programmed cell death even at high 
intracellular ROS levels [Greenwood,E, 2002, Pelengaris,S et.al., 2003].  
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Disease associated regulation of cell cycle proteins 
Notably an up-regulation of proteins influencing cell cycle, cell growth, differentiation, 
survival, apoptosis and migration (such as 14-3-3 protein family), was observed as 
was regulation of nucleosome stability (histone H2A), ribosomal protein assembly 
and transport (nucleophosmin) (Figure 20). A fine example is an up-regulation of the 
elongation factor 1-delta (EF1D), a protein recently associated with the cell division 
cycle 25 (cdc25) phosphatase to influence cell cycle regulation and activity of the 14-
3-3 protein family.  Up-regulation of EF1D was observed at the mRNA level (Table 3) 
and this finding agreed well with reports of HCC patients were mRNA of eEF1s was 
reported to be up-regulated [Chung,EJ et.al., 2002]. Indeed, activity of this elongation 
factor has been linked to oncogenic transformation [Chung,EJ et.al., 2002, Joseph,P 
et.al., 2002]. Additionally, an interaction between 14-3-3 epsilon protein and the 
elongation factor 2 may also influence programmed cell death whereby 14-3-3 
redistributes into the perinuclear region, as reported elsewhere [Chung,EJ et.al., 
2002, Harris,MN et.al., 2004]. 
Likewise, the activator of HSP90 ATPase (AHSA1), a co-chaperone of HSP90 that 
delivers ATP to HSP90, was up-regulated thereby increasing its ATPase activity to 
function in cell proliferation. Targeting oncogenic proteins by the ubiquitin-
proteasome pathway and thus by inhibition of the ATP pocket of HPS90 or by 
destabilization of the super chaperone complex is a much researched area and of 
great importance in liver cancer [Pascale,RM et.al., 2005]. Moreover, regulation of 
AHSA1 was observed in gels at pH ranges 4-7 and 3-10 and to the best of our 
knowledge, this is the first report for Ahsa1 to be regulated by c-Myc hyperactivity, 
even though no E-box motifs could be determined in the genomic sequence of the 
coding gene (Table 4). 
Likewise, induction of ubiquitin-carboxyl-terminal hydrolase isozyme L3 (UCHL3) in 
HCC of c-Myc transgenic mice is a notable finding. It plays an important role in the 
release of ubiquitin from an amino-acid complex to regulate essential cellular 
processes. Dysregulation of de-ubiquitinating enzymes has been observed in multiple 
disease stages such as aberrant activity of the ubiquitin carboxy-terminal hydrolase 
L1 (UCH-L1) in cancer and Parkinson's disease [Miyoshi,Y et.al., 2006, Setsuie,R 
et.al., 2007]. 
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c-Myc induced alterations in cellular metabolism 
High capacity proliferation requires increased energy supply and availability of 
molecular substrates to meet the demand for increased cellular activity. As detailed 
above and next to an up-regulation of elongation factors such as eEF1-2-3, the 
induction of peptidyl-prolyl cis-trans isomerase A (PPIA or Rotamase A) by c-Myc is 
likely to impact cellular mass. Specifically, the elongation factor 1 is responsible for 
the enzymatic delivery of aminoacyl tRNAs to the ribosome by GTP; here EF-1-beta 
and EF-1-delta stimulate the exchange of GDP bound to EF-1-alpha to GTP (e.g. 
guanine nucleotide exchange factors) whereas the isoforms delta and gamma are 
reported as putative Myc-activated targets ([Watson,JD et.al., 2002], Table 4). An up-
regulation of the elongation factor 1 (EF1D), as evidenced in the present study, 
contributes to an understanding of Myc´s activity in HCC.  
Notably, the peptidyl-prolyl cis-trans isomerase A (PPIA) was already reported to 
influence refolding of proteins in HCC and for its role in affecting mitochondrial 
permeability [Lim,SO et.al., 2002]. 
A further example is the regulation of cytochrome oxidase enzymes in HCC. 
Specifically, the cytochrome c oxidase is a large transmembrane protein complex 
found in the mitochondria with the ultimate goal to transfer electrons to reactive 
oxygen to eventually produce water and to establish a transmembrane potential 
thereby enhancing ATP synthesis. In c-Myc transgenic mice, the cytochrome b-5-
COX5A and COX5B- were strongly down-regulated to possible suggest impaired 
mitochondrial energy production. Noteworthy, errors in oxidative phosphorylation was 
already observed in severe hepatocellular dysfunction [Edery,P et.al., 1994]. As 
discussed above, the ability of c-Myc to induce mitochondrial biogenesis in 
proliferating cells is well established even though inhibition of mitochondrial 
respiration is observed [Dang,CV, 2010] possible to foster production of other 
building blocks of growing cells, such as pyrimidines. Recently, a “rethinking” about 
cancer metabolism and c-Myc´s influence has been discussed, with increased 
mitochondrial biogenesis, deregulation of mitochondrial respiration and increases in 
glutamine metabolism to foster tumor growth [Dang,CV, 2010].  
Besides cytochrome b5, additional mitochondrial enzymes were significantly 
repressed at the protein level but not at the mRNA level and included the cytochrome 
b5 outer mitochondrial membrane isofoform precursor (CYB5M) and sulfite oxidase 
(SUOX). Notably, the family of cytochrome b5-like proteins consists of a hemoprotein 
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domain that associates with other redox domains to enable transfer of electrons to 
cytochrome c. In this regard, Suox, a mitochondrial enzyme located in the inner 
membrane, catalyzes oxidative degradation of sulphur-containing amino-acids. 
Activity of this enzyme leads to the production of peroxides whereby Suox catalyzes 
the reaction: Sulfite + O2 = sulphate + H2O2. The reduction of sulphite to sulphide 
leads to a strong inhibition of cytochrome c oxidase. Repression of this mitochondrial 
enzyme prevents apoptosis in HCC [Scheers,I et.al., 2005]. 
Another mitochondrial enzyme repressed in c-Myc transgenic mice is the 
ethylmalonic encephalopathy protein 1 homolog (ETHE1). High thiosulfate and 
sulfide concentrations were reported for Ethe1-ko mice and such sulfides are 
powerful inhibitors of COX and short-chain fatty acid oxidation to modulate vasoactive 
and vasotoxic effects. Sulfide is detoxified by a mitochondrial pathway that includes a 
sulfur dioxygenase and ETHE1 may be considered as a putative c-myc target. 
Furthermore, ROS produced by mitochondrial metabolism may lead to lipid 
peroxidation to insult mitochondrial DNA (mtDNA) that encodes proteins of the 
respiratory chain, such as the cytochromes, but unlike genomic DNA, the mtDNA 
does not contain protective (DNA repair) histones. 
 In response to high capacity cell division, the protective enzymes NADPH-flavin 
reductase (BLVRB) and peroxiredoxins were strongly up-regulated in HCC. Recently, 
c-myc was shown to regulate a nuclear gene encoding the mitochondrial 
peroxiredoxin (PRDX3), which is required for cell proliferation and transformation 
mediated by c-myc [Wonsey,DR et.al., 2002]. In our study, the mitochondrial PRDX3 
and the cytoplasmic PRDX6 were overexpressed, possible in response to hypoxia 
and oxidative stress that is frequently observed in cancers, as detailed below.  
 
Oxidative stress and ROS production 
Chronic oxidative stress has been reported to result in increased lipid peroxidation in 
c-myc/TGF induced dysplastic cells with deficiency in DNA repair [Calvisi,DF et.al., 
2005b]. While reactive oxygen and peroxides play important roles in cellular 
signalling, excessive ROS can result in DNA damage. Indeed, peroxides such as 
H2O2 are products from normal cellular processes and are considered as  important 
intracellular messengers for instance to function as hyperpolarization factor in the 
control of vascular tone. Excessive H2O2 can lead to toxic radicals, but efficient 
mechanisms are in place to scavenge such radicals notably through activity of 
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antioxidant defence enzymes such as catalase, glutathione peroxidases and 
peroxiredoxins. These proteins have been reported to be strongly down-regulated in 
HCC [Irmak,MB et.al., 2003], possible due to the selenium deficiency provoked by 
oxidative stress. In the present study, Gpx1 and Gpx3 were strongly repressed, while 
Gpx3 was up-regulated at the gene expression level (Table 4). It is well established 
that selenium is necessary for Gpx activity and deficiency of this mineral leads to 
apoptosis [Ghose,A et.al., 2001]. In the present study, a significant down-regulation 
of selenium-binding protein 1 and 2 at the gene and protein levels was observed but 
a recent report highlights the ability of HCC cell lines to escape such programmed 
cell death and to survive in Se deficient medium [Irmak,MB et.al., 2003]. Noteworthy, 
the serine/threonine-protein phosphatase 2A (or 2AAA) was identified as two spots 
on 2D gels at pH 4-7 with one being repressed (Table 3).  
As the serine/threonine phosphatases are important in selenite-induced apoptosis, 
our study supports the hypothesis that such phosphatases are regulated in c-Myc-
induced cell growth.  
Further possibilities to detoxify ROS are based on the activity of peroxiredoxines 
(Prxs). These enzymes are abundant in cytosol (Prx 1,2,6) and in mitochondria (Prx 
3). They function without Se and cycle thiol and sulfinic acids, which uses 
thioredoxins, thioredoxin reductase and sulfinic reductase but not glutathione (as 
Gpx) or glutaredoxin to reduce the disulfide binding. In c-Myc transgenic mice 
induction of thioredoxin was observed (data not shown) but glutaredoxin was not 
regulated. As Prdxs have been proposed to function as chaperones for Prdx-SO4- 
their up-regulation in tumor tissues may contribute to ROS detoxification.  
Further evidence for oxidative stress in HCC stems from the low expression of the 
protein DJ-1 in HCC of c-Myc transgenic mice. Reduced expression of this oxidative 
stress sensor suggests abnormal function of mitochondria [Hao,LY et.al., 2010]. In 
support of its function, loss of DJ-1 activity leads to deficiency in NADH-ubiquinone 
oxireductases. This agrees well with our observation of reduced expression of the 
mitochondrial NADH-ubiquinone oxidoreductase 75kDa subunit (NUAM) and the 
mitochondrial NADH dehydrogenase ironsulfur protein 3 (NUGM) in HCC bearing 
transgenic mice (Table 4). 
A further mechanism to prevent ROS insult is linked to glutathione metabolism. Here 
5-oxo-prolinase, that is one of the five enzymes of the gamma-glutamyl cycle, was 
down-regulated, whilst glutamate-cystein ligase (GSH0) and GSH S-transferase 
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(GSTM1) were up-regulated. This can be explained by the self-renewal of glutamate 
by the gamma-glutamyl cycle and the reduction of GSH-reductase by cytosolic 
isocitrate dehydrogenase which was also up-regulated in our study. Its induction in 
rapidly growing hepatocytes was already  reported [Tsuboi,S, 1999]. 
 
Nucleotide biosynthesis and DNA metabolism 
As cells enter the S phase, adequate substrates must be made available to ensure 
the fidelity of DNA replication. Several genes important in nucleotide biosynthesis 
and DNA metabolism are targeted by c-Myc and were regulated in tumor tissue of 
transgenic mice. This included carbamoyl phosphate synthase and ornithine 
decarboxylase. Carbamoyl phosphate is the first molecule in the pyrimidine 
biosynthesis (in cytosol) and the urea cycle located in the mitochondria. Deficiency in 
the complete urea cycle converts ammonia into glutamine to cause cellular 
proliferation [Rhoads,JM et.al., 1997]. This agreed well with the more than 4-fold 
increase of protein expression (Table 4) and the more than 9-fold up-regulation of 
glutamine synthetase mRNA (data not shown), a finding that has also been observed 
in other HCC studies [Kuramitsu,Y et.al., 2006]. Again, up-regulation of glutamine 
metabolism fits well with the “re-thinking” in cancer metabolism [Dang,CV, 2010]; the 
ASCT2, a gene involved in glutamine transport to be strongly up-regulated (T/C: 
8.499, p=0.0009) also observed, thereby providing further evidence for c-Myc´s 
concerted action in nucleotide biosynthesis and DNA metabolism.  
Furthermore, mitochondrial carbamoyl-phosphate synthase (CSPM), mitochondrial 
ornithine carbamoyltransferase (OTC) as well as arginase I (ARGI1) were down-
regulated at the mRNA and at the protein level (Table 4); this highlights low 
functional activity of the urea cycle in liver cancer, as previously discussed [Butler,SL 
et.al., 2008]. A decreased activity in the urea cycle allows cancer cells to utilize 
substrates such as carbamoyl phosphate and ornithine for pyrimidine synthesis and 
polyamine biosynthesis as such molecules are required in high abundance in 
proliferating cells.  
Strong up-regulation of ornithine aminotransferase (OAT), which uses glutamine as 
substrate to foster purine/pyrimidine synthesis, was also observed. In fact, tumor cells 
need large amounts of dTMP for DNA synthesis. Here the 10-formyltetrahydrofolate 
dehydrogenase is a rate limiting enzyme in folate synthesis and was shown to be 
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strongly down regulated in several cancers. Our results had also confirmed low 
expression of the protein in HCC transgenic mice.  
 
Lipid metabolism and transport 
Lipid metabolism is greatly changed in cancers. Enhanced fat synthesis in tumor cells 
supports increased membrane synthesis and energy metabolism. A relationship 
between HCC and lipid metabolism has been argued that included regulation of 
ApoA1 and ApoE as previously reported [Gray,J et.al., 2009, Yokoyama,Y et.al., 
2006]. In the present study, the liver fatty acid-binding protein (FABPL) was strongly 
repressed. This protein carries fatty acids and other lipophilic substances such as 
eicosanoids and retinoids to facilitate the transfer of fatty acids between extra- and 
intracellular membranes. Some family members are also believed to transport 
lipophilic molecules from outer cell membrane to certain intracellular receptors such 
as PPAR. Noteworthy, numerous studies revealed PPARα and PPARγ agonists to 
exert anti-inflammatory effects and for PPAR γ antagonist to inhibit growth of cells. 
Thus PPAR γ antagonists are explored for their therapeutic efficacy in liver cancer.  
A further mitochondrial enzyme regulated in HCC is 3-hydroxyisobutyrate 
dehydrogenase. This enzyme is involved in amino acid degradation. It regulates the 
last step towards ketone production. Normally, the ketone bodies are synthesized by 
the Acetyl-CoA when there is an excess of lipid degradation. Previously, Thompson 
and colleagues reported that inhibition of a key enzyme linking glucose metabolism to 
lipid synthesis suppresses tumour growth [Hatzivassiliou,G et.al., 2005]; aberrations 
in lipid metabolism have already been reported in patients with the chronic hepatitis B 
infection, leading to HCC [Jiang,JT et.al., 2006]. 
In the present study a more than 4-fold up-regulation of cathepsin B was evidenced. 
This lysosomal cysteine proteinase is composed of a dimer of disulfide-linked heavy 
and light chains and it is significantly elevated in a variant of the B16 melanoma with 
high metastatic potential. Recent studies, however, emphasized low expression of 
cathepsin B [Li,C et.al., 2004] and that the protein is repressed by c-myc. In the 
present study the opposite was observed and may possible be linked to an activation 
of Miz-1 that heterodimerises with c-Myc to repress activity of targeted genes. 
Likewise, the MIR-interacting saposin (MSAP) was recently reported to be associated 
with metastasis; it is a positive regulator of neurite outgrowth by stabilizing myosin 
regulatory light chain (MRLC) to prevent MIR-mediated MRLC ubiquitination and its 
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subsequent proteasomal degradation. In the present study, a more than 5-fold up-
regulation of this protein was observed in conjunction with an 3.5-fold up-regulation of 
the Rho GDP-dissociation inhibitor 1 (GDIR, chaperone family) and an 3-fold up-
regulation of the chloride intracellular channel protein 1 (CLIC1)  to provide further 
evidence for its disease driven regulation and to possible foster metastatic spread. 
 
Ribosomal biosynthesis 
Myc is a global regulator of various cell processes [van Riggelen,J et.al., 2010]; 
recently, its contribution in tumorigenesis through the modulation of ribosome 
biogenesis has been discovered [van Riggelen,J et.al., 2010]. Indeed, ribosome 
biogenesis and protein translation are inter-linked to determine cell fate. Ribosome 
biogenesis requires the synthesis and the assembly of several ribosomal proteins 
(RPL and RPS) [van Riggelen,J et.al., 2010], which are synthesised in the cytoplasm, 
then imported into the nucleus and assembled into small and large ribosomal units. 
So far, few of them have been reported as increased in human cancers while some 
are considered targets of c-Myc. In the present study, the microarray analysis (see 
Table 5) identified most of the genes encoding for ribosome proteins to be up-
regulated. In agreement with the processing of rRNA precursors for ribosomal 
assembly, as well as transport of mature ribosomal units, nucleophosmin (Table 6) 
and nucleolin (only at the mRNA level) were up-regulated.  
Translational research into human HCC 
In general, candidate biomarkers for malignancy should be accessible in bio fluids, 
such as blood and urine, for non-invasive diagnosis. As discussed earlier [Ritorto,MS 
et.al., 2008] the zooming of 2-D gels allowed better resolution of spots thereby 
avoiding co-migration of proteins. Thus, high molecular weight proteins are well 
resolved by trains of spots and permitted identification of phosphatidylinositol-glycan-
specific phospholipase D, polymeric immunoglobulin receptor, some isoforms of 
major urinary protein as well as hemopexin to be statistically significantly regulated. 
Unlike with gels at pH 3-10, good sequence coverage, i.e., up to 77% was obtained 
from in-gel digest at pH 4-7 that also permitted in-depth tandem MS analysis (Table 
2). Overall, 17 highly regulated serum proteins were identified. A notable finding was 
the identification of the secretory component of the polymeric immunoglobulin 
receptor (SC-PIGR), as well as the up-regulation of phosphatidylinositol 
phospholipase D (PHLD) and the down-regulation of afamin (AFM) in serum of 
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human HCC. Specifically, the secretory component of PIGR is the extracellular 
cleaved part of this receptor and known to be responsible for the transcytosis of pIgA 
to achieve mucosal immunity. In liver this protein is secreted at the apical surface of 
the polarized hepatocytes toward the bile ducts and it has been reported that PIGR 
plays a role in viral liver disease possibly facilitating infection of hepatocytes by HAV 
[Dotauer,A et.al., 2005]. Regulation of SC-PIGR is a novel finding which brings to 
hypothesize that this protein may likewise facilitate viral infection of other DNA and 
RNA viruses. 
Furthermore, the PHLD (known also as GPI-PLD) is an important enzyme for 
modifications of GPI-anchored proteins of the plasma membrane. Its role in liver 
cancer remains enigmatic [Jian-Hua,T et.al., 2009, Rhode,H et.al., 1999] but may 
serve as biomarker candidate as discussed for glypican-3 and CEA, which are GPI-
anchored proteins as well and are the subject of a separated report (Ritorto et al. in 
preparation).   
The similarity in regulation of plasma retinol binding protein 4 (RET4) and 
transthyretin (TTHY) in sera and liver tissue extracts attracted our attention. Notably, 
retinol-binding protein is the retinol (vitamin A) specific carrier, which circulates in 
blood as a 1:1 complex with the homotetrameric protein transthyretin (TTHY). Both 
RET4 and TTHY are synthesized and secreted by the hepatocytes. The binding with 
TTHY increases the molecular weight of RET4 and thus prevents its glomerular 
filtration and catabolism in the kidney. Importantly, dysfunctions of the liver and 
kidneys are known to influence RET4 homeostasis [Wu,HY et.al., 2008]. 
The retinol-binding protein has already been associated with ovarian and lung cancer 
[Stephensen,CB et.al., 2000, Um,SJ et.al., 2001]. Likewise, proteomic studies 
conducted in our laboratory had shown earlier increased expression of RET4 in 
serum of SPC-myc transgenic mice that develop lung cancer [Chatterji,B et.al., 2009] 
but not in SPC/c-Raf transgenic mice [Chatterji,B et.al., 2007], which developed lung 
cancer as well. In an EGF-transgenic mouse model of liver cancer [Gazzana,G et.al., 
2008], RET4 was not regulated therefore suggesting this protein to be a good 
diagnostic marker for c-Myc associated carcinogenesis. Other groups had shown that 
over-expression of N-myc in a neuroblastoma cell line with no endogenous N-myc 
expression caused a marked reduction in retinoid-induced growth inhibition 
[Goodman,LA et.al., 1997]. 
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Diabetes appeared to enhance c-myc expression (ref) and, indeed, up-regulation of 
RET4 only in HCC patients with diabetes and alcoholic steatosis was observed 
(Chart 2). 
 
 
 
 
 
Chart 2: Western immunoblotting of sera from a cohort of 31 patients. The RET4 was up-regulated only in cases 
of alcoholic steatosis (C2) and diabetes mellitus type II (DDMII) (circled parts). The α-tubulin was used as loading 
control, whilst HepG2 cell extracts as positive control (+)  
 
Taken collectively, RET4 should be considered as a biomarker of c-Myc induced 
HCC. Further evidence stems from our genomic studies where significant down-
regulation of ATRA reductase, the enzyme involved in the metabolism of retinol was 
observed (data not shown). Co-regulation of transthyretin (transports thyroxine and 
retinol also called pre-albumin, due its chromatography behaviour) is another 
important finding since it forms a complex with RET4 to prevent RET4 glomerular 
filtration. High expression of these proteins in mouse and human liver tissue (Table 
4) provided strong evidence for its value in disease diagnostics and appears to be 
particularly regulated in patients diagnosed with HCC and insulin resistance. 
A further disease regulated proteins are major urinary proteins (MUPs). Notably, 
MUPs are predominantly secreted from the liver. Structurally, they belong to the 
lipocalin family, which carries small hydrophobic ligands such as pheromones. As of 
today, the physiological functions of MUPs remain poorly understood. However, this 
study is the first report on their regulation in human beings, albeit at different levels 
when individual MUPs are composed. Specifically, there is evidence for MUP-1 to be 
an important player in regulating energy expenditure and metabolism in mice 
[Zhou,YJ et.al., 2009]. At the molecular level, MUP-1-mediated improvement in 
metabolism was accompanied by increased expression of genes involved in 
mitochondrial biogenesis, elevated mitochondrial oxidative capacity, and decreased 
triglyceride accumulation. Consequently, MUP-1 deficiency contributes to metabolic 
dysregulation in obese/diabetic mice. In c-Myc transgenic mice, MUP gene and 
protein expression was significantly repressed in both serum and liver (Table 6). 
Healthy individuals HCC patients 
+ 
α-tubulin 
Retinol binding protein 20 
55 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
C2 
 
DDMII 
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Results on human liver tissues showed, however, strong cytoplasmatic and nuclear 
up-regulation of MUP in HCC patients (Figure 29), therefore demonstrating species 
dependent regulation. 
Significance of the present study  
Several proteins identified in the present study are novel and have not been 
associated with HCC as yet. This includes an up-regulation of galactokinase (GALK1) 
which catalyzes the phosphorylation of the galactose to galactose 1-P. It is known 
that galactose 1-P is the precursor of UDP-galactose, a nucleotide sugar important in 
activation of purigenic receptors. UDP-glucose plays an important role in 
glycosylation reactions. Moreover, the UDP-sugars are high-donor substrates in 
biosynthetic reactions, which are released from cells for signalling [Viola,M et.al., 
2008]. The question remains whether GALK1 induces production of UDP-galactose. 
Note in this study regulation of any of the urydiltransferase enzyme was detected but 
it may be an index of galactosemia, i.e. the inability to use galactose for energy 
production, to possible impact HCC disease progression. 
A further example is the down-regulation of the indolethylamine N-methyltransferase 
(TEMT) which catalyzes the N-methylation of tryptamine and structurally related 
compounds. This protein is more than 2-fold down-regulated in the genomic and 
proteomic studies and may result in aberrant methylation of regulatory molecules 
frequently observed in malignancies.  
Likewise, the present study identified phosphatidylethanolamine-binding protein 1 
(PEBP1 or RKIP, due to its inhibition role in Raf/MEK/ERK cascade) as strongly up-
regulated in HCC bearing mice. Hepatocellular carcinoma cell lines and HCC liver 
tissue showed decreased RKIP expression as compared to primary human 
hepatocytes or adjacent peritumoral tissues. Low RKIP expression was correlated 
with increased ERK activation and modulation of RKIP expression to antagonize 
MAPK signaling in vitro [Yeung,K et.al., 2000]. Note, Pebp  is considered to be a Myc 
target [Kuystermans,D et.al., 2010] but in this study only a slight up-regulation of the 
Pebp1 gene (T/C=1.55, p=0.06) was recorded. Thus, its regulation appears to be 
post-translational. 
The strong point of our study is the confirmation of regulated proteins identified in a c-
Myc transgenic mouse model into human HCC. Indeed, translational research of 
specific proteins in HCC patients highly helps to overcome the variability in human 
samples and focusing on specific targets in liver cancer. 
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As well known, several concomitant diseases or alterations are correlated to cancer 
development in humans. In this study, HCC patients were divided in different groups, 
related to different concomitant diseases (such as diabetes, alcoholic steatohepatitis, 
chronic viral infections).  
For instance, the regulation of secretory component of the polymeric immunoglobulin 
receptor (SC-PIGR) could be trace back to specifically chronic Hepatitis C/ HCC 
patients; whilst the serum GPI-PLD was reported over-expressed mostly in HCC 
patients with concomitant non-alcoholic steatohepatitis (NASH). On the other hand, 
the expression of retinol binding protein and the transthyretin was correlated to 
diabetes and alcoholic steatohepatitis in human HCC. Moreover, an opposite 
regulation of hemopexin in either serum or tissue was observed in our transgenic 
mice and confirmed in human HCC by Western blot (WB) and immunohistochemistry 
(IHC), respectively. 
Comparison of genomic and proteomic studies of gene products in c-Myc transgenic 
mice, revealed that regulation of candidate biomarkers in cancer may often occur at a 
post-transcriptional level. For example, the GPI-PLD and the SC-PIGR were not 
statistically regulated at the gene level and an approach based only on genomic 
study would have left those proteins out of human validations as candidate 
biomarkers for HCC. Serum proteomics has the potential to give direct answer for 
possible candidate biomarkers to screen in bio fluids, avoiding highly invasive 
approaches, such as biopsy. 
 
Perspectives 
 
Over the last two decades significant progress has been made in an understanding of 
c-myc function in normal and cancer cells. In the present study a c-Myc protein map 
was constructed suitable for diagnostic and possible therapeutic intervention 
strategies.Furthermore, disease associated regulation of some proteins in human 
serum and tissue was achieved therefore validating findings from a disease mouse 
model in human HCC. More than 29% of identified proteins had already been 
reported as c-Myc targets. The newly identified proteins enable a better 
understanding of c-Myc in HCC and function in diverse biological processes 
compatible with the versatile activity of c-Myc. 
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Part 3: 
 
 -  Investigate the role of GPI-phospholipase D in liver cancer 
 
This part of the doctoral work is also included in an article in preparation: 
 
 
 
 
 
 
Background 
 
One of the candidate biomarker identified by us in the c-Myc mouse model of HCC was the GPI-
specific phospholipase D (GPI-PLD). Notably, glycosylphosphatidylinositol-specific phospholipase D 
(Gpld1) codes for an 815-amino acid protein (GPI-PLD) that is widely expressed in tissue and human 
serum [Chalasani,N et.al., 2006]. Indeed, the liver is the main source of serum GPI-PLD [Rhode,H 
et.al., 2000]. This protein differs, however, when expressed in tissue or serum and several putative 
inhibitors of serum activity have been reported [Low,MG et.al., 1993, Rhode,H et.al., 2000]. 
Furthermore, high expression of serum GPI-PLD has been attributed to disorders of lipid metabolism 
and atherosclerosis [Deeg,MA et.al., 2001a], as well as insulin resistance and NASH [Chalasani,N 
et.al., 2006]. Changes in mRNA expression of GPI-PLD has also been reported for different human 
cancers [Foster,DA, 2006, Hui,L et.al., 2005, Zheng,Y et.al., 2006] including HCC [Jian-Hua,T et.al., 
2009], but an evaluation of GPI-PLD activity in serum of c-Myc transgenic mice and an evaluation of c-
Myc´s role in the regulation of the GPI-anchored proteins (GPI-APs) is still lacking behind, even though 
a possible link between estrogens and phospholipase D1 (PLD1) was reported to be dependent on c-
Myc in MCF-7 breast cancer cell line [Rodrik,V et.al., 2005]. While c-Myc´s role in survival signalling is 
well established [Joseph,T et.al., 2002, Rodrik,V et.al., 2005, Shi,M et.al., 2007], the role of GPI-PLD 
in c-Myc induced carcinogenesis is less clear and possible confounded by additional factors, such as 
NASH, diabetes mellitus type II (DDMII), alcohol abuse (C2) or chronic viral infection (HCV/HBV) as 
observed in the present study. Indeed, activity of serum GPI-PLD was clearly linked to the complexity 
of disease and was most pronounced in patients diagnosed with NASH. While the c-Myc transgenic 
mouse model enabled in vivo mechanistic studies, cultures of human hepatocytes under conditions of 
NASH were employed to investigate GPI-PLD activity, as well as transcriptional responses of other 
GPI-APs. A comparison of data from the transgenic mouse model and human hepatocytes as well as 
activity measurements of GPI-PLD provide evidence for GPI-PLD to stabilize c-Myc protein and to 
“Induction of the GPI-specific phospholipase D signalling in a c-Myc 
transgenic mouse model of hepatocellular carcinoma” 
 
Maria Stella Ritorto, Heidrun Rhode and Jürgen Borlak 
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sustain c-Myc activity. Specifically, repression of the serine/threonine phosphatase 2A 
(2AAA_MOUSE) was observed. This phosphatase dephosphorylates the c-Myc protein which is then 
dressed up by the ubiquitination system for its degradation by the ubiquitin-proteasome pathway and it 
is known to be inhibited by PLD. Evidence is therefore presented for the GPI-PLD to stabilize c-Myc 
protein and activity. Furthermore, certain lipoproteins, such as ApoA1, ApoE and the paraoxonase-1 
(PON1) were significantly regulated in sera of transgenic mice. Notably, ApoE and PON1 were 
specifically up-regulated in HCC/NASH patients (Ritorto et al, submitted) and are known to stabilize 
activity of GPI-PLD.  
Taken collectively, this study reported a novel role of GPI-PLD in HCC and the importance of this 
phospholipase in the regulation of c-Myc mRNA and protein expression of serum GPI-PLD in c-Myc 
transgenic mice and HCC patients. 
            
Figure 31: Western blot for the GPI-PLD expression in sera from HCC patients with different concomitant disease 
(C2: alcoholic steatohepatitis; DDMII (D): diabetes mellitus type II; viral: HCV/HBV chronic infections; NASH: non-
alcoholic steatohepatitis). Sera from patients with NASH but not HCC were also analysed. LC: loading control. 
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mRNA and protein expression of serum GPI-PLD in c-Myc transgenic mice and 
HCC patients 
 
By Western immunoblotting expression of GPI-PLD was measured in liver and serum 
of n=9 mice at the age of 6 and 12 months and in n=52 patient sera. Notably, this 
patient cohort consisted of HCC patients diagnosed with either NASH (n=13), 
diabetes mellitus type II (DDMII, n=10), ethyl-toxic steatohepatitis (C2, n=16) and 
chronic viral liver disease (HCV/HBV, n=13). Additionally, expression of GPI-PLD 
was measured in NASH patient sera without liver cancer (n=4) and compared to 
n=10 healthy controls. As shown in Figure 1A the expression of serum GPI-PLD 
differed amongst patients and depended on the disease, with GPI-PLD expression 
being high in NASH (92%) and C2 + DDMII (86%) patients but low in chronic viral 
liver disease. Moreover, in c-Myc transgenic mice expression of serum GPI-PLD 
increased with time being 5-fold up-regulated, when compared with healthy non-
transgenic controls (Figure 31). 
 
In contrast, Gpld1 gene expression was significantly reduced in liver tissue of 
transgenic mice and human hepatocyte cultures under conditions of NASH (Table 7). 
The Gpld1 as well as Pld1 itself were slightly reduced in both HCC mice and cultures 
of human hepatocytes, being statistically significant (p=0.012) only for Pld1 in 12 
months old mice, while Gpld1 was significantly reduced (p=0.034) in cultures of 
human hepatocytes (Table 7). 
 
 
 
GPI-PLD enzyme activity 
 
GPI-PLD is a secreted mammalian enzyme that specifically cleaves GPI-anchored 
proteins (Figure 32). In addition, the enzyme has been shown to cleave GPI anchor 
intermediates in cell lysates. 
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Figure 32: Cleavage site for the phospholipases. The GPI-PLD cleaves exactly the inositol-P, releasing 
specifically the phosphatidic acid (PA). 
 
Serum GPI-PLD cleaves the GPIs (free GPIs or GPI-anchored proteins) in a specific 
manner, producing phosphatidic acid (PA). PA is a critical component of mTOR 
signalling and mitogenic stimulation of mammalian cells leads to a phospholipase D-
dependent accumulation of cellular PA, which is required for activation of mTOR 
downstream effectors [Fang,YM et.al., 2001]. Indeed, PA directly interacts with 
mTOR that is targeted by rapamycin, and this interaction is positively correlated with 
mTOR's ability to activate downstream effectors. The involvement of PA in mTOR 
signaling reveals an important function of this lipid in signal transduction and protein 
synthesis, as well as a direct link between mTOR and mitogens. Moreover, LPA, a 
metabolite of PA, stimulates tumor angiogenesis through activation of the c-Myc and 
Sp-1 transcription factors [Song,YD et.al., 2009]. 
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Figure 33: Measurement of GPI-PLD activity (=release of alkaline phosphatase from substrate) in mouse sera  
(A) and in liver tissue (B) of HCC mice and human, respectively. 
 
 
 
The phosphatidic acid phosphatase 2A (PPAP2A) is an enzyme that catalyzes the 
conversion of phosphatidic acid (PA) to diacylglycerol (DG). Importantly, in the 
present study the Ppap2a gene expression was repressed in HCC mice (T/C=0.24, 
p=0.0007) and NASH hepatocytes (T/C=0.5, p=0.098). 
 
c-Myc stabilization 
 
Stabilization of c-Myc is at least in part dependent upon mTOR activity and two 
upstream activators of mTOR that is PI3K and PLD. While in the present study no 
major regulation of Pld1 and Gpld1 coding genes was observed, other specific 
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checkpoints in Myc stabilization need to be considered that suppress ubiquitination 
and degradation of Myc by the proteasome through Gsk3β and PLD. In this regard, 
the serine/threonine phosphatase 2A (PP2A) plays a key role in the 
dephosphorylation of Myc at Ser62 and in the further dressing of c-Myc to enhance 
proteasomal degradation [Rodrik,V et.al., 2006]. PLD is the only enzyme, known to 
suppress PP2A. In our previous research on AAT-c-Myc transgenic mice, the 
serine/threonine protein phosphatase 2A was shown to be strongly down-regulated. 
Furthermore, Chalasani and co-workers demonstrated that over-expression of GPI-
PLD repressed expression of the orthologue gene in the human hepatoma cell line, 
HepG2. In the present study, down-regulation of this gene was also observed in 
cultures of primary human hepatocytes. 
The activity of PLD1 is regulated by several factors and include the small GTPases 
notably members of Rho- and Ral-family of GTPases. Specifically, the Rho-family 
GTPases play a critical role in the regulation of PLD activity in cell migration, as 
evidenced in stress fibres  [Deeg,MA et.al., 2001b] and modulation of its activity by 
RalA [Liscovitch,M et.al., 2000]. Recent research in the c-Myc transgenic model of 
liver cancer identified the Rho GDP-dissociation inhibitor 1 to be 3-fold up-regulated 
in HCC mice. A similar regulation of the GDP/GTP exchange and of RalA was 
observed at the gene expression level in HCC mice. However, RalA alone is not 
sufficient to activate PLD1 [Foster,DA et.al., 2003]. 
There is growing evidence for PLD to play essential role in survival signalling in 
cancer cells that carry mutations in Raf [Joseph,T et.al., 2002], Ras [Shi,M et.al., 
2007] or display hyperactivity of c-Myc [Rodrik,V et.al., 2005] due to oncogenic 
Raf/Ras signalling [Kerkhoff,E et.al., 1998] (Figure 33).   
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Figure 33: Interactions among Myc, Raf/Ras family (A) and PLD family (B). Data collected from GeneMANIA.   
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In the present study the Raf kinase inhibitor protein, Pebp1 (also termed RKIP) was 
significantly up-regulated. Notably, PLD overcomes cell cycle arrest induced by high 
intensity Raf signalling [Joseph,T et.al., 2002]. 
One of the most corroborate inhibitors of GPI-PLD is PA [Low,MG et.al., 1993]. 
Indeed, GPI-PLD isolated from plasma or serum is unable to release GPI-APs 
directly from the surface of intact mammalian cells, probably due to the presence of 
inhibitors, such as PA or LPA [Du,XH et.al., 2001]. However, inhibition of the protein 
phosphatase 1 (PP-1) has been specifically associated with PA in neurons 
[Plummer,G et.al., 2005]. The present work on HCC mice showed strongly up-
regulation of Ppp1r14b gene even at early stages of disease (Table 7). The 
Ppp1r14b is a gene, which codify for a strong inhibitor of PPP1CA (Pp-1c); on the 
other hand, phosphatidic acid is a very selective inhibitor of PP-1c. 
High [PA] leads to inhibition of GPI-phospholipase D. Down-regulation of Gpld1 in 
mouse liver tissues and human hepatocytes was indeed reported, but the activity of 
GPI-PLD was high in serum and very low in tissue. That brings to the suggestion that 
PA may concentrate in tissue after release in serum produced by serum GPI-PLD, 
might pass through a perturbed membrane (through possible membrane diffusion or 
perturbation) and act in the cell on the phosphatases blocking apoptosis [Plummer,G 
et.al., 2005] and leading to c-Myc stabilization directly. 
 
HDL particles and serum GPI-PLD 
 
HDL plays a key role in the cholesterol transport pathway and has become a 
therapeutic target in liver diseases [Jiang,JT et.al., 2006]. Importantly, GPI-PLD 
associates with ApoA-I (Lp[A-I]), ApoA-IV (Lp[A-I, A-II]) of the HDL particle but not 
with ApoC2, ApoC3 and ApoE [Deeg,MA et.al., 2001b]. Regulation of these 
lipoproteins in HCC and NASH has been reported [Chalasani,N et.al., 2006, Jian-
Hua,T et.al., 2009]. Specifically, GPI-PLD is mostly found in Lp[A-I]) particles 
[Deeg,MA et.al., 2001b]. Interestingly, paraoxonase interacts with Lp[A-I] as well and 
Apo A-I acts as a repository for Apo E that is required in the metabolism of 
chylomicrons and VLDL; in the study of Ooi et al [Ooi,K et.al., 2005] slow alpha HDL 
appeared during bile stagnation and eventually metastatic liver cancer, accompanied 
by increased ApoE levels.   
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In the present study, Gpld1 was not regulated at the gene level, while our recent 
research identified ApoE protein expression to be strongly up-regulated in sera of 
HCC mice as well as human HCC (Ritorto et al, submitted). Moreover, increased 
expression of serum paraoxonase 1 was observed in c-Myc transgenic mice with 
advanced disease and in HCC/NASH patients (Ritorto et al, submitted). 
Thus, the recently identified regulation of ApoA-I and ApoA-II in HCC of c-Myc 
transgenic mice can now be linked to the activity of GPI-PLD and its survival 
signalling. ApoA-I participates in the reverse transport of cholesterol from tissues to 
the liver for excretion thereby promoting cholesterol efflux from tissues and by acting 
as a cofactor for the lecithin cholesterol acyltransferase (LCAT). At the gene level, 
LCAT was down-regulated in 2 months (1.5 fold, p=0.02), 6 months (1.6 fold, p=0.02) 
and 12 months (2 fold, p=0.0005) old c-Myc transgenic mice. Likewise, a similar 
down-regulation of LCAT (1.60 fold, p=0.1) was observed in cultures of human 
hepatocytes under conditions of NASH (Table 7).  
Altogether, this suggests a complex interplay of GPI-PLD and apolipoproteins in HCC 
and NASH with recent literature linking obesity, diabetes mellitus, NASH to risk for 
HCC based on the “first hit” theory postulated for progression of steatosis to NASH 
and cirrhosis, the irreversible step toward HCC. Indeed, the present study with 
cultures of human hepatocytes evidences regulation of genes observed by over-
expression of GPI-PLD [Chalasani,N et.al., 2006] that were similarly to findings of 
HCC in c-Myc transgenic mice. Reduced levels of serum (but not mRNA) GPI-PLD 
after statin therapy corroborates our results [Deeg,MA et.al., 2007].  
 
Perspectives 
 
This preliminary study on the function of GPI-PLD in liver cancer after c-Myc over-
expression suggests a pivotal role of this phosphatase in cancer.  
The [PA] in tissues seems the key in understanding the lacking connection between 
serum activity of GPI-PLD and liver dysfunction under over-expression of c-Myc. 
Moreover, it may help also in understanding the significance of high serum GPI-PLD 
in HCC/NASH, which leads to considered serum GPI-PLD as main strength in early 
detection of HCC and NASH. 
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Based on different experimental strategies, an improved method for the identification 
of proteins was developed and applied to the serum and the liver tissue of c-Myc 
transgenic model of HCC.  
A total of 28 novel disease regulated proteins were identified of which two were 
regulated in both “compartents” (namely, retinol binding protein 4 and transthyretin). 
Knowledge on these proteins helps to better define the role of c-Myc in liver cancer; 
indeed, some of them were validated for human HCC, carrying the hope for early 
detection of disease and improvement of disease management, under specific 
conditions. In fact, translational studies of the GPI-PLD expression and activity in 
sera from HCC mice into HCC patients showed specific regulation of this enzyme in 
HCC patients with concomitant non-alcoholic steatohepatitis (NASH), suggesting a 
role of c-Myc in HCC induced by NASH. 
 
 
 
 
 
 
 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            87
 
 
 
 
 
 
 
 
 
 
 
 
                                     
                                                      Font: Companionsoftware 
 
 
 
 
 
 
 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            88
 
 
 
 
 
 
 
 
                                                                                       Bibliography 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            89
 
Adhikary,S, Marinoni,F, Hock,A, Hulleman,E, Popov,N, Beier,R, Bernard,S, 
Quarto,M, Capra,M, Goettig,S, Kogel,U, Scheffner,M, Helin,K, & Eilers,M,"The 
ubiquitin ligase HectH9 regulates transcriptional activation by myc and is 
essential for tumor cell proliferation". Cell, 2005;123, 409-421. 
Aebersold,R & Mann,M,"Mass spectrometry-based proteomics". Nature, 2003;422, 
198-207. 
Alexandrescu,DT, McClure,R, Farzanmehr,H, & Dasanu,CA,"Secondary 
erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and 
sorafenib". Journal of Clinical Oncology, 2008;26, 4047-4048. 
Amati,B, Dalton,S, Brooks,MW, Littlewood,TD, Evan,GI, & Land,H,"Transcriptional 
Activation by the Human C-Myc Oncoprotein in Yeast Requires Interaction 
with Max". Nature, 1992;359, 423-426. 
Anderson,GR,"Genomic instability in cancer". Current Science, 2001;81, 501-507. 
Arango,D, Mariadason,JM, Wilson,AJ, Yang,W, Corner,GA, Nicholas,C, Aranes,MJ, 
& Augenlicht,LH,"c-Myc overexpression sensitises colon cancer cells to 
camptothecin-induced apoptosis". British Journal of Cancer, 2003;89, 1757-
1765. 
Arvanitis,C & Felsher,DW,"Conditionally MYC : insights from novel transgenic 
models". Cancer Letters, 2005;226, 95-99. 
Beckhaus,T, Corvey,C, Burre,J, Morciano,M, Zimmermann,H, Volknandt,W, & 
Karas,M,"Different approaches for the characterisation of the synaptic vesicle 
proteome; Comparison of 1 D and 2D PAGE followed by mass spectrometry 
(MALDI-TOF; NANO-LC ESI MS/MS)". Molecular & Cellular Proteomics, 
2005;4, S89-S89. 
Blackwood,EM & Eisenman,RN,"Max - A Helix-Loop-Helix Zipper Protein That Forms 
A Sequence-Specific Dna-Binding Complex with Myc". Science, 1991;251, 
1211-1217. 
Butler,SL, Dong,H, Cardona,D, Jia,M, Zheng,R, Zhu,H, Crawford,JM, & Liu,C,"The 
antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate 
synthetase 1". Laboratory Investigation, 2008;88, 78-88. 
Calvisi,DF, Conner,EA, Ladu,S, Lemmer,ER, Factor,VM, & 
Thorgeirsson,SS,"Activation of the canonical Wnt/beta-catenin pathway 
confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver 
cancer". Journal of Hepatology, 2005a;42, 842-849. 
Calvisi,DF & Thorgeirsson,SS,"Molecular mechanisms of hepatocarcinogenesis in 
transgenic mouse models of liver cancer". Toxicologic Pathology, 2005b;33, 
181-184. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            90
Castelli,A,"How many patients with HCC have normal des-gamma-carboxy 
prothrombin and alpha-fetoprotein levels?". Panminerva Medica, 2009;51, 
188-188. 
Chalasani,N, Vuppalanchi,R, Raikwar,NS, & Deeg,MA,"Glycosylphosphatidylinositol-
specific phospholipase D in nonalcoholic fatty liver disease: A preliminary 
study". Journal of Clinical Endocrinology & Metabolism, 2006;91, 2279-2285. 
Chan,KL, Guan,XY, & Oi-Lin,I,"High-throughput tissue microarray analysis of c-myc 
activation in chronic liver diseases and hepatocellular carcinoma". Human 
Pathology, 2004;35, 1324-1331. 
Chatterji,B & Borlak,J,"Serum proteomics of lung adenocarcinomas induced by 
targeted overexpression of c-raf in alveolar epithelium identifies candidate 
biomarkers". Proteomics, 2007;7, 3980-3991. 
Chatterji,B & Borlak,J,"A 2-DE MALDI-TOF study to identify disease regulated serum 
proteins in lung cancer of c-myc transgenic mice". Proteomics, 2009;9, 1044-
1056. 
Chen,R, Pan,S, Brentnall,TA, & Aebersold,R,"Proteomic profiling of pancreatic 
cancer for biomarker discovery". Molecular & Cellular Proteomics, 2005;4, 
523-533. 
Chen,X, Zhao,J, Guan,YH, Lu,S, Zuo,CT, Hua,FC, & Lin,XT,"Prognostic value of 2-
[F-18]fluoro-2-deoxy-D-glucose uptake as measured by PET scan in patients 
with non-small cell lung cancer". Molecular Medicine Reports, 2008;1, 889-
893. 
Chen,YY, Lin,SY, Yeh,YY, Hsiao,HH, Wu,CY, Chen,ST, & Wang,AHJ,"A modified 
protein precipitation procedure for efficient removal of albumin from serum". 
Electrophoresis, 2005;26, 2117-2127. 
Cho,WCS,"Contribution of oncoproteomics to cancer biomarker discovery". Molecular 
Cancer, 2007;6 
Chung,EJ, Sung,YK, Farooq,M, Kim,Y, Im,S, Tak,WY, Hwang,YJ, Kim,YI, Han,HS, 
Kim,JC, & Kim,MK,"Gene expression profile analysis in human hepatocellular 
carcinoma by cDNA microarray". Molecules and Cells, 2002;14, 382-387. 
Conner,EA, Lemmer,ER, Omori,M, Wirth,PJ, Factor,VM, & Thorgeirsson,SS,"Dual 
functions of E2F-1 in a transgenic mouse model of liver carcinogenesis". 
Oncogene, 2000;19, 5054-5062. 
Cravatt,BF, Simon,GM, & Yates,JR,"The biological impact of mass-spectrometry-
based proteomics". Nature, 2007;450, 991-1000. 
Dalemans,W, Perraud,F, Le Meur,M, Gerlinger,P, Courtney,M, & 
Pavirani,A,"Heterologous protein expression by transimmortalized 
differentiated liver cell lines derived from transgenic mice (hepatomas/alpha 1 
antitrypsin/ONC mouse)". Biologicals, 1990;18, 191-198. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            91
Dang,CV,"Rethinking the Warburg Effect with Myc Micromanaging Glutamine 
Metabolism". Cancer Research, 2010;70, 859-862. 
Dang,CV, Kim,JW, Gao,P, & Yustein,J,"Hypoxia and metabolism - Opinion - The 
interplay between MYC and HIF in cancer". Nature Reviews Cancer, 2008;8, 
51-56. 
Dang,CV & Lewis,BC,"Role of oncogenic transcription factor c-Myc in cell cycle 
regulation, apoptosis and metabolism". Journal of Biomedical Science, 1997;4, 
269-278. 
Dang,CV, Resar,LMS, Emison,E, Kim,S, Li,Q, Prescott,JE, Wonsey,D, & 
Zeller,K,"Function of the c-Myc oncogenic transcription factor". Experimental 
Cell Research, 1999a;253, 63-77. 
Dang,CV & Semenza,GL,"Oncogenic alterations of metabolism". Trends in 
Biochemical Sciences, 1999b;24, 68-72. 
Deeg,MA, Bierman,EL, & Cheung,MC,"GPI-specific phospholipase D associates with 
an apoA-I- and apoA-IV-containing complex". Journal of Lipid Research, 
2001a;42, 442-451. 
Deeg,MA, Bowen,RF, Williams,MD, Olson,LK, Kirk,EA, & LeBoeuf,RC,"Increased 
expression of GPI-specific phospholipase D in mouse models of type 1 
diabetes". American Journal of Physiology-Endocrinology and Metabolism, 
2001b;281, E147-E154. 
Deeg,MA, Raikwar,NS, Johnson,C, & Williams,CD,"Statin therapy reduces serum 
levels of glycosylphosphatidylinositol-specific phospholipase D". Translational 
Research, 2007;150, 153-157. 
Dellafavera,R, Gelmann,EP, Martinotti,S, Franchini,G, Papas,TS, Gallo,RC, & 
Wongstaal,F,"Cloning and Characterization of Different Human Sequences 
Related to the Onc Gene (V-Myc) of Avian Myelocytomatosis Virus (Mc29)". 
Proceedings of the National Academy of Sciences of the United States of 
America-Biological Sciences, 1982;79, 6497-6501. 
Domon,B & Aebersold,R,"Review - Mass spectrometry and protein analysis". 
Science, 2006;312, 212-217. 
Dotauer,A, Brenner,M, Gebhardt,U, & Vallbracht,A,"IgA-coated particles of Hepatitis 
A virus are translocalized antivectorially from the apical to the basolateral site 
of polarized epithelial cells via the polymeric immunoglobulin receptor". 
Journal of General Virology, 2005;86, 2747-2751. 
Du,XH & Low,MG,"Down-regulation of glycosylphosphatidylinositol-specific 
phospholipase D induced by lipopolysaccharide and oxidative stress in the 
murine monocyte-macrophage cell line RAW 264.7". Infection and Immunity, 
2001;69, 3214-3223. 
Duan,XB, Yarmush,D, Berthiaume,F, Jayaraman,A, & 
Yarmush,ML,"Immunodepletion of albumin for two-dimensional gel detection 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            92
of new mouse acute-phase protein and other plasma proteins". Proteomics, 
2005;5, 3991-4000. 
Duan,XB, Yarmush,DM, Berthiaume,F, Jayaraman,A, & Yarmush,ML,"A mouse 
serum two-dimensional gel map: Application to profiling burn injury and 
infection". Electrophoresis, 2004;25, 3055-3065. 
Dubois,N, Bennoun,M, Allemand,I, Molina,T, Grimber,G, Daudetmonsac,M, 
Abelanet,R, & Briand,P,"Time-Course Development of Differentiated 
Hepatocarcinoma and Lung Metastasis in Transgenic Mice". Journal of 
Hepatology, 1991;13, 227-239. 
Durazo,FA, Blatt,LM, Corey,WG, Lin,JH, Han,S, Saab,S, Busuttil,RW, & 
Tong,MJ,"Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in 
patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma". 
Journal of Gastroenterology and Hepatology, 2008;23, 1541-1548. 
Edery,P, Gerard,B, Chretien,D, Rotig,A, Cerrone,R, Rabier,D, Rambaud,C, Fabre,M, 
Saudubray,JM, Munnich,A, & Rustin,P,"Liver Cytochrome-C-Oxidase 
Deficiency in A Case of Neonatal-Onset Hepatic-Failure". European Journal of 
Pediatrics, 1994;153, 190-194. 
Facchini,LM & Penn,LZ,"The molecular role of Myc in growth and transformation: 
recent discoveries lead to new insights". Faseb Journal, 1998;12, 633-651. 
Fang,YM, Vilella-Bach,M, Bachmann,R, Flanigan,A, & Chen,J,"Phosphatidic acid-
mediated mitogenic activation of mTOR signaling". Science, 2001;294, 1942-
1945. 
Felsher,DW & Bishop,JM,"Reversible tumorigenesis by MYC in hematopoietic 
lineages". Molecular Cell, 1999;4, 199-207. 
Foster,DA,"Targeting phospholipase D-mediated survival signals in cancer". Current 
Signal Transduction Therapy, 2006;1, 295-303. 
Foster,DA & Xu,LZ,"Phospholipase D in cell proliferation and cancer". Molecular 
Cancer Research, 2003;1, 789-800. 
Garaguso,I & Borlak,J,"Matrix layer sample preparation: An improved MALDI-MS 
peptide analysis method for proteomic studies". Proteomics, 2008;8, 2583-
2595. 
Gartel,AL & Shchors,K,"Mechanisms of c-myc-mediated transcriptional repression of 
growth arrest genes". Experimental Cell Research, 2003;283, 17-21. 
Gazzana,G & Borlak,J,"Mapping of the serum proteome of hepatocellular carcinoma 
induced by targeted overexpression of epidermal growth factor to liver cells of 
transgenic mice". J Proteome Res, 2008;7, 928-937. 
Ghose,A, Fleming,J, & Harrison,PR,"Selenium and signal transduction: Roads to cell 
death and anti-tumour activity". Biofactors, 2001;14, 127-133. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            93
Giannelli,G & Antonaci,S,"New frontiers in biomarkers for hepatocellular carcinoma". 
Digestive and Liver Disease, 2006;38, 854-859. 
Goodman,LA, Liu,BCS, Thiele,CJ, Schmidt,ML, Cohn,SL, Yamashiro,JM, Pai,DSM, 
Ikegaki,N, & Wada,RK,"Modulation of N-myc expression alters the 
invasiveness of neuroblastoma". Clinical & Experimental Metastasis, 1997;15, 
130-139. 
Gorg,A, Weiss,W, & Dunn,MJ,"Current two-dimensional electrophoresis technology 
for proteomics". Proteomics, 2004;4, 3665-3685. 
Gray,J, Chattopadhyay,D, Beale,GS, Patman,GL, Miele,L, King,BP, Stewart,S, 
Hudson,M, Day,CP, Manas,DM, & Reeves,HL,"A proteomic strategy to identify 
novel serum biomarkers for liver cirrhosis and hepatocellular cancer in 
individuals with fatty liver disease". Bmc Cancer, 2009;9 
Greenwood,E,"The many faces of MYC". Nature Reviews Cancer, 2002;2, 485-485. 
Guo,QM, Malek,RL, Kim,S, Chiao,C, He,M, Ruffy,M, Sanka,K, Lee,NH, Dang,CV, & 
Liu,ET,"Identification of c-Myc responsive genes using rat cDNA microarray". 
Cancer Research, 2000;60, 5922-5928. 
Haggerty,TJ, Zeller,KI, Osthus,RC, Wonsey,DR, & Dang,CV,"A strategy for 
identifying transcription factor binding sites reveals two classes of genornic c-
Myc target sites". Proceedings of the National Academy of Sciences of the 
United States of America, 2003;100, 5313-5318. 
Hao,LY, Giasson,BI, & Bonini,NM,"DJ-1 is critical for mitochondrial function and 
rescues PINK1 loss of function". Proceedings of the National Academy of 
Sciences of the United States of America, 2010;107, 9747-9752. 
Harris,MN, Ozpolat,B, Abdi,F, Gu,S, Legler,A, Mawuenyega,KG, Tirado-Gomez,M, 
Lopez-Berestein,G, & Chen,X,"Comparative proteomic analysis of all-trans-
retinoic acid treatment reveals systematic posttranscriptional control 
mechanisms in acute promyelocytic leukemia". Blood, 2004;104, 1314-1323. 
Hatzivassiliou,G, Zhao,FP, Bauer,DE, Andreadis,C, Shaw,AN, Dhanak,D, 
Hingorani,SR, Tuveson,DA, & Thompson,CB,"ATP citrate lyase inhibition can 
suppress tumor cell growth". Cancer Cell, 2005;8, 311-321. 
Huang,HL, Stasyk,T, Morandell,S, Dieplinger,H, Falkensammer,G, Griesmacher,A, 
Mogg,M, Schreiber,M, Feuerstein,I, Huck,CW, Stecher,G, Bonn,GK, & 
Huber,LA,"Biomarker discovery in breast cancer serum using 2-D differential 
gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical 
assays". Electrophoresis, 2006;27, 1641-1650. 
Hui,L, Rodrik,V, Pielak,RM, Knirr,S, Zheng,Y, & Foster,DA,"mTOR-dependent 
suppression of protein phosphatase 2A is critical for phospholipase D survival 
signals in human breast cancer cells". Journal of Biological Chemistry, 
2005;280, 35829-35835. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            94
Hui,LJ, Zatloukal,K, Scheuch,H, Stepniak,E, & Wagner,EF,"Proliferation of human 
HCC cells and chemically induced mouse liver cancers requires JNK1-
dependent p21 downregulation". Journal of Clinical Investigation, 2008;118, 
3943-3953. 
Irmak,MB, Ince,G, Ozturk,M, & Cetin-Atalay,R,"Acquired tolerance of hepatocellular 
carcinoma cells to selenium deficiency: A selective survival mechanism?". 
Cancer Research, 2003;63, 6707-6715. 
Jemal,A, Siegel,R, Ward,E, Hao,Y, Xu,J, Murray,T, & Thun,MJ,"Cancer statistics, 
2008". CA Cancer J Clin, 2008;58, 71-96. 
Jenssen,TK, Laegreid,A, Komorowski,J, & Hovig,E,"A literature network of human 
genes for high-throughput analysis of gene expression". Nature Genetics, 
2001;28, 21-+. 
Jhappan,C, Stahle,C, Harkins,RN, Fausto,N, Smith,GH, & Merlino,GT,"Tgf-Alpha 
Overexpression in Transgenic Mice Induces Liver Neoplasia and Abnormal-
Development of the Mammary-Gland and Pancreas". Cell, 1990;61, 1137-
1146. 
Jian-Hua,T, Wang-Jiao,H, He,H, Chao-Chao,T, Qiong,D, Kai-Jia,W, Xian-Yu,Y, & Xu-
Jin,Z,"Important roles of glycosylphosphatidylinositol (GPI)-specific 
phospholipase D and some GPI-anchored proteins in the pathogenesis of 
hepatocellular carcinoma". Clinical Biochemistry, 2009;42, 400-407. 
Jiang,JT, Nilsson-Ehle,P, & Xu,N,"Influence of liver cancer on lipid and lipoprotein 
metabolism". Lipids in Health and Disease, 2006;5 
Joseph,P, Lei,YX, Whong,WZ, & Ong,TM,"Oncogenic potential of mouse translation 
elongation factor-15, a novel cadmium-responsive proto-oncogene". Journal of 
Biological Chemistry, 2002;277, 6131-6136. 
Joseph,T, Bryant,A, Frankel,P, Wooden,R, Kerkhoff,E, Rapp,UR, & 
Foster,DA,"Phospholipase D overcomes cell cycle arrest induced by high-
intensity Raf signaling". Oncogene, 2002;21, 3651-3658. 
Juan,HF, Chen,JH, Hsu,WT, Huang,SC, Chen,ST, Lin,JYC, Chang,YW, Chiang,CY, 
Wen,LL, Chan,DC, Liu,YC, & Chen,YJ,"Identification of tumor-associated 
plasma biomarkers using proteomic techniques: From mouse to human". 
Proteomics, 2004;4, 2766-2775. 
Kerkhoff,E, Houben,R, Loffler,S, Troppmair,J, & Rapp,UR,"Regulation of c-myc 
expression by Ras/Raf signalling". Oncogene, 1998;16, 211-216. 
Kleine-Kohlbrecher,D, Adhikary,S, & Eilers,M,"Mechanisms of transcriptional 
repression by Myc". Myc/Max/Mad Transcription Factor Network, 2006;302, 
51-62. 
Krutchinsky,AN & Chait,BT,"On the nature of the chemical noise in MALDI mass 
spectra". Journal of the American Society for Mass Spectrometry, 2002;13, 
129-134. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            95
Kuick,R, Misek,DE, Monsma,DJD, Webb,CP, Wang,H, Peterson,KJ, Pisano,M, 
Omenn,GS, & Hanash,SM,"Discovery of cancer biomarkers through the use of 
mouse models". Cancer Letters, 2007;249, 40-48. 
Kuramitsu,Y, Harada,T, Takashima,M, Yokoyama,Y, Hidaka,I, Iizuka,N, Toda,T, 
Fujimoto,M, Zhang,XL, Sakaida,I, Okita,K, Oka,M, & Nakamura,K,"Increased 
expression and phosphorylation of liver glutamine synthetase in well-
differentiated hepatocellular carcinoma tissues from patients infected with 
hepatitis C virus". Electrophoresis, 2006;27, 1651-1658. 
Kuystermans,D, Dunn,MJ, & Al Rubeai,M,"A proteomic study of cMyc improvement 
of CHO culture". Bmc Biotechnology, 2010;10 
Lai,KKY, Kolippakkam,D, & Beretta,L,"Comprehensive and quantitative proteome 
profiling of the mouse liver and plasma". Hepatology, 2008;47, 1043-1051. 
Land,H, Chen,AC, Morgenstern,JP, Parada,LF, & Weinberg,RA,"Behavior of Myc 
and Ras Oncogenes in Transformation of Rat Embryo Fibroblasts". Molecular 
and Cellular Biology, 1986;6, 1917-1925. 
Larson,SM,"Positron emission tomography-based molecular imaging in human 
cancer: Exploring the link between hypoxia and accelerated glucose 
metabolism". Clinical Cancer Research, 2004;10, 2203-2204. 
Larsson,LG & Henriksson,MA,"The Yin and Yang functions of the Myc oncoprotein in 
cancer development and as targets for therapy". Experimental Cell Research, 
2010;316, 1429-1437. 
Laugesen,S & Roepstorff,P,"Combination of two matrices results in improved 
performance of MALDI MS for peptide mass mapping and protein analysis". 
Journal of the American Society for Mass Spectrometry, 2003;14, 992-1002. 
Lee,GH, Merlino,G, & Fausto,N,"Development of Liver-Tumors in Transforming 
Growth Factor-Alpha Transgenic Mice". Cancer Research, 1992;52, 5162-
5170. 
Li,C, Hong,Y, Tan,YX, Zhou,H, Ai,JH, Li,SJ, Zhang,L, Xia,QC, Wu,JR, Wang,HY, & 
Zeng,R,"Accurate qualitative and quantitative proteomic analysis of clinical 
hepatocellular carcinoma using laser capture microdissection coupled with 
isotope-coded affinity tag and two-dimensional liquid chromatography mass 
spectrometry". Molecular & Cellular Proteomics, 2004;3, 399-409. 
Li,LH, Nerlov,C, Prendergast,G, Macgregor,D, & Ziff,EB,"C-Myc Represses 
Transcription In-Vivo by A Novel Mechanism Dependent on the Initiator 
Element and Myc Box-Ii". Embo Journal, 1994;13, 4070-4079. 
Lim,SO, Park,SJ, Kim,W, Park,SG, Kim,HJ, Kim,YI, Sohn,TS, Noh,JH, & 
Jung,G,"Proteome analysis of hepatocellular carcinoma". Biochemical and 
Biophysical Research Communications, 2002;291, 1031-1037. 
Liscovitch,M, Czarny,M, Fiucci,G, & Tang,XQ,"Phospholipase D: molecular and cell 
biology of a novel gene family". Biochemical Journal, 2000;345, 401-415. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            96
Liu,Q, Basu,S, Qiu,Y, Tang,F, & Dong,F,"A role of Miz-1 in Gfi-1-mediated 
transcriptional repression of CDKN1A". Oncogene, 2010;29, 2843-2852. 
Low,MG & Huang,KS,"Phosphatidic-Acid, Lysophosphatidic Acid, and Lipid-A Are 
Inhibitors of Glycosylphosphatidylinositol-Specific Phospholipase-D - Specific-
Inhibition of A Phospholipase by Product Analogs". Journal of Biological 
Chemistry, 1993;268, 8480-8490. 
Luo,GH, Marginean,I, & Vertes,A,"Internal energy of ions generated by matrix-
assisted laser desorption/ionization". Analytical Chemistry, 2002;74, 6185-
6190. 
McMahon,SB, Wood,MA, & Cole,MD,"The essential cofactor TRRAP recruits the 
histone acetyltransferase hGCN5 to c-Myc". Molecular and Cellular Biology, 
2000;20, 556-562. 
Menssen,A & Hermeking,H,"Characterization of the c-MYC-regulated transcriptome 
by SAGE: Identification and analysis of c-MYC target genes". Proceedings of 
the National Academy of Sciences of the United States of America, 2002;99, 
6274-6279. 
Miyoshi,Y, Nakayama,S, Torikoshi,Y, Tanaka,S, Ishihara,H, Taguchi,T, Tamaki,Y, & 
Noguchi,S,"High expression of ubiquitin carboxy-terminal hydrolase-L1 and -
L3 mRNA predicts early recurrence in patients with invasive breast cancer". 
Cancer Science, 2006;97, 523-529. 
Mostafavi,S, Ray,D, Warde-Farley,D, Grouios,C, & Morris,Q,"GeneMANIA: a real-
time multiple association network integration algorithm for predicting gene 
function". Genome Biology, 2008;9 
Nalepa,G & Harper,JW,"Therapeutic anti-cancer targets upstream of the 
proteasome". Cancer Treatment Reviews, 2003;29, 49-57. 
Oike,Y, Ito,Y, Maekawa,H, Morisada,T, Kubota,Y, Akao,M, Urano,T, Yasunaga,K, & 
Suda,T,"Angiopoietin-related growth factor (AGF) promotes angiogenesis". 
Blood, 2004;103, 3760-3765. 
Ooi,K, Shiraki,K, Sakurai,Y, Morishita,Y, & Nobori,T,"Clinical significance of abnormal 
lipoprotein patterns in liver diseases". International Journal of Molecular 
Medicine, 2005;15, 655-660. 
Oskarsson,T & Trumpp,A,"The Myc trilogy: lord of RNA polymerases". Nature Cell 
Biology, 2005;7, 215-217. 
Padliya,ND & Wood,TD,"A strategy to improve peptide mass fingerprinting matches 
through the optimization of matrix-assisted laser desorption/ionization matrix 
selection and formulation". Proteomics, 2004;4, 466-473. 
Palmiter,RD, Brinster,RL, Hammer,RE, Trumbauer,ME, Rosenfeld,MG, Birnberg,NC, 
& Evans,RM,"Dramatic Growth of Mice That Develop from Eggs Micro-Injected 
with Metallothioneine-Growth Hormone Fusion Genes". Nature, 1982;300, 
611-615. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            97
Pan,S, Aebersold,R, Chen,R, Rush,J, Goodlett,DR, McIntosh,MW, Zhang,J, & 
Brentnall,TA,"Mass Spectrometry Based Targeted Protein Quantification: 
Methods and Applications". Journal of Proteome Research, 2009;8, 787-797. 
Pascale,RM, Simile,MM, Calvisi,DF, Frau,M, Muroni,MR, Seddaiu,MA, Daino,L, 
Muntoni,MD, De Miglio,MR, Thorgeirsson,SS, & Feo,F,"Role of HSP90, 
CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver 
carcinogenesis and human liver cancer". Hepatology, 2005;42, 1310-1319. 
Patel,JH & McMahon,SB,"Targeting of Miz-1 is essential for Myc-mediated 
apoptosis". Journal of Biological Chemistry, 2006;281, 3283-3289. 
Pelengaris,S & Khan,M,"The many faces of c-MYC". Archives of Biochemistry and 
Biophysics, 2003;416, 129-136. 
Penque,D,"Two-dimensional gel electrophoresis and mass spectrometry for 
biomarker discovery". Proteomics Clinical Applications, 2009;3, 155-172. 
Pietenpol,JA, Holt,JT, Stein,RW, & Moses,HL,"Transforming Growth Factor-Beta-1 
Suppression of C-Myc Gene-Transcription - Role in Inhibition of Keratinocyte 
Proliferation". Proceedings of the National Academy of Sciences of the United 
States of America, 1990;87, 3758-3762. 
Plummer,G, Perreault,KR, Holmes,CFB, & De Chaves,EIP,"Activation of 
serine/threonine protein phosphatase-1 is required for ceramide-induced 
survival of sympathetic neurons". Biochemical Journal, 2005;385, 685-693. 
Prendergast,GC & Ziff,EB,"Methylation-Sensitive Sequence-Specific Dna-Binding by 
the C-Myc Basic Region". Science, 1991;251, 186-189. 
Ramana,CV, Grammatikakis,N, Chernov,M, Nguyen,H, Goh,KC, Williams,BRG, & 
Stark,GR,"Regulation of c-myc expression by IFN-gamma through Stat1-
dependent and -independent pathways". Embo Journal, 2000;19, 263-272. 
Reymann,S & Borlak,J,"Transcription profiling of lung adenocarcinomas of c-myc-
transgenic mice: Identification of the c-myc regulatory gene network". Bmc 
Systems Biology, 2008;2 
Rhoads,JM, Argenzio,RA, Chen,WN, Rippe,RA, Westwick,JK, Cox,AD, 
Berschneider,HM, & Brenner,DA,"L-glutamine stimulates intestinal cell 
proliferation and activates mitogen-activated protein kinases". American 
Journal of Physiology-Gastrointestinal and Liver Physiology, 1997;35, G943-
G953. 
Rhode,H, Lopatta,E, Schulze,M, Pascual,C, Schulze,HP, Schubert,K, Schubert,H, 
Reinhart,K, & Horn,A,"Glycosylphosphatidylinositol-specific phospholipase D 
in blood serum: Is the liver the only source of the enzyme?". Clinica Chimica 
Acta, 1999;281, 127-145. 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            98
Rhode,H, Schulze,M, Cumme,GA, Gohlert,A, Blume,E, Bublitz,R, Schilling,K, & 
Horn,A,"Glycosylphosphatidylinositol-specific phospholipase D of human 
serum-activity modulation by naturally occurring amphiphiles". Biological 
Chemistry, 2000;381, 471-485. 
Ritorto,MS & Borlak,J,"A simple and reliable protocol for mouse serum proteome 
profiling studies by use of two-dimensional electrophoresis and MALDI 
TOF/TOF mass spectrometry". Proteome Sci, 2008;6, 25- 
Robinson,L, Grau,P, & Crandall,BF,"Pregnancy Outcomes After Increasing Maternal 
Serum Alpha-Fetoprotein Levels". Obstetrics and Gynecology, 1989;74, 17-20. 
Rocchiccioli,S, Citti,L, Boccardi,C, Ucciferri,N, Tedeschi,L, Lande,C, Trivella,MG, & 
Cecchettini,A,"A gel-free approach in vascular smooth muscle cell proteome: 
perspectives for a better insight into activation". Proteome Science, 2010;8 
Rodrik,V, Gomes,E, Hui,L, Rockwell,P, & Foster,DA,"Myc stabilization in response to 
estrogen and phospholipase D in MCF-7 breast cancer cells". Febs Letters, 
2006;580, 5647-5652. 
Rodrik,V, Zheng,Y, Harrow,F, Chen,YH, & Foster,DA,"Survival signals generated by 
estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on 
Myc". Molecular and Cellular Biology, 2005;25, 7917-7925. 
Roigas,J, Deger,S, Schroeder,J, Wille,A, Turk,I, Brux,B, Jung,K, Schnorr,D, & 
Loening,SA,"Tumor type M2 pyruvate kinase expression in metastatic renal 
cell carcinoma". Urological Research, 2003;31, 358-362. 
Santi,V, Trevisani,F, Gramenzi,A, Casadio,R, Di Nolfo,MA, Del Poggio,P, 
Benvegnu,L, Rapaccini,G, Farinati,F, Zoli,M, Borzio,E, Giannini,EG, 
Caturelli,E, & Bernardi,M,"Surveillance for early diagnosis of hepatocellular 
carcinoma: Is it effective in intermediate/advanced cirrhosis?". Journal of 
Hepatology, 2007;46, S110-S110. 
Scheers,I, Bachy,V, Stephenne,X, & Sokal,EM,"Risk of hepatocellular carcinoma in 
liver mitochondrial respiratory chain disorders". Journal of Pediatrics, 
2005;146, 414-417. 
Schlaeger,C, Longerich,T, Schiller,C, Bewerunge,P, Mehrabi,A, Toedt,G, Kleeff,J, 
Ehemann,V, Eils,R, Lichter,P, Schirtnacher,P, & Radwimmer,B,"Etiology-
dependent molecular mechanisms in human hepatocarcinogenesis". 
Hepatology, 2008;47, 511-520. 
Schulein,C & Eilers,M,"An unsteady scaffold for Myc". Embo Journal, 2009;28, 453-
454. 
Sears,R, Leone,G, DeGregori,J, & Nevins,JR,"Ras enhances Myc protein stability". 
Molecular Cell, 1999;3, 169-179. 
Setsuie,R & Wada,K,"The functions of UCH-L1 and its relation to neurodegenerative 
diseases". Neurochemistry International, 2007;51, 105-111. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            99
Sherman,M,"Alphafetoprotein: an obituary". Journal of Hepatology, 2001;34, 603-
605. 
Shi,M, Zheng,Y, Garcia,A, Xu,LZ, & Foster,DA,"Phospholipase D provides a survival 
signal in human cancer cells with activated H-Ras or K-Ras". Cancer Letters, 
2007;258, 268-275. 
Shuldiner,AR,"Transgenic animals". New England Journal of Medicine, 1996;334, 
653-655. 
Singh,M & Kumar,V,"Transgenic mouse models of hepatitis B virus-associated 
hepatocellular carcinoma". Reviews in Medical Virology, 2003;13, 243-253. 
Smirnov,IP, Zhu,X, Taylor,T, Huang,Y, Ross,P, Papayanopoulos,IA, Martin,SA, & 
Pappin,DJ,"Suppression of alpha-cyano-4-hydroxycinnamic acid matrix 
clusters and reduction of chemical noise in MALDI-TOF mass spectrometry". 
Analytical Chemistry, 2004;76, 2958-2965. 
Song,YD, Wu,JH, Oyesanya,RA, Lee,Z, Mukherjee,A, & Fang,XJ,"Sp-1 and c-Myc 
Mediate Lysophosphatidic Acid-Induced Expression of Vascular Endothelial 
Growth Factor in Ovarian Cancer Cells via a Hypoxia-Inducible Factor-1-
Independent Mechanism". Clinical Cancer Research, 2009;15, 492-501. 
Soucek,L, Jucker,R, Panacchia,L, Ricordy,R, Tato,F, & Nasi,S,"Omomyc, a potential 
Myc dominant negative, enhances Myc-induced apoptosis". Cancer Research, 
2002;62, 3507-3510. 
Stephensen,CB & Gildengorin,G,"Serum retinol, the acute phase response, and the 
apparent misclassification of vitamin A status in the third National Health and 
Nutrition Examination Survey". American Journal of Clinical Nutrition, 2000;72, 
1170-1178. 
Sundsten,T, Eberhardson,M, Goransson,M, & Bergsten,P,"The use of proteomics in 
identifying differentially expressed serum proteins in humans with type 2 
diabetes". Proteome Science, 2006;4 
Supino S., Scovassi A.I. "c-myc: a double-headed Janus that regulates cell survival 
and death". Gene Ther. Mol. Biol. 2004: 385-394. 
Terradillos,O, Billet,O, Renard,CA, Levy,R, Molina,T, Briand,P, & Buendia,MA,"The 
hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in 
transgenic mice". Oncogene, 1997;14, 395-404. 
Thorgeirsson,SS & SantoniRugiu,E,"Transgenic mouse models in carcinogenesis: 
Interaction of c-myc with transforming growth factor alpha and hepatocyte 
growth factor in hepatocarcinogenesis". British Journal of Clinical 
Pharmacology, 1996;42, 43-52. 
Tsuboi,S,"Elevation of glutathione level in rat hepatocytes by hepatocyte growth 
factor via induction of gamma-glutamylcysteine synthetase". Journal of 
Biochemistry, 1999;126, 815-820. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            100
Um,SJ, Lee,SY, Kim,EJ, Han,HS, Koh,YM, Hong,KJ, Sin,HS, & 
Park,JS,"Antiproliferative mechanism of retinoid derivatives in ovarian cancer 
cells". Cancer Letters, 2001;174, 127-134. 
Vafa,O, Wade,M, Kern,S, Beeche,M, Pandita,TK, Hampton,GM, & Wahl,GM,"c-Myc 
can induce DNA damage, increase reactive oxygen species, and mitigate p53 
function: A mechanism for oncogene-induced genetic instability". Molecular 
Cell, 2002;9, 1031-1044. 
Valledor,L & Jorrin,J,"Back to the basics: Maximizing the information obtained by 
quantitative two dimensional gel electrophoresis analyses by an appropriate 
experimental design and statistical analyses". J Proteomics, 2010;1. 
 
van de Wetering,M, Sancho,E, Verweij,C, de Lau,W, Oving,I, Hurlstone,A, van der 
Horn,K, Batlle,E, Coudreuse,D, Haramis,AP, Tion-Pon-Fong,M, Moerer,P, van 
den Born,M, Soete,G, Pals,S, Eilers,M, Medema,R, & Clevers,H,"The beta-
catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal 
cancer cells". Cell, 2002;111, 241-250. 
van Riggelen,J, Yetil,A, & Felsher,DW,"MYC as a regulator of ribosome biogenesis 
and protein synthesis". Nature Reviews Cancer, 2010;10, 301-309. 
Vennstrom,B, Sheiness,D, Zabielski,J, & Bishop,JM,"Isolation and Characterization 
of C-Myc, A Cellular Homolog of the Oncogene (V-Myc) of Avian 
Myelocytomatosis Virus Strain-29". Journal of Virology, 1982;42, 773-779. 
Viola,M, Vigetti,D, Genasetti,A, Rizzi,M, Karousou,E, Moretto,P, Clerici,M, Bartolini,B, 
Pallotti,F, De Luca,G, & Passi,A,"Molecular control of the hyaluronan 
biosynthesis". Connective Tissue Research, 2008;49, 111-114. 
Wait,R, Chiesa,G, Parolini,C, Miller,I, Begum,S, Brambilla,D, Galluccio,L, Ballerio,R, 
Eberini,I, & Gianazza,E,"Reference maps of mouse serum acute-phase 
proteins: Changes with LPS-induced inflammation and apolipoprotein A-I and 
A-II transgenes". Proteomics, 2005;5, 4245-4253. 
Warburg, O, "On the origin of cancer cells" Science 1956; 123:309-14. 
Watson,JD, Oster,SK, Shago,M, Khosravi,F, & Penn,LZ,"Identifying genes regulated 
in a Myc-dependent manner". Journal of Biological Chemistry, 2002;277, 
36921-36930. 
Wise,DR, DeBerardinis,RJ, Mancuso,A, Sayed,N, Zhang,XY, Pfeiffer,HK, Nissim,I, 
Daikhin,E, Yudkoff,M, McMahon,SB, & Thompson,CB,"Myc regulates a 
transcriptional program that stimulates mitochondrial glutaminolysis and leads 
to glutamine addiction". Proceedings of the National Academy of Sciences of 
the United States of America, 2008;105, 18782-18787. 
Wonsey,DR, Zeller,KI, & Dang,CV,"The c-Myc target gene PRDX3 is required 
mitochondrial homeostasis and neoplastic transformation". Proceedings of the 
National Academy of Sciences of the United States of America, 2002;99, 
6649-6654. 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            101
Wu,HY, Jia,WP, Bao,YQ, Lu,JX, Zhu,JH, Wang,R, Chen,YQ, & Xiang,K,"Serum 
retinol binding protein 4 and nonalcoholic fatty liver disease in patients with 
type 2 diabetes mellitus". Diabetes Research and Clinical Practice, 2008;79, 
185-190. 
Wulfkuhle,JD, Liotta,LA, & Petricoin,EF,"Proteomic applications for the early 
detection of cancer". Nature Reviews Cancer, 2003;3, 267-275. 
Xuan,SY, Xin,YN, Chen,H, Shi,GJ, Guan,HS, & Li,Y,"Significance of hepatitis B virus 
surface antigen, hepatitis C virus expression in hepatocellular carcinoma and 
pericarcinomatous tissues". World Journal of Gastroenterology, 2007;13, 
1870-1874. 
Yates,JR,"Mass spectral analysis in proteomics". Annual Review of Biophysics and 
Biomolecular Structure, 2004;33, 297-316. 
Yeung,K, Janosch,P, McFerran,B, Rose,DW, Mischak,H, Sedivy,JM, & 
Kolch,W,"Mechanism of suppression of the Raf/MEK/extracellular signal-
regulated kinase pathway by the Raf kinase inhibitor protein". Molecular and 
Cellular Biology, 2000;20, 3079-3085. 
Yokoyama,Y, Kuramitsu,Y, Takashima,M, Iizuka,N, Terai,S, Oka,M, Nakamura,K, 
Okita,K, & Sakaida,I,"Protein level of apolipoprotein E increased in human 
hepatocellular carcinoma". International Journal of Oncology, 2006;28, 625-
631. 
Zhang,MQ,"Prediction, annotation, and analysis of human promoters". Cold Spring 
Harbor Symposia on Quantitative Biology, 2003;68, 217-225. 
Zheng,Y, Rodrik,V, Toschi,A, Shi,M, Hui,L, Shen,YJ, & Foster,DA,"Phospholipase D 
couples survival and migration signals in stress response of human cancer 
cells". Journal of Biological Chemistry, 2006;281, 15862-15868. 
Zhou,YJ, Jiang,L, & Rui,LY,"Identification of MUP1 as a Regulator for Glucose and 
Lipid Metabolism in Mice". Journal of Biological Chemistry, 2009;284, 11152-
11159. 
Zhu,X & Papayannopoulos,IA,"Improvement in the detection of low concentration 
protein digests on a MALDI TOF/TOF workstation by reducing alpha-cyano-4-
hydroxycinnamic acid adduct ions". J Biomol.Tech., 2003;14, 298-307. 
 
Zinkin,NT, Grall,F, Bhaskar,K, Otu,HH, Spentzos,D, Kalmowitz,B, Wells,M, 
Guerrero,M, Asara,JM, Libermann,TA, & Afdhal,NH,"Serum proteomics and 
biomarkers in hepatocellular carcinoma and chronic liver disease". Clin Cancer 
Res, 2008;14, 470-477. 
 
 
 
 
 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            102
 
 
 
 
 
 
 
 
 
 
 
Webgraphy 
 
 
 
 
 
 
 
 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            103
¾ Big-PI predictor                                    
http://mendel.imp.ac.at/gpi/gpi_server.html 
Application for the prediction of protein GPI lipid anchor cleavage sites (update 2005) 
 
¾ BioPortfolio                                          
http://www.bioportfolio.com/ 
The biotechnology, pharmaceutical, healthcare, medical device, diagnostic and life 
science portal. 
 
¾ c-Myc Gene Database                         
http://www.myccancergene.org/ 
It provides a hub for the integration of information on Myc target genes, the role of 
Myc in human cancers, and proteins that interact with the Myc transcription factors. 
Links are provided that connect to PUBMED citations, Unigene database, and in 
specific cases to original data. 
 
¾ ChemSpider                                        
http://www.chemspider.com/ 
It is a free-to-access collection of compound data from across the web, provided by 
the Royal Society of Chemistry (RSC). It aggregates chemical structures and their 
associated information into a single searchable repository and makes it available to 
everybody. ChemSpider builds on the collected sources by adding additional 
properties, related information and links back to original data sources. ChemSpider 
offers text and structure searching to find compounds of interest and provides unique 
services to improve this data by curation and annotation and to integrate it with users’ 
applications. 
 
¾ CSHL Promoter Database                  
http://rulai.cshl.edu/cgi-bin/CSHLmpd2/mmpd.pl 
MmPD (mouse database) supports to search promoter location based on keyword 
search. keywords include the NCBI mRNA Accession number, NCBI Unigene cluster 
ID, NCBI LocusLink ID, and others (some gene name, like Cdc2a). 
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¾ Expasy                                                
http://expasy.org/ 
The ExPASy (Expert Protein Analysis System) proteomics  server of the Swiss 
Institute of Bioinformatics (SIB) is dedicated to the analysis of protein sequences and 
structures as well as 2-D PAGE. 
 
¾ FragAnchor                                          
http://navet.ics.hawaii.edu/%7efraganchor/cgi-bin/I8db.pl 
It is based on the tandem use of a Neural Network predictor and a Hidden Markov 
Model predictor. The Neural Network is used to select the potential GPI-anchored 
sequences and the Hidden Markov Model classifies the selected sequences 
according to four different levels of precision (highly probable, probable, weakly 
probable, potential false positive). The Hidden Markov Model proposes also up to 
three possible locations for the anchor/cleavage site.  
 
¾ GeneMANIA                                        
http://genemania.org/ 
It helps to predict the function of query gene sets. 
GeneMANIA finds other genes that are related to a set of input genes, using a very 
large set of functional association data. Association data include protein and genetic 
interactions, pathways, co-expression, co-localization and protein domain similarity. 
You can use GeneMANIA to find new members of a pathway or complex, find 
additional genes you may have missed in your screen or find new genes with a 
specific function, such as protein kinases. Your question is defined by the set of 
genes you input./                   
¾ Globocan 
http://globocan.iarc.fr/ 
Provides access to the most recent estimates (for 2008) of the incidence  of, and 
mortality  from 27 major cancers worldwide 
 
¾ Go-Proteomics                                 
http://www.wileyvch.de/goproteomics/index.php?page=meetingsdiary 
The premier source of proteome information 
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¾ GPI-SOM (KohGPI)                         
http://gpi.unibe.ch/ 
GPI-SOM: Identification of GPI-anchor signals by a Kohonen Self Organizing Map 
 
¾ IPI                                                    
http://www.ebi.ac.uk/IPI/IPIhelp.html 
IPI (International Protein Index) provides a top level guide to the main databases that 
describe the proteomes of higher eukaryotic organisms. Single species databases 
from species whose genome has been sequenced. Content includes protein entries 
in the UniProtKB database, plus predicted protein sequences from Ensembl and 
RefSeq. 
 
¾ Mascot                                             
http://www.matrixscience.com/ 
It is a powerful search engine that uses mass spectrometry data to identify proteins 
from primary sequence databases. Mascot incorporates code from Mowse, 
developed by Darryl Pappin and David Perkins when working at the former Imperial 
Cancer Research Fund, and licensed from its technology transfer subsidiary, Cancer 
Research Technology. Swiss-Prot is on this web site for searching with Mascot. 
 
¾ MF Calc                                           
http://home.pacbell.net/jdeline/ 
MF Calc ("Molecular Fragment Calculator") takes a user defined mass and calculate 
all of the possible elemental combinations possible with that mass.  The program is 
very flexible in that the user can control the degree of the precision of the mass, as 
well as which elements (and the amounts) that should be included in the search.   It 
calculates an exact formula from a high-resolution mass spec value.   
 
¾ MolE                                                
http://library.med.utah.edu/masspec/mole.htm 
It calculates molecular masses and isotope ratios from elemental compositions. 
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¾ MSDB 
http://proteomics.leeds.ac.uk/bioinf/msdb.html 
The Mass Spectrometry protein sequence DataBase is compiled by the Proteomics 
Group at Imperial College London. MSDB is a composite, non-identical protein 
sequence database built from a number of primary source databases. Sequences 
from the higher priority databases are preferentially retained. The present source 
databases (in order of priority) are: PIR, Trembl, GenBank, Swiss-Prot, and NRL3D. 
One of the main advantages of MSDB is the accompanying full-text reference file. 
 
¾ NCBI                                                
http://www.ncbi.nlm.nih.gov/ 
The National Center for Biotechnology Information has been developed in 1988 as a 
division of the National Library of Medicine (NLM) at the National Institutes of Health 
(NIH) to develop new information technologies to aid in the  understanding of 
fundamental molecular and genetic processes that control health and disease. More 
specifically, the NCBI has been charged with creating automated systems for storing 
and analyzing knowledge about molecular biology, biochemistry, and genetics; 
facilitating the use of such databases and software by the research and medical 
community; coordinating efforts to gather biotechnology information both nationally 
and internationally; and performing research into advanced methods of computer-
based information processing for analyzing the structure and function of biologically 
important molecules. 
NCBInr: a non-redundant database compiled by NCBI by combining most of the 
public domain databases (EST's not included). 
 
¾ oncoDB                                                
http://oncodb.hcc.ibms.sinica.edu.tw/index.htm 
It is based on physical maps of rodent and human genomes containing quantitative 
trait loci of rodent HCC models and various human HCC somatic aberrations 
including chromosomal data from loss of heterozygosity and comparative genome 
hybridization analyses, altered expression of genes from microarray and proteomic 
studies, and finally experimental data of published HCC genes. 
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¾ PredGPI                                           
http://gpcr2.biocomp.unibo.it/predgpi/ 
It is a prediction system for GPI-anchored proteins. It is based on a support vector 
machine (SVM) for the discrimination of the anchoring signal, and on a Hidden 
Markov Model (HMM) for the prediction of the most probable omega-site 
 
¾ ProteinLounge™Beta                      
http://www.proteinlounge.com/ 
It is  a Bioinformatics Portal, Now Available to NIH Staff. 
Protein Lounge organizes gene/protein data into a single gateway, improving access 
and supporting greater understanding of systems biology. 
 
¾ ProteinProspector™                        
http://prospector.ucsf.edu/prospector/mshome.htm 
Proteomics tools for mining sequence databases in conjunction with Mass 
Spectrometry experiments. 
 
¾ PubGENEBeta                                
http://www.pubgene.org/ 
PubGene is designed to present information on genes, proteins and related keywords 
in an organized and intuitive form. PubGene subscribers use a graphic interface to 
access databases that catalogue the occurrence of symbols and phrases identifying 
genes in the scientific literature. Databases are updated on a biweekly basis through 
searches of MEDLINE records. Searches are performed using a list of synonyms for 
each gene that include the primary gene ID (as listed in Entrez Gene) and other 
symbols and phrases used to identify the gene and its protein product. Furthermore, 
the graphic interface can present lists of articles, allowing the researcher to find all 
records mentioning the gene. PubGene uses co-citation to create networks of gene 
identifiers, allowing the possibility for the discovery of relationships between two 
genes via an intermediary gene. In addition to lists of articles, PubGene can search 
for keywords using gene identifiers, or use keywords to find genes (MeSH, GO and 
chemical identifiers). 
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¾ PubMed                                               
http://www.ncbi.nlm.nih.gov/sites/entrez 
PubMed, a service of the National Library of Medicine, includes over 15 million 
citations for biomedical articles back to the 1950's. These citations are from 
MEDLINE and additional life science journals. PubMed includes links to many sites 
providing full text articles and other related resources. 
 
¾ SwissProt 
http://www.expasy.ch/sprot/sprot-top.html 
A curated protein sequence database which strives to provide a high level of 
annotations (such as the description of the function of a protein, its domains 
structure, post-translational modifications, variants, etc), a minimal level of 
redundancy and high level of integration with other databases. 
 
¾ UniProtKB                                       
http://expasy.org/sprot/ 
Merger of the information contained in Swiss-Prot, TrEMBL and PIR to produce a 
comprehensive database. All entries are highly annotated, some manually (Swiss-
Prot and PIR) whilst other in an automated fashion using sequence similarity to 
previously annotated proteins (TrEMBL). 
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            CIX 
 
No. SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) PI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref        
Map 5 
Ref    
Map 6 
1 A1AG1 MOUSE Q60590 24 5.6 124 32 1703.91 
CHCA        
DHB 10 
not 
present 4 12 
5   (up 
regulated) present 
2 AMBP MOUSE Q07456 40 6 38 4 1669.85 CHCA    1 3* 
not 
present 
 not 
present 
not 
present  
not 
present  
3 APOM  MOUSE Q9Z1R3 21.6 6 105 36 938.42 
CHCA        
DHB 9 
not 
present 
not 
present  
not 
present  
not 
present  present 
MUP1 
MOUSE P11588 20.9 5 115 55   DHB 12 0 10 
not 
present 
not 
present  
not 
present  
MUP2  
MOUSE P11589 20.9 5 146 68   DHB 14 0 11 19 not present 
not 
present  
MUP6  
MOUSE P02762 20.9 5 133 74   DHB 13 0 10 
not 
present 
 not 
present 
not 
present   
 
 
 
 
4 
  
  
  MUP8  
MOUSE P04938 17.7 5 137     DHB 
 not 
present  0 
not 
present   
not 
present 
not 
present   
not 
present   
A1AT1  
MOUSE P07758 46.1 5.4 145 41 
981.56      
1137.66     
1232.70     
2003.04    
2327.09     
2405.17    
3498.80     
CHCA       
DHB 15 
10*        
2' 13 12 
20  (up 
regulated) not present 
A1AT2  
MOUSE P22599 46.1 5.3 104 36 
2405.17     
2003.04    
2327.09    
3498.80    
CHCA       
DHB 12 9' 
not 
present 7 
3   (up 
regulated) present 
 
 
5 
  
  
A1AT3  
MOUSE Q00896 46 5.3 146 44 
981.56     
1137.66    
2003.04    
2327.09     
2405.17     
3498.80    
CHCA       
DHB 15 
not 
present 16 15 not present 
not 
present   
Table 1 
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            CX 
No. 
SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) PI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref        
Map 5 
Ref    
Map 6 
A1AT4   
MOUSE Q00897 46.1 5.2 162 51 
1232.74   
2003.04    
2327.09   
3498.80     
CHCA       
DHB 17 
not 
present 
not 
present   
 not 
present  
not 
present   present 
A1AT5  
MOUSE Q00898 46 5.4 105 35 
1232.71    
2327.09   
2405.17 
CHCA       
DHB 12 
not 
present 
 not 
present  
not 
present   
not 
present   present 
 
  
  5 
  
  
A1AT6  
MOUSE P81105 46 5.2 161 47 
981.56     
1137.66     
1232.70   
2003.04    
2327.09  
2405.17     
3498.80   
CHCA       
DHB 16 2 
not 
present 8 not present present 
6 ANT3  MOUSE P32261 52.5 6.1 298 56 
1198.70  
1340.69  
1359.67  
1700.89 
CHCA        
DHB 29 6 
not 
present 
not 
present   
not 
present   present 
7 A2AP  MOUSE Q61247 55.1 5.8 169 36 
1591.80  
1680.81 
CHCA        
DHB 15 3 
not 
present 
 not 
present  
not 
present   present 
8 CBG  MOUSE Q06770 44.9 5 148 32   
CHCA        
DHB 10 3 
not 
present  
not 
present   
not 
present   present 
9 SPA3K  MOUSE P07759 47 5 113 29   
CHCA        
DHB 12 12 v 21 
7  (up 
regulated) present 
10 A2MG  MOUSE      Q61838 167 6.27 153 19 2068.21 
CHCA        
DHB 18 25 
16 
(immuno   
depletion) 
not 
present  
not 
present   present 
Table1…continued 
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            CXI 
No. 
SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) PI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref       
Map 5 
Ref    
Map 6 
10a 
A2MG  
MOUSE  C-
term  
Q61839 28 7 62 6 
1031.50  
1111.58    
1216.61  
1787.96   
CHCA        
DHB 9 ? 
not 
present 13 
16  (up 
regulated) present 
11 ADIPO  MOUSE Q60994 26.9 5.3 63 19 1504.72 DHB 5 
not 
present 
 not 
present  
not 
present   
not 
present   present 
12 AFAM  MOUSE O89020 71.5 5.5 155 31   
CHCA        
DHB 15 1 9 
not 
present 
  not 
present present 
13 ALBU  MOUSE P07724 70.7 5.7 426 68 
1455.83   
1479.70   
1609.90   
1882.96  
1960.15     
1981.98 
CHCA        
DHB 40 
26*       
46' 17 48 
12  (up 
regulated) present 
14 ALS  MOUSE P70389 67.7 6.1 97 28   DHB 13 
not 
present 
 not 
present 
not 
present not present present 
15 CPN2  MOUSE Q9DBB9 61.3 5.5 131 25   CHCA 10 
not 
present 
not 
present  
 not 
present  not present present 
16 ANGL6  MOUSE Q8R0Z6 51.4 9.2 56 16   DHB 4 
not 
present 
 not 
present 
not 
present not present not present 
17 ANXA2  MOUSE P07356 38.8 7.5 82 18   CHCA 5 
not 
present 
not 
present  
not 
present not present not present 
18 APOA1  MOUSE Q00623 30.5 5.6 207 49 
1237.67      
1318.61     
1331.53      
1340.77 
CHCA        
DHB 17 
5*         
18' 13 18 22 present 
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            CXII 
No. 
SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) PI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref        
Map 5 
Ref    
Map 6 
19 APOA2  MOUSE P09813 11.3 6.6 85 14 
1193.62    
1831.98 
CHCA        
DHB 2 4' 7 3 
3 (up 
regulated) present 
20 APOA4  MOUSE P06728 45 5.4 223 60 
1131.66     
1231.61    
1461.75    
2023.05 
CHCA        
DHB 21 
2*         
5' 15 29 
6 (up 
regulated) present 
21 APOE   MOUSE P08226 35.9 5.6 166 51 
968.52   
1075.60     
1599.82    
CHCA        
DHB 21 5' 7 17 
16 (up 
regulated) present 
22 APOC3   MOUSE P33622 10.9 4.6 140 19 
1062.46  
1078.45  
1987.94     
CHCA 3 not present 3 3 not present present 
23 APOH  MOUSE Q01339 39.9 8.6 276 62 
1325.68    
1544.85      
2719.48 
CHCA        
DHB 22 7 
not 
present 17 
22 (up 
regulated) present 
24 CLUS MOUSE Q06890 55.2 5.5 103 19   CHCA 11 2* 9 12 not present present 
25 C1R  
MOUSE 
Q8CG16 81.5 5.4 78 17   CHCA 8 not present 
 not 
present 
 not 
present not present not present 
26 CFAB  MOUSE P04186 86.3 7.2 269 37   
CHCA        
DHB 23 3 
not 
present 
 not 
present not present present 
27 CFAI  MOUSE Q61129 69.5 7.4 103 21 1726.85 DHB 11 3 
not 
present 
not 
present  not present not present 
28 HGFA   MOUSE Q9R098 72.9 6.6 58 13   DHB 6 
not 
present 
 not 
present 
not 
present not present present 
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            CXIII 
No. 
SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) PI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref        
Map 5 
Ref    
Map 6 
29 HPT  MOUSE Q61646 39.2 5.9 146 49 
980.49      
1320.74    
1373.61 
DHB 21 not present 11 5 
14 (up and 
down 
regulated) 
present 
29a HPT  MOUSE Q61646     81 11 1679.78 DHB 6 ? ? 14 not present  not present 
30 PLMN  MOUSE P20918 93.4 6.2 387 53 1138.46 
CHCA        
DHB 35 8 
not 
present 32 6 present 
31 CFAH  MOUSE P06909 144 6.6 269 31   
CHCA        
DHB 29 6 
not 
present 18 not present present 
32 CS1A  MOUSE Q8CG14 78.3 5 66 15   DHB 6 
not 
present 
 not 
present 
not 
present not present not present 
33 F13B  MOUSE Q07968 78.3 5.6 148 26   CHCA 15 
not 
present 
not 
present 
not 
present not present present 
34 CO3  MOUSE P01027 188 6.4 312 29 1886.93 
CHCA        
DHB 40 
23*        
1' 
not 
present 
not 
present 
17 (up 
regulated) present 
35 CO4  MOUSE P01029 194 7.5 123 9   CHCA 14 3 
not 
present 
not 
present not present present 
36 CO9  MOUSE P06683 63.2 5.6 80 29   DHB 14 1 
not 
present 
not 
present  not present  
not 
present  
37 C1QB MOUSE P14106 27 8.6 69 20   CHCA 5 1* 
not 
present 
not 
present  not present  present 
38 EGFR MOUSE Q01279 138 6.5 171 16   
CHCA        
DHB 15 
not 
present 
not 
present 18 not present present 
39 FIBB MOUSE Q8K0E8 55.4 6.7 112 39   
CHCA        
DHB 20 
not 
present 
not 
present  
not 
present  not present  present 
40 FINC MOUSE P11276 276 5.4 90 8   CHCA 16 9* 
not 
present 
not 
present  not present  present 
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            CXIV 
No. 
SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) PI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref        
Map 5 
Ref    
Map 6 
41 FCN1  MOUSE O70165 36.8 6 65 12   DHB 5 
not 
present 
not 
present 8 not present 
not 
present  
42 FETUA  MOUSE P29699 38.1 6 135 47 
1653.75    
2138 
CHCA        
DHB 11 3 6 8 not present present 
43 FETUB  MOUSE Q9QXC1 43.5 6.2 113 30 
1382.89    
1159.7 
CHCA        
DHB 14 1 5 13 not present present 
44 GPX3  MOUSE P46412 25.6 8.3 98 45 1955 
CHCA        
DHB 12 
not 
present 
not 
present  
not 
present  not present  present 
45 HA10  MOUSE P01898 37.2 5.2 173 46 1671.86 
CHCA        
DHB 16 3 
not 
present 
not 
present  not present  
not 
present  
46 HBA  MOUSE P01942 15 8 79 31 
1589.82 
1819.93 CHCA 5 
2*         
6' 
not 
present 
not 
present  8 present 
47 HBB1 MOUSE P02088 16 7.3 68 73 1274.72 
CHCA        
DHB 9 
not 
present 
not 
present  
not 
present  
7 (up 
regulated) present 
48 HEMO  MOUSE Q91X72 52 7.9 188 43 
1100.47   
1212.63   
1504.76   
1516.71    
1727.77     
2472.12 
CHCA        
DHB 21 14 8 25 
3 (up 
regulated) present 
49 IGHG1  MOUSE P01868 36.2 7.2 94 45   DHB 9 3 
not 
present 
not 
present  not present  
not 
present  
50 KNG1  MOUSE O08677 74.1 6 164 29 
1010.56   
1060.56   
1515.68 
CHCA        
DHB 18 9 12 24 
5 (up 
regulated) not present 
51 KLKB1 MOUSE P26262 73.4 8.4 105 22   CHCA 14 1* 2 
not 
present not present  present 
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            CXV 
 
No. SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) PI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref       
Map 5 
Ref    
Map 6 
KV3A1/2/4  
MOUSE P01654 12 5 116 16 
1616.89     
1855.04 
CHCA       
DHB 2 
not 
present 
not 
present  
not 
present  
not 
present  present 
 52 
 
KV3AD  
MOUSE P01665 12 4.9 54 44 
1155.46     
1616.89     
1855.04 
CHCA       
DHB 4 
not 
present 
not 
present  
not 
present 
not 
present present 
KV5AB  
MOUSE P01644 12 7.9 88 17 
1028.56     
1926.92     
2455.35 
CHCA       
DHB 3 
not 
present 
 not 
present 
 not 
present 
 not 
present 
not 
present  
53 
  
KV5J  
MOUSE P01645 11.9 9.2 93 16 1926.81 
CHCA       
DHB 1 
not 
present 
not 
present 
not 
present 
not 
present present 
54 KV3N  MOUSE P01666 12 4.5 58 53   DHB 3 
not 
present 
not 
present  
not 
present  not present  present 
55 MUC  MOUSE P01872 50 6.6 184 30 
1330.78     
1603.91 
CHCA        
DHB 14 4 
not 
present 
not 
present  not present  
not 
present  
56 MUG1  MOUSE 
P28665 
(Q80XE6) 166.4 6 168 20   
CHCA        
DHB 24 12 
not 
present 
 not 
present not present  present 
57 PHLD   MOUSE O70362 93.8 6.6 151 23   
CHCA        
DHB 20 1 
not 
present 
not 
present  not present  present 
58 PON1  MOUSE P52430 34.6 5 117 32 1853.9 
CHCA        
DHB 8 2 
not 
present 
not 
present  not present  present 
59 PROP  MOUSE P11680 50 8.4 87 21   CHCA 8 
not 
present 
not 
present  
not 
present  not present  present 
60 RETBP  MOUSE Q00724 23.5 5.7 138 59 
1226.63    
1360.58   
1789.84     
2079.88 
CHCA        
DHB 15 1 
not 
present 
not 
present  not present  present 
61 SAMP  MOUSE P12246 26.4 6 88 38 2133.03 
CHCA        
DHB 8 1 8 8 not present present 
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            CXVI 
No. 
SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) PI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref        
Map 5 
Ref    
Map 6 
62 THRB  MOUSE P19221 71.6 6 156 28 1189.56 
CHCA        
DHB 19 4 
not 
present 26 
9 (up 
regulated) present 
63 TRFE MOUSE Q921I1 78.8 7 308 51 
1171.61   
1419.86 
1656.81 
1990.82  
2007.94 
CHCA        
DHB 38 
39*        
1' ? 26 not present present 
64 KAC  MOUSE P01837 11.9 5 91 87 990.51 
CHCA        
DHB 8 
not 
present 
 not 
present 
not 
present  not present  
not 
present  
65 ZA2G  MOUSE Q64726 35.4 5.8 173 55 
1274.60     
1318.81    
1409.72    
1610.74 
CHCA        
DHB 15 1 
not 
present 19 not present present 
66 VTDB  MOUSE P21614 55.1 5.4 266 44 
1051.6     
1303.77      
2441.13 
CHCA        
DHB 24 3 12 31 not present present 
67 
  
  
 
TTHY  
MOUSE 
  
  
 
P07309 
  
  
 
15.9 
  
  
 
5.8 
  
  
 
122 
  
  
 
67 
  
  
1382.62 
1554.89 
2438.17 
2517.22    
 
CHCA        
DHB 
  
  
 
8 
  
  
 
4*         
1' 
  
  
 
10 
  
  
 
9 
  
  
 
not present 
  
  
 
present 
  
  
68 GELS   MOUSE P13020 86.3 5.8 233 39 
1254.75    
1275.73 
CHCA        
DHB 22 6 
not 
present 19 not present present 
69 VTNC  MOUSE P29788 55.6 5.7 82 23   
CHCA        
DHB 10 2 
not 
present 
not 
present  not present  present 
70 GCAB  
MOUSE 
P01864 37 8.5 31.5 5 1913.84 DHB 1 not present 
not 
present  
not 
present 
not 
present  
not 
present  
71 GCB  MOUSE P01866 37.3 7.2 79 30 1778.87 
CHCA        
DHB 8 
not 
present 
not 
present  
not 
present  not present  
not 
present  
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            CXVII 
No. 
SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) pI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref        
Map 5 
Ref    
Map 6 
72 LAC1  MOUSE P01843 11.7 5.9 70 61   DHB 4 
not 
present 
 not 
present 
not 
present  not present  
not 
present  
73 LAC2  MOUSE P01844 11.4 5.9 70 89   DHB 5 
not 
present 
not 
present  
not 
present  not present present 
ACTG  
MOUSE P63260  42.1 5.3 188 53 
1198.75  
1790.93  
1954.14 
CHCA       
DHB 16 
not 
present 
not 
present 
not 
present not present not present  
74 
  ACTB  
MOUSE P60710 42 5.3 171 49 
1198.75  
1790.93  
1954.14  
CHCA       
DHB 15 
not 
present 
not 
present 
not 
present not present not present 
75 APC  MOUSE Q61315 313 7.4 53 6   CHCA 15 
not 
present 
not 
present 
not 
present not present present 
76 CT160  MOUSE Q8VCC6 22 9.5 56 20   CHCA 5 
not 
present 
not 
present 
not 
present not present not present 
77 CUL1  MOUSE  Q9WTX6 90.3 8.2 62 15   CHCA 7 
not 
present 
not 
present 
not 
present not present not present 
78 ESTN  MOUSE P23953 61.4 5.1 168 37 911.45 
CHCA        
DHB 21 12 7 
not 
present not present  present 
79 ITIH2  MOUSE Q61703 106 6.8 150 24 1337.73 
CHCA        
DHB 14 2 
not 
present 
not 
present  not present present 
80 ITIH4  MOUSE 9055252 104.8 6 133 20   CHCA 17 
not 
present 
 not 
present 18 not present not present 
81 K2C6B  MOUSE Q9Z331 60.5 8.5 76 29   
CHCA        
DHB 15 
not 
present 
not 
present 
not 
present not present not present 
82 LIFR  MOUSE P42703 123.8 5.7 151 19   DHB 15 
not 
present 
not 
present 22 not present present 
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            CXVIII
No. 
SwissProt 
entry 
SwissProt 
accession 
Mw 
(KDa) pI 
Mascot 
score 
 
sequence 
coverage 
(%) 
msms     
(m/z)  matrix 
Our Map 
1 
Ref 
Map 2 
Ref     
Map 3 
Ref 
Map 4 
Ref        
Map 5 
Ref    
Map 6 
83 MBL1  MOUSE P39039 25.8 7.5 100 27 1544.89 CHCA 9 
not 
present 
 not 
present 
not 
present 
8 (up 
regulated) present 
84 MBL2  MOUSE P41317 26.3 5 70 29 
1323.60  
1522.72  
1766.83 
CHCA        
DHB 6 2 
not 
present 8 not present 
not 
present  
85 OST5  MOUSE Q8BSL4 40.7 9.7 70 23   CHCA 6 
not 
present 
not 
present  
 not 
present not present not present 
86 SYT2  MOUSE P46097 47.7 8.2 61 19   CHCA 6 
not 
present 
not 
present  
not 
present not present present 
87 TPH1  MOUSE P17532 51.9 6 59 17   CHCA 7 
not 
present 
not 
present  
not 
present not present not present 
88 KPYM  MOUSE  P52480 58 7 53 30   DHB 12 
not 
present 
 not 
present 
not 
present not present not present 
89 
DYN2  
MOUSE  P39054 98 7 68 12   
CHCA        
DHB 9 
not 
present 
not 
present  
not 
present not present not present 
90 GAB2  MOUSE   Q9Z1S8 73.6 8.5 33 2 1794.8 DHB 1 
not 
present 
not 
present 
not 
present not present present 
          
Table 1: Mouse serum protein map 
Mouse serum proteins identified by us in serum from C57Bl/6 mice (“Our Map”) in comparison with previous mouse serum maps 
(see Ritorto, Borlak, Proteome Science 2008, PMID:   PMC2563006). In bold, we highlighted the proteins identified only with  
tandem MS (LIFT-MS/MS technology). For full details, please refer to the PMID: PMC2563006. 
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            I 
 
Table 2: Newly identified proteins  
No SwissProt entry 
SwissProt   
accession 
putative 
PTM 
Subcellular 
location 
Mw      
(KDa) pI 
RMS 
error    
(ppm) 
matrix SwissSprot   NCBInr MSDB 
Nr of 
matched 
peptides      
(Mascot) 
Nr of matched 
peptides 
(PeptideMap)  
1 ANGL6  MOUSE Q8R0Z6 G 
Secreted; highly 
expressed in the 
liver 
51.4 9 38 DHB 56 58 55 4 3 
2 ANXA2  MOUSE P07356 P 
Secreted, 
extracellular 
space, 
extracellular 
matrix, basement 
membrane. 
Melanosome 
38.8 8 45 CHCA 82 81 82 5 3 
3 C1R  MOUSE Q8CG16 G Secreted 81.5 5 15 
DHB        
CHCA 78 78 78 8 5 
4 CS1A  MOUSE Q8CG14 G 
Predominantly 
expressed in liver 78.3 5 11 DHB 66 66 66 6 5 
5 LAC1  MOUSE P01843  Secreted 11.7 6 4 DHB 70 70 70 4 3 
6 ACTG  MOUSE P63260  P 
Cytoplasm, 
cytoskeleton 42.1 5 28 
DHB        
CHCA 188 188 188 16 15 
7 CT160  MOUSE Q8VCC6   22 10 35 CHCA 55 56 56 5 4 
8 CUL1  MOUSE  Q9WTX6 G 
Embryo fibroblasts 
and embryo 
preadipocytes 
90.3 8 49 CHCA 62 62 62 7 6 
9 K2C6B  MOUSE Q9Z331 P 
Expressed in adult 
epithelia 60.5 8.5 36 
DHB        
CHCA 60 60 60 11 11 
10 OST5  MOUSE Q8BSL4 G 
Golgi apparatus 
membrane; Single-
pass type II 
membrane protein  
40.7 10 35 CHCA 70 70 70 6 5 
11 TPH1  MOUSE P17532 P 
Cytoplasmatic 
enzyme, pineal 
gland 
51.9 6 30 CHCA 57 57 57 7 5 
12 KPYM  MOUSE  P52480 P 
Liver, red cells, 
muscles, brain 58 7 39 DHB 53 53 53 11 10 
13 DYN2  MOUSE  P39054 P Cytoplasm 98 7 51 
DHB        
CHCA 68 68 68 9 9 
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Statistical validation 
a) 
Mass spectrometer validation b) Immuno validation c)  
Protein 
Name 
t-test Mann PLS MS/MS peptide-mass observed 
PFF 
Score Sequence (AA) 
Western 
Blot 
WB Semi-Quantitative 
(T/C) Immunohistochemistry 
AFAM     
MOUSE P<.05 P>.05 P<.01  - -  - ↓ (human) 0.21±2.4 (h)  
FETA      
MOUSE P<.05 P<.05 P>.05  - - - ↑ (mouse) 1.81±0.45 (m)  
1359.78 59 DIPVNPLCIYR (47-57)    
ANT3     
MOUSE P<.05 P<.05 P>.05 1700.94 63 LQPLDFKENPEQSR (203-216)    
1075.58 59 LQAEIFQAR (262-270)   up 
1599.78 87 ELEEQLGPVAEETR (87-100) 2.29±0.13 (m)  
APOE     
MOUSE P<.05 P<.05 P>.05 
968.52 67 LGPLVEQGR (191-199) 1.95±0.68 (h)  
1599.77 105 ELEEQLGPVAEETR (87-100)   
APOE    
MOUSE P<.05 P<.01 P>.05 
1759.84 56 (ox) NEVHMLGQSTEEIR (130-144) 
↑ (mouse, 
human) 
  
APOE    
MOUSE P<.05 P<.01 P>.05 1599.77 44 ELEEQLGPVAEETR (87-100) 
only T 
(mouse) Only T (m)  
2.20±0.61 (m)  
APOM   
MOUSE P<.05 P<.01 P<.05 938.42 27 ETGQGYQR (138-145) ↑ (human) 
1.98±0.29 (h)  
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            III
 
Statistical validation 
a) 
 
Mass spectrometer validation b) 
 
Immuno validation c) 
 
 
Protein 
Name 
t-test Mann PLS MS/MS peptide-mass observed 
PFF 
Score Sequence (AA) 
Western 
Blot 
WB Semi-Quantitative 
(T/C) Immunohistochemistry 
GPX3    
MOUSE P<.05 P<.01 P<.01 1955.01 41 
YVRPGGGFVPNFQLFEK (121-
137)    
1928.11 65 FNPVTGEVPPRYPLDAR (208-224) 
2448.07 151 ELGSPPGISLETIDAAFSCPGSSR (346-369) 
1727.77 64 GECQSEGVLFFQGNR (151-165) 
2472.15 90 LFQEEFPGIPYPPDAAVECHR (130-150) 
1516.7 45 GATYAFTGSHYWR (270-282) 
1504.79 28 WKNPITSVDAAFR (90-102) 
1212.64 47 FNPVTGEVPPR (208-218) 
1100.47 41 DYFVSCPGR (225-233) 
HEMO  
MOUSE P<.01 P<.01 P<.01 
1855.85 66 GECQSEGVLFFQGNRK (151-166) 
  ↑ (cyto) 
1320.74 33 DITPTLTLYVGK (157-168)    
1373.61 65 SCAVAEYGVYVR (321-332)    
1832.93 68 VMPICLPSKDYIAPGR (203-218)    
980.53 34 VGYVSGWGR (219-227)    
HPT      
MOUSE P<.01 P<.01 P<.01 
920.4 56 GSFPWQAK   (112-119)    
1679.85 63 LRAEGDGVYTLNDEK (58-72)    
      HPT α MOUSE P<.05 P<.05 P<.01 
1387.68 58 LPECEAVCGKPK (83-94)    
MUP      
MOUSE P<.01 P<.01 P>.05 - - - ↓ (mouse) <0.01 (m) 
↑ (m, cyto) 
↓ (h) 
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            IV 
 
 
Statistical validation 
a) 
 
 
 
 
Mass spectrometer validation b) 
 
 
Immuno validation c) 
 
 
 
Protein 
Name 
t-test Mann PLS MS/MS peptide-mass observed 
PFF 
Score Sequence (AA) 
Western 
Blot 
WB Semi-Quantitative 
(T/C) Immunohistochemistry 
8.29±0.33(m)  PHLD    
MOUSE P<.05 P<.05 P>.05 - - - 
↑ (mouse, 
human) 2.21±0.93 (h)  
 
T (human HCV)  
PIGR    
MOUSE P<.05 P<.05 P>.05 1282.66 19 AIPNPGPFANER (603-614) 
T(mouse, 
human) 
  
2.23± 0.23(m) PON1   
MOUSE P<.05 P<.01 P<.01 1853.84 82 IFFYDAENPPGSEVLR (209-305) ↑ (mouse) 
0.77± 0.36(h) 
↑ 
1226.73 71 YWGVASFLQR (108-117) 
1360.67 57 QRQEELCLER (172-181) 
1789.83 63 WIEHNGYCQSRPSR (185-198) 
RETBP   
MOUSE P<.01 P<.01 P<.01 
2079.98 132 LQNLDGTCADSYSFVFSR (140-157) 
↑(mouse) 7.19±0.29 (m) 0.84±0.29 (h) ↑ 
6.00±0.29 (m) 
SAMP     
MOUSE P<.05 P<.05 P<.05  -  -  - 
↑ (mouse, 
human) 5.63±0.76 (h) 
↑ 
2270.23 28 AVLDVAETGTEAAAATGVIGGIRK  (361-384)    
SPA3K/M  
MOUSE P<.01 P<.05 P<.01 
2366.01 66 ISFDPQDTFESEFYLDEKR (218-236)    
Table 3…continued 
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Statistical validation 
a) 
 
 
 
 
 
Mass spectrometer validation b) 
 
 
 
Immuno validation c) 
 
 
 
Protein 
Name 
t-test Mann PLS MS/MS peptide-mass observed 
PFF 
Score Sequence (AA) 
Western 
Blot 
WB Semi-Quantitative 
(T/C) Immunohistochemistry 
2517.24 178 TLGISPFHEFADVVFTANDSGHR  (101-123) T(m) 
869.45 41 FVEGVYR (84-90)  
1382.63 91 TSEGSWEPFASGK (56-68)  
TTHY     
MOUSE P<.05 P<.01 P>.05 
2438.26 193 TAESGELHGLTTDEKFVEGVYR (69-90)  
↑ 
1382.63 54 TSEGSWEPFASGK (56-68) 
2597.36 43 HYTIAALLSPYSYSTTAVVSNPQN (124-147) 
 
 
TTHY     
MOUSE 
P<.05 P<.05 P<.05 
2438.26 135 TAESGELHGLTTDEKFVEGVYR (69-90) 
↑(mouse) 
 
 
 
8.92±0.04 (m)    
0.94±0.29 (h) 
 
 
 
↑ 
 
Table 3: Methods of validations used in the present work 
 
The 2-DE analysis was validated by bioinformatics (PDQuest™) with unvariate and multivariate methods available into the software 
package (a). The MS spectra identifications were confirmed by Tandem MS (b). The regulation of the proteins were further validated by 
immunoassays (Western Blot and Immunohistochemistry).  
 
 
 
 
Table 3….continued 
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Table 4   New identified regulation of proteins in HCC bearing AAT-c-Myc transgenic mice  
 
Nr   Protein Name              Swiss-Prot name         T/C1    serum/tissue                   Gene                 T/C1              OncoDB (HCC)2                            E-box3                                   Matrices4 
 
1     Afamin             AFM_MOUSE              ↓                           serum                            Afm                 ↓                 ↓ in tissue                                                                              
  
2     Antithrombin III            ANT3_MOUSE             ↑                           serum                            Serpinc1           ↓ (12)                           ↓ (gene)                            959(+) cCACCTggcc                               Ebox 
 
3    Transthyretin            TTHY_MOUSE                ↑          serum/tissue                 Ttr                 ↓                                  ↓ (gene)                            247(-)  ggtcAGGTGg                        Ebox                    
 
4    Phosphatidylinosytol  
      phospholipase D            PHLD_MOUSE                ↑                           serum                           Gpld1   
 
5    Polymeric  
      immunoglobulin  
      receptor                           PIGR*_MOUSE          only in tumor              serum                           PigR                                                        890(+) tggcagtCACGTgatctggc   Myc/Max  
                           890(-) tggcagtcACGTGatctggc              Myc/Max 
                                                                                                                                                                                                                                                                            894(-) agtcACGTGa                                 Ebox 
                                                                                                                                                                                                                                                                            945(-) agccAGGTGc                                Ebox 
 
6   Retinol binding protein 4   RET4_MOUSE               ↑                          serum/tissue       Rtbp4                                     ↓ (mRNA)             1031(+) tCCACGcgcg                     Myc/Max B        
           
7   3-hydroxyisobutyrate  
     dehydrogenase, 
     mitochondrial           3HIDH_MOUSE              ↓               tissue                          Hibadh               ↓ (12)              type 2 ↓ (gene)                           
  
 
8   Elongation factor 1- 
     delta                             E1FD_MOUSE              ↑                          tissue                          Eef1d                ↑ (6-12)               in rat                               1080(-) gcgcACGTGc                       Ebox 
                                                                                                                                          
                                                                                                                                                                       
9   Protein ETHE1          ETHE1_MOUSE              ↓                          tissue                          Ethe1                ↓ (12)                                  730(+) agccgaaCACGTgttttcct  Myc/Max             
                                                                                                                 730(-)  agccgaacACGTGttttcct  Myc/Max                     
                                                                                                                 734(-)  gaacACGTGt                       Ebox 
                                                                                                                                                                                                                                                                            736(+) aCACGTgttt                                Ebox 
              
10  Galactokinase 1          GALK1_MOUSE             ↑                          tissue                          Galk1                 ↑                                 ↓ (gene)/ ↑ (gene)             949(+) tccgcgcCACGTggctccgc            Myc/Max 
                                                                                                                 949(-)  tccgcgccACGTGgctccgc            Myc/Max 
                                                                                                                953(-)  cgccACGTGg                               Ebox     
                                                                                                                                                                                                                                                                           954(+) gCCACGtggc                              Myc/Max B        
                                                                                                                                                                                                                                                                           954(-)  gccaCGTGGc                             Myc/Max B 
                                                                                                                                                                                                                                                                           955(+) cCACGTggct                                Ebox 
11 Isocitrate dehydrogenase    
      [NAD] subunit alpha, 
     mitochondrial           IDH3A_MOUSE             ↑                         tissue                         Idh3a                 ↑ (6-12)                               1038(-) tccgCGTGGg                    Myc/Max 
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Table 4 …continued…  
 
Nr   Protein Name              Swiss-Prot name         T/C1    serum/tissue                   Gene                 T/C1              OncoDB (HCC)2                            E-box3                                   Matrices4 
 
 
12  Protein canopy  
      homolog 2           MSAP_MOUSE             ↑                         tissue                         Cnpy2               slightly ↑ (12)                                                  873(+) ggttggtCACGTgaaccaat Myc/Max 
                                                                                                                873(-)  ggttggtcACGTGaaccaat Myc/Max  
                                                                                                                877(-) ggtcACGTGa                                Ebox 
13  Selenium binding  
      protein 1/2           SBP1/2_MOUSE           ↓                        tissue                         Selenbp1/2           ↓ (12)                                 666(+) aCACCTgtgc                      Ebox 
                                                                                                                                                                                                                                                                          810(+)  aCACCTgtgc                               Ebox 
14  Indolethylamine         
      N-methyltransferas          TEMT_MOUSE             ↓                        tissue                         Inmt               strongly ↓ (12)              732(+) cCACATgcca                      Ebox 
     
 
15   Actin-related protein 3      ARP3_MOUSE            ↓                       tissue   Actr3                  slightly ↑ (12)                                   91(-) cagcATGTGg                     Ebox 
 
 
16   Serine/threonine-protein 
       phosphatase 2A             2AAA_MOUSE            ↓                       tissue                    Ppp2r1a                           
 
 
17   3-hydroxylanthranilate  
       3,4 dioxygenase             3HAO_MOUSE           ↓                      tissue                    Haao                                                               ↓ (gene)                             782(+) cCACCTgtgg                     Ebox 
  
18  Abhydrolase domain- 
      containing protein 14B      ABHEB_MOUSE        ↑↓                         tissue                    Abhd14b                                                                                                          117(+) gCACCTgctg                     Ebox 
                                                                                                                  524(+) aactgtaCACGTgttgcccc         Myc/Max 
                                                                                                                  524(-)  aactgtacACGTGttgcccc        Myc/Max 
                                                                                                                  530(+) aCACGTgttg                      Ebox 
19  Activator of 90kDa   
       heat shock protein  
       ATPase homolog 1          AHSA1_MOUSE         ↑                      tissue                     Ahsa1  
 
 
20  Coatomer subunit 
      epsilon                              COPE_MOUSE           ↓                      tissue                     Cope                                                                                                          148(+) cCACCTgctc                       Ebox 
           
 
21  Cytochrome c oxydase  
       subunit 5A,  
      mitochondrial                    COX5A_MOUSE         ↓                      tissue                    Cox5a                                                              ↑↓ (gene)                              261(+) cCACCTgatg                     Ebox 
                                                                                                                      447(-) gatcATGTGa                     Ebox 
         
22   Cytochrome c oxydase  
        subunit 5B,  
       mitochondrial                   COX5B_MOUSE         ↓                     tissue                    Cox5b  
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Table 4 …continued…  
 
Nr   Protein Name              Swiss-Prot name         T/C1    serum/tissue                   Gene                 T/C1              OncoDB (HCC)2                            E-box3                                   Matrices4 
 
 
23    Dynein light intermediate  
        chain 2, cytosolic            DYI2_MOUSE            ↓                     tissue                    Dync1i2                                                             ↓ (RT_PCR)                421(+) gCACATgcct                     Ebox 
 
24    Malate dehydrogenase,  
        cytoplasmatic            MDHC_MOUSE          ↓                     tissue                    Mdh1                                                                                                            498(-) gctcAGGTGa                    Ebox 
 
 
25    Phosphatidylethanol- 
        amine binding protein 1  PEBP*_MOUSE         ↑                     tissue                    Pbp                                            ↓ (gene)                  996(-) tgcgCGTGCc                Myc/Max B 
 
26    Phenylanlanine- 
         4-hydroxylase            PH4H_MOUSE           ↑                     tissue                    Pah                                             ↓ (gene)  
               
27    Sulfite oxidase,  
        mitochondrial            SUOX_MOUSE          ↓                     tissue                    Suox                                                                                                 245(-) ttctCGTGGc               Myc/Max B 
                                                                                                                    1044(-) tcccCGTGGc               Myc/Max B 
28   Ubiquitin carboxyl- 
        terminal hydrolase  
        isozyme L3           UCHL3_MOUSE         ↑                    tissue                   Uchl3                                                                                                           
 
 
Table 4: Regulation of proteins at both protein and gene level 
The table shows the regulations of serum and tissue proteins and the comparison of those results with genomic data on the same 
transgenic mice. Moreover, results on HCC protein/gene regulation in the literature (by oncoDB) and the search for possible  
c-Myc targets (presence of E-boxes on the related gene promoter) by BIOBASE software (matrices are discussed in the Applied Method 
section) are also shown. 
 
 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            IX 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 months (AAT-cMyc) 
 
 
6 months (AAT-cMyc) 
 
 
2 months (AAT-cMyc) 
 
 
Gene 
  T/C  P T/C  P T/C  P 
Note 
  
Myc 32.05 0 7.54 0.005 7.41 0.005 HCC 
RPL13a 6.26 0 3.09 0.0001 3.09 0.0093 HCC 
RPL36a 2.46 0.0006 1.6 0.0069 1.77 0.007 HCC 
RPL27 1.85 0.0001 1.55 0.006 1.82 0.001 HCC, c-Myc (c-DNA microarray) 
MRPL30  -  - 2.18 0.0011  -  - HCC, c-Myc (c-DNA microarray) 
Rps19 4.31 0.0051 2.37 0.002 2.64 0.001 c-Myc (SAGE) 
Rpl3 2.08 0.0001  -  -  -  - c-Myc (SAGE) 
Rplp1 2.24 0 1.75 0.0001 1.71 0.003 c-Myc (c-DNA microarray) 
Rpl7 2.15 0.0001 1.66 0.0002  -  - c-Myc (c-DNA microarray) 
Rpl19 1.99 0 1.23 0.005 1.64 0.004 c-Myc (c-DNA microarray) 
Rps15a 1.91 0.0017 1.74 0.0003  -  - c-Myc (c-DNA microarray) 
Rpl6 1.83 0 1.89 0.0002 1.64 0.0005 c-Myc (c-DNA microarray) 
Rpl22l1 3.09 0.0006 2.55 0 2.9 0.016  - 
Rpl10a 2.93 0 2.13 0.005 1.91 0.031  - 
Rpsa 2.54 0.0004 1.84 0.0012 2.19 0.005  - 
Rps5 2.46 0 1.69 0.0001 1.84 0  - 
Rps11 2.18 0 1.77 0.0001 1.72 0.03  - 
Rpl18 2.17 0 1.88 0 1.64 0.008  - 
Rpl37 1.93 0 1.65 0.0005 / /  - 
Rps3 1.91 0.0005  -  - 1.61 0.0003  - 
Rpl28 1.85 0.0011  -  - 1.63 0.018  - 
Rpl8 1.84 0.0001  -  - 1.64 0.0003  - 
Table 5 
 Table 5: Ribosomal protein regulation 
Regulation of transcription of several ribosomal proteins is shown. Some of them were already reported as HCC 
related or Myc targets. Moreover, we identified other n=10 genes regulated in our study on c-Myc transgenic mice 
which develop HCC (gray part of the Note section). 
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Table 6 
Function Protein SwissProt T/C (FC>1.8; p<0.05) MS/MSMS Protein Name 
Cell progression and 
proliferation         
1 H2A1 ~10 MS/MSMS Histone H2A type 1 
2 14-3-3T/Z/B/G 100 MS/MSMS 14-3-3 protein zeta/delta/beta 
3 H2B2 3.5 MS Histone H2B type 1-M 
4 14-3-3E 2.7 MS/MSMS 14-3-3 protein epsilon 
5 NPM 2.5 MS Nucleophosmin 
6 UCHL3 2.48 MS/MSMS Ubiquitin carboxyl-terminal hydrolase isozyme L3 
7 EF1D 2.53 MS/MSMS Elongation factor 1-delta 
8 AHSA1 3.2 MS Activator of 90 kDa heat shock protein ATPase homolog 1 
9 HS90A/B 1.8 MS Heat shock protein HSP 90-alpha/beta 
10 HSP70 1.8 MS Heat shock cognate 71 kDa protein 
Metabolism         
11 PRDX6 5 MS/MSMS Peroxiredoxin-6 
12 BLVRB 3.2 MS/MSMS Flavin reductase 
13 PRDX3 2.7 MS/MSMS Thioredoxin-dependent peroxide reductase, mitochondrial 
14 ENOA 2.6 MS Alpha-enolase 
15 PRDX2 2.6 MS Peroxiredoxin-2 
16 PPIA 2.25 MS Peptidyl-prolyl cis-trans isomerase A 
17 F16P1 0.46 MS/MSMS Fructose-1,6-bisphosphatase 1 
18 COX5A 0.6 MS Cytochrome c oxidase subunit 5A, mitochondrial 
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Function Protein SwissProt T/C (FC>1.8; p<0.05) MS/MSMS Protein Name 
19 SUOX 0.4 MS/MSMS Sulfite oxidase, mitochondrial 
20 COX5B 0.4 MS/MSMS Cytochrome c oxidase subunit 5B, mitochondrial 
21 CYB5M 0.18 MS Cytochrome b5 outer mitochondrial memrane isoform precursor 
Oxidative stress         
22 LAM1 3.4 MS Lamin-B1 
23 TXNL1 2.53 MS/MSMS Thioredoxin-like protein 1 
24 PARK7 0.44 MS Protein DJ-1 
25 NUAM 0.4 MS NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 
26 NUGM 0.4 MS NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial 
27 SBP1/2 0.38 MS/MSMS Selenium-binding protein 1 and 2 
28 2AAA 0.37 MS/MSMS 
Serine/threonine-protein 
phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform 
29 GPX1 0.2 MS/MSMS Glutathione peroxidase 1 
GSH metabolism         
30 GSH0 4 MS/MSMS Glutamate--cysteine ligase regulatory subunit 
31 GSTM1 2.7 MS Glutathione S-transferase Mu 1 
32 GSTP1 2.7 MS Glutathione S-transferase P 1 
33 IDHC 2 MS Isocitrate dehydrogenase [NADP] cytoplasmic 
Nucleotide biosynthesis & 
DNA Metabolism         
34 OAT 100 MS Ornithine aminotransferase, mitochondrial 
35 GLNA 4.8 MS/MSMS Glutamine synthetase 
Table 6…continued 
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Function Protein SwissProt T/C (FC>1.8; p<0.05) MS/MSMS Protein Name 
36 OTC 0.58 MS Ornithine carbamoyltransferase, mitochondrial 
37 CPSM 0.4/0.7 MS/MSMS Carbamoyl-phosphate synthase [ammonia], mitochondrial 
38 FTHFD 0.32 MS/MSMS 10-formyltetrahydrofolate dehydrogenase 
39 ETHE1 0.3 MS/MSMS Protein ETHE1, mitochondrial 
40 ARGI1 0.2 MS/MSMS Arginase-1 
Serum study         
41 RETBP*/** 9.16 MS/MSMS Retinol-binding protein 4 
42 TTHY*/** 2.77 MS/MSMS Transthyretin 
43 MUP1  0.2 MS/MSMS Major urinary protein 1 
44 MUP2-6-8*/** 0 MS/MSMS Major urinary protein 2-6-8 
  (GPX3)*/**     (Glutathione peroxidase 3) 
  (APOE)     Apolipoprotein E 
Fat metabolism and trasport         
45 APOA2 8.64 only MSMS Apolipoprotein A2 
46 APOE 4.7 MS/MSMS Apolipoprotein E 
47 APOA1 1.8 MS/MSMS Apolipoprotein A1 
48 FABPL 0.46 MS Fatty acid-binding protein, liver 
Metastasis         
49 MSAP 5.44 MS/MSMS Protein canopy homolog 2 
50 CATB 4.34 MS/MSMS Cathepsin B 
51 CLIC1 3 MS/MSMS Chloride intracellular channel protein 1 
52 GDIR 3.45 MS Rho GDP-dissociation inhibitor 1 
53 COPE 0.33 MS Coatomer subunit epsilon 
Other         
54 NAGK 4.9 MS N-acetyl-D-glucosamine kinase       
55a ABHEB (C1IB) 2.58 MS/MSMS Abhydrolase domain-containing protein 14B 
56 IDH3A 2.07 MS/MSMS Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial     
57 GALK1 2.07 MS/MSMS Galactokinase 1 
58 PEBP1 2.13 MS/MSMS Phosphatidylethanolamine-binding protein 1 
55b ABHEB 0.48 MS/MSMS Abhydrolase domain-containing protein 14B 
Table 6…continued 
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Function Protein SwissProt T/C (FC>1.8; p<0.05) MS/MSMS Protein Name 
59 CAH3 0.56 MS/MSMS Carbonic anhydrase 3 
60 PH4H 0.46 MS/MSMS Phenylalanine-4-hydroxylase 
61 OPLA 0.46 MS 5-oxoprolinase 
62 3HIDH 0.36 MS/MSMS 
3-hydroxyisobutyrate 
dehydrogenase, 
mitochondrial 
63 MDHC 0.57 MS/MSMS Malate dehydrogenase, cytoplasmic 
64 GNMT 0.44 MS Glycine N-methyltransferase 
65 RGN 0.4 MS/MSMS Regucalcin 
66 DOPD 0.38 MS D-dopachrome decarboxylase 
67 DYI2 0.37 MS Dynein light intermediate chain 2, cytosolic 
68 ARP3 0.42 MS/MSMS Actin-related protein 3 
69 FTCD 0.34 MS/MSMS Formimidoyltransferase-cyclodeaminase 
70 (TEMT) INMT 0.14 MS/MSMS Indolethylamine N-methyltransferase 
71 3HAO 0.47 MS/MSMS 3-hydroxyanthranilate 3,4-dioxygenase 
72 SARDH 0.37 MS Sarcosine dehydrogenase, mitochondrial 
73 HA10 4 MS H-2 class I histocompatibility antigen, Q10 alpha chain 
74 LEG1 1.81 MS/MSMS Galectin-1/Beta-galactoside-binding lectin L-14-I 
75 DHSO 0.01 MS Sorbitol dehydrogenase 
 
Table 6: All regulated proteins in mouse liver tissue (red: up-regulated; green: down-regulated). 
         
Table 6…continued 
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   Table 7    
 
Table 7: Gene expression comparison 
Protein genes related to GPI-PLD expression and activity have been compared between c-Myc mice (at 2-6-12 months) and human 
hepatocytes where NASH was induced. Moreover, we showed also the protein pattern (“Protein expression (mouse)” 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            I
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Cancer proteomics of mouse serum and liver tissue samples to discover candidate biomarkers for HCC in c-Myc transgenic mice       
                                                       
  
            II
Appendix 1: c-Myc expression in liver tissue by IHC 
 
 
 
 
 
 
 
 
 
The c-Myc expression in livers from control  and tumor transgenic mice 
(“MOUSE”) compared to the c-Myc expression in healthy –control- and HCC patients 
-tumor- (“HUMAN”).   
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Appendix 2: Immunohistochemistry of regulated proteins 
 
 
 
 
Immunohistochemistry of Apolipoprotein E, Hemopexin, Major urinyry protein, 
Paraoxonase 1, Retinol-binding protein 4, Serum amyloid component P protein and 
Transthyretin. Comparison between mouse and human results in control and tumor 
tissues, respectively. 
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Appendix 3: Publication 1, title-page 
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Appendix 4: Publication 2, submission 
 
 
 
11. Februar 2011 “Just Accepted”, Journal of Proteome Research 
http://pubs.acs.org/toc/jprobs/0/ja  
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Abbreviation                                                                         Full-Name 
AAT…………………………………………………………….…………Alpha-1-antitrypsin 
APOA(X)………………………………………………………….………Apolipoprotein A(x) 
CHCA…………………………………………………….α-Cyano-4-hydroxycinnamic acid                        
C2………………………………………………………………………...Ethyl-toxic cirrhosis                        
DDMII…………………………………………………...…………..Diabetes Mellitus type II 
DHB………………………………………………………………2,5-dihydroxybenzoic acid   
GPI-PLD…………………………...……..Glycosylphosphatidylinositol-phospholipase D 
HCC……………………………………………..........................Hepatocellular carcinoma    
HBV………………………………………………………………………….Hepatitis B virus                        
HCV………………………………………………………………………….Hepatitis C virus                        
HIF-1…………………………………………………………….. Hypoxia-inducible factor 1 
IEF………………………………………………………………………..Isoelectric focusing                        
IHC……………………………………………………………………Immunohistochemistry                        
IPGs………………………………………………Focused immobilized pH gradient strips                       
MALDI-MS…………….Matrix-assisted laser desorption/ionization-Mass Spectrometry 
Myc…………………………..v-myc myelocytomatosis viral oncogene homolog (avian) 
NASH…………………………………………………………Non-alcoholic steatohepatitis 
PFF………………………………………………………….Peptide fragment fingerprinting 
PMF……………………………………………………………..Peptide mass fingerprinting 
TFA…………………………………………………………….…………Trifluoroacetic acid 
TOF……………………………………………………………………………..Time-of-Flight 
WB………………………………………………………………..Western (immuno)blotting 
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Instrument                                                                              Company                    
Alpha 1-2 LD Freeze dryer…………………………………………………………….Christ 
Biofuge FRESCO………………………………………………….….Heraeus Instruments 
Buffer recirculation pump 256 BR…………………………………………………...BioRad 
Criterion™ Cell………………………………………………………………………..BioRad 
Criterion™ XT Precast Cell…………………………………………………………..BioRad 
Duomax 1030……………………………………...………………….Heidolph instruments 
Electrophoresis power supply PS 3002……………….….……………Life Technologies 
Electrophoresis-Double chamber………………………………..………………….BioRad 
Espresso centrifuge…………………………………………Thermo electron corporation 
Expression10000XL…………………………………….………………………..……Epson 
ExQuest™ Spot Cutter...…………………………………………..…………………BioRad 
External Laser Molecular Imager FX…………………………….………………….BioRad 
Famos (nanoHPLC)……………………..……………..………………………LC Packings                  
Haake k20 Circulating Refrigerator Bath …………………………...….Thermo Scientific 
Kodak Imager Kodak ds -IS 440CF......................................................................Kodak 
Mini-PROTEAN® Dodeca™Cell……………………………………………..……..BioRad 
Mini-Protean 3 Multi-Casting Chamber………………………………….………….BioRad 
Mini-PROTEAN® Tetra Cell…..……….…………………………………………….BioRad 
Mini Trans-Blot® Cell…………………………………………………………………BioRad 
MS2 Minishaker………………………………………….………………………………IKA® 
Multi-Casting Chamber…………………………………………………………..…Biometra 
Multifuge 1S…………………………………………………..……….Heraeus Instruments 
Pharos FX™ Plus Molecular Imager…………………………….………………….BioRad 
Pipetboy acu.............................................................................IBS Integra Biosciences 
Protean IEF Cell..................................................................................................BioRad 
Power Pac 200…………………………………………………...…………………...BioRad 
Protean® Plus Dodeca™Cell……………………………….…………………….…BioRad                        
Rotary Vane Vacuum Pump R22…………………………..………………….Vacuubrand 
RTCbasic……………………………………………………….………………………..IKA® 
RVC (Rotations Vakuum Konzetratoren) 2-25………………………….......………Christ 
SIGMA 1-15 Microfuge………………………..……………………………...…SciQuip Ltd 
Switchos (nanoHPLC)………………………………………………………….LC Packings 
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Thermomixer compact………………………………………..…………………..Eppendorf 
Sonorex Super RK 514 BH…………………………………………………………Bandelin 
Universal Shaker (:::?)………………………………..….Edmund Bühler Lab Tec GmbH 
Ultimate (nanoHPLC)……………………..……………………………………LC Packings 
Ultraflex II (MALDI-TOF/TOF)………………………………...…..………Bruker Daltonics 
Vortex-genie 2……………………………………………….………….Scientific industries 
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Softwares & Chemicals 
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Softwares licenced by Fraunhofer ITEM                                                                   
BioTools …….…………………………………………...…………………..Bruker Daltonics 
Chromeleon…………………………………………………………………..…………Dionex 
FlexAnalysis……..……………………………………………….………….Bruker Daltonics 
FlexControl……..…………………………………………………..………..Bruker Daltonics 
MATCH™…………………………………….……………BIOBASE, Biological Databases 
Origin………………………………………………………………..…OriginLab Corporation 
PDQuest ™ v..………………………………………………………… BioRad Laboratories 
ProteinScape v2.1…………………………………………….…………… Bruker Daltonics  
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